Caring for a patient with cancer: the psychosocial impact on informal caregivers by Langenberg, S.M.C.H






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2021-11-05 and may be subject to
change.
CARING FOR A 
PATIENT WITH CANCER
The psychosocial impact on informal caregivers
Simône  Langenberg
CARING FOR A 
PATIENT WITH CANCER
The psychosocial impact on informal caregivers
Simône  Langenberg
The work presented in this thesis was carried out within the Radboud Institute for 
Health Sciences at the Department of Medical Oncology of the Radboud university 
medical center, Nijmegen, the Netherlands. 
ISBN: 978-94-6416-115-1
Cover design and layout: © evelienjagtman.com
Printed by: Ridderprint BV
© S.M.C.H Langenberg, 2021. All rights reserved. 
CARING FOR A 
PATIENT WITH CANCER
The psychosocial impact on informal caregivers
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken,
volgens besluit van het college van decanen
in het openbaar te verdedigen
op donderdag 30 september 2021 
om 12:30 uur precies
door
Simone  Marie  Claire  Hélène  Langenberg
geboren op 30 september 1984
te Loosdrecht
Promotoren: 
Prof. dr. W.T.A. van der Graaf 
Prof. dr. J.B. Prins 
Prof. dr. C.M.L. van Herpen
Copromotor: 
Dr. A.N.M. Wymenga (Medisch Spectrum Twente)
Manuscriptcommissie: 
Prof. dr. A.E.M. Speckens (voorzitter) 
Prof. dr. N.M.A. Blijlevens 
Prof. dr. C.C.D van der Rijt (Erasmus MC) 
“What is the bravest thing you’ve ever said?” asked the boy




Chapter 1 General introduction 11
Part I Caring for a patient during the treatment phase
Chapter 2 Caregivers’ burden and fatigue during and after patients’ 
treatment with concomitant chemoradiotherapy for 
locally advanced head and neck cancer: a prospective, 
observational pilot study
Simone M.C.H. Langenberg, Carla M.L. van Herpen, Claudia 
C.M. van Opstal, Anke N.M. Wymenga, Winette T.A. van der 
Graaf, Judith B. Prins 
Supportive Care in Cancer (2019) 27: 4145–4154
29
Chapter 3 Informal caregiver well-being during and after patients’ 
treatment with adjuvant chemotherapy for colon cancer: 
a prospective,  exploratory study
Simone M.C.H. Langenberg, Hanneke Poort, Anke N.M. 
Wymenga, Jan Willem de Groot, Erik W. Muller, Winette 
T.A. van der Graaf, Judith B. Prins, Carla M.L. van Herpen 
Supportive Care in Cancer (2020) 29 (5): 2481-2491
49
Chapter 4 Caregivers of patients receiving long-term treatment 
with a tyrosine kinase inhibitor (TKI) for gastrointestinal 
stromal tumour (GIST): a cross-sectional assessment of 
their distress and burden
Simone M.C.H. Langenberg, An K.L Reyners, Anke N.M. 
Wymenga, Gerry C.M. Sieling, Carel M.M Veldhoven, Carla 
M.L. van Herpen, Judith B. Prins, Winette T.A. van der Graaf 
Acta oncologica (2019) 58 (2): 191-199
73
Part II Informal caregivers of patients after treatment
Chapter 5 Fear of cancer recurrence: a significant concern among 
partners of prostate cancer survivors
Marieke van de Wal, Simone M.C.H. Langenberg, Marieke 
F.M. Gielissen, Belinda Thewes, Inge M. van Oort, Judith B. 
Prins 
Psycho-Oncology (2017) 26 (12): 2079-2085
97
Part III Bereaved informal caregivers
Chapter 6 How did partners experience cancer patients’ participation 
in a phase I study? An observational study after a patient's 
death
Simone M.C.H. Langenberg, Marlies E.W.J. Peters, Winette 
T.A. van der Graaf, Anke N.M. Wymenga, Judith B. Prins, Carla 
M.L. van Herpen 
Palliative and supportive care (2016) 14 (3): 241-249
117
Chapter 7 Summary 137























In 2018, 18 million people were diagnosed with cancer and 9.6 million people died 
as a consequence of the disease worldwide [1]. In this same year, 116,537 inhabitants 
of the Netherlands were diagnosed with cancer and 45,206 patients died as a 
consequence of cancer [2]. There are several treatments for cancer, applied 
separately or in combination: surgery, radiotherapy and/or systemic treatment. 
Systemic therapy can be chemotherapy, targeted therapy, immunotherapy and/
or hormonal treatment. Regarding systemic treatment, we distinguish three phases 
when this therapy is applied with curative intent: 1) neo-adjuvant (prior to surgery), 
2) concomitant (together with radiotherapy) and 3) adjuvant (after surgery and/or 
radiotherapy). When curative treatment is not possible, systemic treatment is also 
applied in the palliative phase. During treatment, a patient faces many challenges, 
which makes good support indispensable. Most of the time, this care is provided 
by informal caregivers. 
Informal caregivers and their challenges
An informal caregiver provides unpaid and often long-term care for a family 
member or friend in need. In the Netherlands, 4.4 million individuals (25%) provide 
care to a significant other [3]. Of these 750,000 provide long-term care (> 3 months 
and/or > 8 hours every week) [3]. Of the informal caregivers who provide long-
term care, it is not clear how they are distributed between caring for patients with 
dementia, cancer or other morbidities. The informal caregiver is often a spouse, 
parent, child or sibling, but can also be a friend or neighbour. Furthermore, for 
paediatric cancer patients and Adolescent and Young Adults (AYA’s), the parent(s) 
can be their informal caregiver(s). Informal caregivers support patients in many 
ways. They provide practical support (transportation, accompany a patient to the 
hospital, both planned (for treatment) or unplanned (for treating complications), do 
administration tasks, arrange practical instruments at home, support with activities 
of daily living, managing the household, as well as emotional support dealing 
with the patients’ disease. Supporting a patient emotionally is an often difficult 
though important aspect. Furthermore, informal caregivers play an important 
role in helping the patient navigate and decide what treatment option suits them 
best. This challenges informal caregivers, as they also have their personal life 
and responsibilities [4]. This can lead to burden, psychological distress (hereafter 
described as “distress”) and depression in informal caregivers when a patient 
is treated for cancer [4]. When a patient survives after cancer treatment, fear of 
patients’ cancer recurrence might be a problem for informal caregivers as well [5]. 
When a patients dies as a consequence of cancer, depression is seen and may 
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coincide with complicated grief [6]. Both informal caregivers’ mental health and 
their physical health can be affected. Before describing the studies performed 
in this thesis, more background information about burden, distress, depression, 
complicated grief, health-related quality of life, fatigue, and fear of recurrence will 
be given.
Burden
Experiencing burden is different for every informal caregiver as a consequence of 
the multidimensional aspect of providing support to a significant other [7,4]. Informal 
caregiver burden has adverse effects on their general health and other roles they 
fulfil in life [4,7]. When burden is experienced as a problem, there is an imbalance 
between informal caregivers’ resilience, resources and personal capacities and 
patients’ care demands. Risk factors for higher levels of informal caregivers’ burden 
are divers and range from demographic factors (being female, living together with 
the care recipient), psychological factors (depression, fewer coping strategies, 
distress), social factors (social isolation), financial factors (discontinuation of own 
employment, financial stress) to care-related factors (spending more hours caring, 
lack of choice becoming a caregiver) [4]. In the Netherlands, overall, 380,000 
informal caregivers are heavily burdened [3]. Although this number of burdened 
informal caregivers is not specific for informal caregivers of patients with cancer, it 
delineates that there is a vulnerable group of informal caregivers that might need 
extra support. 
Distress, depression and complicated grief 
Distress, defined by the National Cancer Institute as ‘emotional, social, spiritual, 
physical pain or suffering that may cause a person to feel sad, afraid, depressed, 
anxious or lonely’, is an important psychological morbidity, which often coincides 
with burden [4,8]. Distress extends along a continuum, ranging from common 
normal feeling of vulnerability and sadness, and fears to problems that can 
become disabling, such as depression, anxiety, panic, social isolation, and 
existential and spiritual crisis [9]. High levels of informal caregiver distress may 
result in 1) patients having difficulties adjusting to their disease on the long-
term, 2) patients who are influenced by informal caregiver’s anxiety and thereby 
experiencing anxiety themselves 3) informal caregivers facing difficulties taking 
proper care of their significant other, for example administering medication and 
4) informal caregivers with physical problems as a consequence of changes in 
functioning of their immune system and increased vulnerability for cardiovascular 
disease [10]. Sources for high levels of distress are different for every informal 




sources of distress are associated with disruption of informal caregivers’ own 
schedule and include treatment-related factors (treatment efficacy, managing 
side effects, lack of preparation providing complex care, patients’ symptom 
distress), psychosocial factors (social isolation, role social functioning, feeling 
overwhelmed, helping the patient cope with emotional distress, complex family 
relationships) and/or arise from unmet needs (psychosocial, medical, financial, 
informational) [10]. It is known that women have a higher risk for distress than men 
[11]. The incidence of distress among informal caregivers of patients after cancer 
diagnosis is approximately 20% [12-14]. 
Distress can result in depression on the long-term. The National Cancer 
Institute defined depression as “a mental condition marked by ongoing feelings of 
sadness, despair, loss of energy, and difficulty dealing with normal daily life” [15]. 
People suffering from depression experience changes in their sleeping patterns, 
changes in appetite, loss of energy, anxiety, reduced concentration, restlessness, 
indecisiveness, feelings of guilt, hopelessness, worthlessness, thoughts of self-
harm or suicide [16]. The prevalence of depressive symptoms among informal 
caregivers of cancer patients varies between 12 and 41% and partly depends on 
the (treatment) phase a patient is in [17-20]. 
Grief is described as “the normal response to a major loss, such as the death 
of a loved one” [21]. Generally spoken, on average the intensity of bereavement 
diminishes over time, without any intervention needed and grief becomes 
integrated in a person life. However, there is a group of individuals that suffers 
from complicated grief. Complicated grief has been defined as “a deviation from 
the normal (in cultural and societal terms) grief experience in either time course, 
intensity, or both, entailing a chronic and more intense emotional experience or 
an inhibited response, which either lacks the usual symptoms or in which onset of 
symptoms is delayed” [22]. These individuals experience problems in their personal 
life, as a consequence of the loss of a significant other, and natural recovery does 
not occur [6]. It is important to realize that symptoms of complicated grief resemble 
symptoms of depression and psychological distress [6]. Complicated grief may 
coincide with depression and worsening of depressive symptoms is often seen 
[6,22]. 
Health-related quality of life and fatigue
Taking care of a significant other has consequences for informal caregivers’ health-
related quality of life as well. In a study of Hays et al. health-related quality of life 
(HRQoL) is described as how health impacts on an individual’s ability to function 
and his or her perceived well-being in physical, mental and social domains of 
life [23]. Research showed that a year after a patient is diagnosed with cancer, an 
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informal caregiver can have (negative) changes in neurohormonal and inflammatory 
processes due to stress [24]. Furthermore, associations between caring for a patient 
with cancer and increased risk for cardiovascular disease are found [25]. This 
impacts their health-related quality of life. 
Another important problem that can impact informal caregivers’ quality of life 
is fatigue. There is a definition of fatigue for patients with cancer, but for informal 
caregivers this definition does not apply. For informal caregivers the definition 
of the Oxford dictionary seems to be more applicable: “an extreme tiredness 
resulting from mental of physical exertion or illness”. Although studies about this 
problem in informal caregivers are scarce, moderate to severe fatigue is reported. 
For example, Peters et al. describe that 23% of informal caregivers are moderate 
to severely fatigued during patients’ palliative treatment [26]. Furthermore, sleep 
disturbances are a risk factor for developing depression [27] and fatigue impacts 
informal caregivers’ daily activities which has implications for the support they can 
offer the patient [28]. Carter et al. even reported that 95% of informal caregiver 
of patients with advanced cancer experience sleep disturbances. They, however, 
did not use the prescribed sleep medication in order to stay available during the 
night to support the patient if they needed that [27]. Sleep disturbances may lead 
to fatigue and it is unknown how informal caregivers’ fatigue is related to patients’ 
difficulties, for example their fatigue or distress. Little research is performed 
concerning informal caregiver fatigue in relation to the problems they face when 
caring for their significant other. 
Fear of recurrence
Fear of recurrence is a common problem among cancer survivors. It is defined as 
“fear, worry, or concern about cancer returning or progressing” [29]. The current 
prevalence of fear of cancer recurrence is on average 49% for cancer survivors [30]. 
Little is known about this concern among informal caregivers of cancer survivors. 
One study reports that 51% of partners of patients having prostate cancer fear that 
the cancer progresses (fear of progression). It is known that high levels of fear 
of recurrence among cancer survivors do not improve over time [31]. Moreover, 
higher levels of fear of recurrence are associated with poorer health behaviours, 
experiencing distress and increased use of health care utilities [30,32,33]. Considering 
these aspects, it seems important to study the levels of fear of recurrence further 




OUTLINE OF THE THESIS
This thesis is divided in three parts. The first part will focus on informal caregivers 
of patients on active treatment for cancer. The second part will focus on informal 
caregivers of patients after active treatment, i.e. cancer survivors and the third part 
will report on bereaved informal caregivers. 
PART 1: 
CARING FOR A PATIENT 
DURING THE TREATMENT PHASE
Informal caregivers of patients treated with curative intent
When a patient is treated with curative intent, it is important that the treatment will 
be completed in order to achieve the best results. Support of informal caregivers 
is therefore of great importance, which will help patients while receiving treatment. 
However, caring for a of patient treated for cancer can be burdensome, considering 
the intensity and the disruption of informal caregivers’ personal lives. 
Head and neck cancer
The incidence of head and neck cancer (HNC) in The Netherlands was 2839 
cases in 2019 [2]. Of the newly diagnosed patients with HNC, approximately 
50% is diagnosed with stage III or IV disease [34]. Squamous cell carcinoma is 
the most common type of HNC. Risk factors are tobacco and alcohol abuse. 
For patients with oropharyngeal cancer, part of the tumours are caused by 
the human papilloma virus (HPV) [35]. Patients with locally advanced HNC (i.e. 
stage III, IVa and IVb) are treated with curative intent, receiving concomitant 
chemoradiotherapy (accelerated radiotherapy with cisplatinum or cetuximab, 
depending on condition, age and / or kidney function) during six or seven weeks. 
Side effects that often occur during this treatment are, amongst others, (severe) 
fatigue, mucositis and dermatitis [36]. This has impact on patients’ quality of life 
and may cause psychological distress [36-38]. Additionally, among patients with 
HNC the prevalence of a major depressive disorder is higher (approximately 
40%) when compared to other groups of patients with cancer (approximately 
12.5%) and the general population (approximately 3%) [39-41]. Getting support 
from their significant other is therefore indispensable, especially since completing 
this treatment gives them a chance of curation. 
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Supporting a patient during this intensive treatment may burden the informal 
caregiver and impact their mental and physical health. Distress is a common 
problem for informal caregivers after a patient is diagnosed with HNC [38,42]. 
Distress on the long-term can cause depression. Furthermore, it is obvious that 
the intense treatment with concomitant chemoradiotherapy, meaning almost 
daily visits to the outpatient clinic, can fatigue an informal caregiver. It is known 
that fatigue is associated with distress [27,28]. Although the number of studies 
with informal caregivers of patients treated for HNC is increasing, there is need 
for prospective studies to enhance understanding of caregivers’ mental and 
physical health in relation to patients’ problems and thereby support them 
properly [42]. 
Therefore, in chapter 2 we present the results of a prospective study with 
informal caregivers of patients treated with concomitant chemoradiotherapy for 
locally advanced HNC. First, we explore the course of informal caregivers’ burden 
and fatigue in relation to patients’ fatigue, distress and health-related quality of life. 
Second, we search for risk factors for informal caregivers’ burden and fatigue after 
patients’ curative treatment with chemoradiotherapy. 
Colon cancer
The incidence of colon cancer in the Netherlands in 2019 was 9237 cases [2]. 
Approximately 65% of the newly diagnosed patients with colon cancer, is diagnosed 
with stage II or III disease [43]. Patients with high risk stage II or stage III colon 
cancer are primarily treated with resection of the tumour, followed by adjuvant 
chemotherapy containing fluoropyrimidines and oxaliplatin (i.e. 5FU/leuvorin or 
capecitabine with oxaliplatin; CAPOX). Of this regimen, the most common side 
effects are hand-feet syndrome, nausea, vomiting, and sensory and peripheral 
neuropathy. Oxaliplatin is often discontinued prematurely, because the side 
effect of nerve damage may not be reversible and patients may develop chronic 
neuropathic problems. 
In the Netherlands, Nijboer et al. studied informal caregivers of patients 
with newly diagnosed colorectal cancer who recently underwent surgery and 
had a prognosis of at least 6 months. They found that younger (<50 year) and 
female informal caregivers are more vulnerable and in need for more support [44]. 
Another finding of Nijboer et al. was that a more negative perception of caregiving 
is associated with a lower income level, living alone with the patient, high level 
of patient dependency, having a distressed relationship, and high involvement 
in caregiving tasks [45]. Nijboer et al. also described that caregivers belonging to 
these risk groups are more prone for longer-term depression, as were informal 




say that caring for a patient with colon cancer who is treated with curative 
intent can be burdensome and may cause distress. Additionally, it may impact 
informal caregivers’ health-related quality of life. However, little is known about 
informal caregivers of patients treated with adjuvant chemotherapy after surgery. 
Informal caregiver support is vital as adjuvant chemotherapy further improves 
their prognosis. 
Chapter 3 reports on a prospective study. First, we will investigate the course 
of caregiver burden and distress over time and identify the number of informal 
caregivers having higher levels of burden and distress. Second, we will search 
risk factors for developing higher levels of burden and distress during and after 
treatment. Third, we will explore whether informal caregivers’ burden and distress 
is associated with patients’ distress. Lastly, we will examine the course of caregivers’ 
health-related quality of life over time and study how it is associated with their own 
burden and distress, and with distress of the patient. 
Informal caregivers of patients on long-term treatment 
When a patient undergoes long-term treatment, it is important that their support is 
stable and resilient during their treatment. One of the groups of patients on long-
term treatment are patients with gastrointestinal stromal tumours. In 2018, the 
incidence and prevalence of GIST in the Netherlands was approximately 220 and 
1360 cases, respectively [2]. GISTs belong to the rare and heterogenous group of soft 
tissue sarcomas. GISTs are known for their resistance to chemo- and radiotherapy 
and the survival used to be poor. In 2000 imatinib, a tyrosine kinase inhibitor (TKI), 
revolutionised the treatment of this disease with long-lasting responses in the 
metastatic setting leading to the registration of this drug in the metastatic setting, 
later followed by studies showing benefit in the adjuvant setting [46,47]. For recurrent/
metastatic disease, this new treatment improved the median overall survival from 
less than one year to more than 5 years [46]. This changed patients’ perspective 
significantly. A challenge for these patients on long-term cancer treatment is 
managing the side effects of treatment with TKIs such as fatigue, diarrhoea, nausea, 
periorbital oedema, muscle cramps and skin rash [48]. Furthermore, another common 
problem that patients with GIST face is fear of recurrence/progression [49]. This can 
impact informal caregivers as well [50]. During visits of patients and their informal 
caregivers to the outpatient clinic we observed that an informal caregiver can be 
as distressed as the patient treated with curative or palliative intent. Additionally, 
they do impress burdened as well. There are no studies yet which describe informal 
caregivers’ burden and distress in the group of patients who are treated on the long-
term for GIST. 
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Chapter 4 includes a cross-sectional, observational study to explore the level 
of informal caregivers’ burden and distress during patients’ long-term treatment 
with TKIs. Furthermore, we will also compare informal caregivers with high levels of 
distress and high levels of burden to informal caregivers with low levels of distress 
and low/moderate levels of burden. This in order to gain more insight in informal 
caregivers who are in need of more support. 
PART 2: 
INFORMAL CAREGIVERS 
OF PATIENTS AFTER TREATMENT
Informal caregivers of patients in the survivorship phase
The incidence of prostate cancer was 12,646 cases in 2018 in The Netherlands 
[2]. For localized prostate cancer, active surveillance, radical prostatectomy or 
radiotherapy are options for treatment. The treatment of choice is made by 
considering the longer-term effects of the used modality and the preferences of 
the patient [51]. The 5-year survival for patients with stage I-III disease is between 
96 and 100% [2]. Most of the patients adjust to their changed life after diagnosis, 
as do their informal caregivers. Nonetheless, fear of cancer recurrence is an 
important problem among cancer survivors and seems to also play a role in 
informal caregivers. However, this is not yet known for this group of informal 
caregivers, as is the relationship between fear of cancer recurrence and their 
health-related quality of life. 
In chapter 5 we describe a cross-sectional study of 1) the prevalence of 
informal caregivers’ fear of recurrence, 2) differences in the percentage of high 
fear of cancer recurrence between informal caregivers and patients, 3) informal 
caregivers’ demographics and survivors’ clinical characteristics associated with 
high fear of cancer recurrence, and 4) the relationship between high fear of 






Bereaved partners of patients treated in a phase I study 
Patients participating in phase I clinical trials generally have no conventional- or 
later-phase clinical trial treatment options left. Their median survival is estimated 
nine months [52]. Participation in phase I clinical trials demands a good performance 
status. A limited chance of benefit could be expected when participating in these 
trials and side effects are seen, together with frequent visits to the outpatient 
clinic [53]. Considering this for patients in their end-of-life phase, critics question 
whether patients participate voluntarily and assume that their participation is a 
consequence of misconception and enforcement [54]. In contrast, there is literature 
reporting about patients who take a well-informed decision to participate, without 
coercion [55]. Clearly, participation has consequences for a patients’ daily life, 
whether it is positive or negative. The studies performed were from the patients’ 
and/or healthcare professionals’ point of view. The point of view of patients’ informal 
caregivers is at least as important, as an informal caregiver is faced with challenges 
during treatment as well. However, the informal caregivers’ point-of-view was not 
actively sought. 
In Chapter 6 we will retrospectively, 1) explore how informal caregivers reflect 
on patients’ participation in a phase I clinical trial after patients’ death, and 2) 
determine their functioning in terms of depression, distress, complicated grief 
and health-related quality of life after a patients’ death. 
AIMS OF THE THESIS
The overall aim of this thesis is to gain more knowledge about informal caregivers’ 
functioning when caring for a patient on (long-term) treatment for cancer, after 
treatment is ended or after a patients’ death. The studies in this thesis aimed to give 
more insight in treatment phase-specific problems, like burden and distress during 
treatment, fear of recurrence after treatment and grief after a patients’ death. The 
results will be used to evaluate how and when healthcare professionals can best 
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ABSTRACT
Introduction: Knowledge of caregivers’ burden and fatigue before and after 
patients’ treatment for locally advanced head and neck cancer is scarce. Therefore, 
we aimed to explore caregivers’ fatigue and burden in relation to patients’ fatigue, 
distress and health-related quality of life (HRQOL). 
Methods: For caregivers, burden and fatigue were assessed. For patients, fatigue 
severity, distress and health-related quality of life was assessed. Measurements 
were conducted prior to treatment, 1 week and 3 months after chemoradiotherapy. 
Results: Caregivers’ burden and fatigue followed patients’ high peak in distress, 
fatigue and diminished HRQOL as a consequence of treatment. Caregivers’ baseline 
fatigue was a predictor for fatigue after chemoradiotherapy. Being a female spouse 
with higher baseline levels of fatigue and burden and caring for a patient with lower 
levels of HRQOL seem risk factors for burden after chemoradiotherapy. 
Conclusions: Attention should be paid to caregivers’ burden and fatigue before 
starting patients’ intense treatment with chemoradiotherapy, as both burden 
and fatigue before starting treatment may contribute to burden and fatigue after 
chemoradiotherapy. 




Every year, globally 650,000 patients are diagnosed with head and neck 
cancer. The most common type of head and neck cancer is head and neck 
squamous cell carcinoma (HNSCC) which is associated with tobacco and 
alcohol abuse. Furthermore, in oropharyngeal cancer part of the tumours are 
caused by the human papillomavirus (HPV). Patients with HPV positive tumours 
have a favourable prognosis when compared to patients with HPV negative 
tumours [1]. Standard treatment in patients with locally advanced head and neck 
cancer (LAHNC) is concomitant chemoradiotherapy with curative intent. This 
is an intensive treatment accompanied with (visible) consequences and side 
effects such as severe fatigue, mucositis and dermatitis [2], which negatively 
influences the patients’ quality of life and may cause psychological distress [2-
4]. Patients with head and neck cancer differ from other cancer patients, as the 
prevalence of major depressive disorder is the highest among head and neck 
cancer patients [5]. 
Considering the aforementioned aspects, social support from patients’ 
informal caregivers is indispensable during and after treatment. Badr and 
colleagues found that patients with head and neck cancer and their caregiver 
cope with distress as a couple [6]. Consequently, caregivers can be burdened 
by care for their significant other. Lazarus and Folkman introduced the stress 
theory and described the construct of “appraisal” [7]. This as a cognitive process 
of an individual to balance environmental demands or stressors in relation to their 
personal life. This theory and the construct of appraisal is often used in caregiver 
literature, as burden can be an outcome of this appraisal [8,9]. Caregiver burden is 
described by Zarit and colleagues as the extent to which giving care to a significant 
other is perceived with an adverse effect on their emotional, social, financial, 
physical, and spiritual functioning [10]. Adelman and colleagues describe that 
this definition emphasizes the multidimensional toll caregiving may demand on 
care providers and that giving care to a significant other is a highly individualized 
experience [11]. Psychopathology may arise when there is an imbalance between 
demands and caregivers’ personal life [8]. High levels of caregiver burden may 
remain high after ending treatment, which is shown in a study with caregivers of 
patients treated for stage II and III oesophageal cancer [12]. Studies performed 
amongst caregivers of patients with head and neck cancer show that head and 
neck cancer caregivers have poorer mental health, with higher distress levels 
when compared to the general population and compared to head and neck 
cancer patients themselves [13,14]. Risk factors for poorer mental health and 
burden are being female, providing more hours of care, having disrupted social 
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interaction, have disrupted self-care and an increased need for patients’ support 
[15]. Additionally, fatigue is a frequently mentioned physical symptom of burden 
and is likely to coincide with burden, which is sparsely studied among caregivers 
of patients with cancer [16], and not yet studied in this group of caregivers.
This prospective, observational pilot study had two exploratory aims. First, 
we wanted to explore the course of caregivers’ burden and fatigue in relation to 
patients’ fatigue, distress and HRQoL before and after chemoradiotherapy. An 
important number of caregivers of head and neck cancer patients report need for 
help themselves [17]. Therefore, we aim to identify caregivers with a high level of 
burden and fatigue and we want to investigate when the levels of burden and fatigue 
are at their highest. This in order to identify when support seems to be needed most. 
Second, we aimed to explore risk factors for developing higher levels of burden 
and fatigue of caregivers after patients’ treatment with chemoradiotherapy. Based 
on clinical observations of informal caregivers of patients treated for LAHNC and 
based on known risk factors for care-related problems supporting a patient with 
cancer, we think that female gender [18], younger age [18,19] and being in a spousal 
relationship with the patient [19-21], caregivers’ higher baseline role problems [22] 
and caregivers of patients with worse HRQoL [9,23,24] have a higher risk for higher 
levels of burden and fatigue after ending treatment for LAHNC.
MATERIALS AND METHODS
Setting and participants
This prospective, observational pilot study was conducted between 2011 and 2013 at 
the Radboud university medical center in the Netherlands. Eligible for participation 
were patients older than 18 years with LAHNC and who were scheduled for 
treatment with chemoradiotherapy with curative intent (stadium III, IVa, IVb), and 
their informal caregivers. Patients and caregivers had to be able to give informed 
consent and read and write in Dutch. Patients receiving the chemoradiotherapy as 
primary treatment were treated with concomitant chemoradiotherapy during 5.5 
weeks. They received accelerated radiotherapy. Patients who were treated with 
concomitant chemoradiotherapy as postoperative therapy were treated with a 
conventional chemoradiotherapy schedule and received treatment for 7 weeks. 
In oropharyngeal cancer patients, HPV positivity was determined by the use of 
immunohistochemical determination of p16. In case p16 was positive, PCR for 
HPV was performed. If also the PCR was positive we identified the patient as HPV 
positive.




The local medical ethical committee gave permission for the study. The attending 
oncologist (CH) and/or nurse practitioner (CO) informed the couples during their 
first visit to the outpatient clinic. If both patient and caregiver gave their informed 
consent, they were included. The attending oncologist or nurse practitioner 
extracted the treatment characteristics from the patient’s medical record, including 
HPV status, postoperative chemoradiotherapy (yes/no) and duration of treatment 
(weeks). Participants were asked to complete self-report questionnaires at three 
time points: (T0) prior to start chemoradiotherapy, (T1) one week after ending 
chemoradiotherapy, and (T2) three months after the end of chemoradiotherapy. 
Completing the paper and pencil questionnaire took between 45 and 60 minutes. 
Questionnaires
A general questionnaire assessed caregivers’ and patients’ demographic 
characteristics, including gender, age, nationality, education and employment. 
Caregiver burden
Caregivers' burden was assessed by the Self-Perceived Pressure from Informal Care 
questionnaire (SPPIC), which is a Dutch, validated questionnaire [8]. It measures how 
personal interests (i.e. possibility to have own thoughts, activities and/or other roles 
they want to fulfil in life) interfere with the pressure they perceive as a consequence 
of giving care to a significant other. Examples of questions are “As a consequence 
of the situation of my significant other, less time is available managing my personal 
life” and “Combining the responsibility for my significant other and my family and 
work is challenging”. It consists of nine items and is scored on a 5-point Rasch 
scale. According to the manual of the questionnaire, the scores are dichotomized 
to 0 (“no!” and “no”) and 1 (“yes!”, “yes” and “more or less”), and scores range from 0 
to 9. Higher scores indicate higher levels of caregivers’ burden. Total scores on the 
scale were defined as low (0-3), moderate (4-6) and high levels of burden (7-9) [12]. 
The internal consistency of the questionnaire in this sample was sufficient (α=0.74).
Patient psychological distress and quality of life 
Patients completed The Hospital Anxiety and Depression Scale (HADS) [25], which 
is a 14-item self-assessment questionnaire to assess psychological distress. Each 
item is rated on a scale from 0 (not at all) to 3 (very much). Total scores range 
between 0 and 42, with higher scores indicating higher distress. A cutoff score of 
11 was used for detecting manifest distress [26]. The scale has been translated and 
validated in the Dutch general population and showed a good internal consistency 
(α=0.82 – 0.90) [27]. 
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The EORTC QLQ-C30 (version 3.0) is a well-validated questionnaire to assess 
HRQoL.[28] It consists of five functional scales (physical, role, emotional, cognitive 
and social functioning), three symptom scales (fatigue, pain, nausea), six single 
item scales (dyspnoea, sleep disturbance, appetite loss, constipation, diarrhoea, 
financial impact) and the global HRQoL scale. Final scores range between 0 and 
100. Higher scores of the functional scales representing better functioning and 
higher levels of the symptoms scales representing more symptoms. The internal 
consistency of this questionnaire is good (α=0.84) [28]. We decided to only use 
the global HRQoL scale in our exploratory analyses, as this variable gives a 
more overall view of the well-being while treated with chemoradiotherapy. An 
increase or decrease of 10 points or more on the subscale global HRQoL is 
regarded as a clinically relevant change [29]. Additionally, the EORTC QoLQ-
H&N35 (head and neck module) which assesses treatment-related symptoms; 
six symptom scales (pain, swallowing, senses, speech, social eating, social 
contact, sexuality), six symptom items (problems with teeth, problems with 
opening mouth, sticky saliva, coughing, feeling ill), five additional items (pain 
medication use, nutritional supplement use, feeding tube, changes in body 
weight). Higher scores indicate more symptoms. The internal consistency of the 
subscales is good (α=0.72 – 0.95) [28].
Caregiver and patient fatigue
For caregivers and patients, the severity of fatigue was assessed by the validated 
subscale fatigue severity of the Checklist Individual Strength (CIS). The 8-item 
subscale is scored on a 7-point Likert scale. The final score ranges from 8 to 56. 
Higher scores indicating more fatigue [30]. A cutoff score of 35 and higher was used 
to indicate severe fatigue. This cutoff score was validated in healthy subjects in 
the general population and patients with chronic fatigue [31]. The cutoff was used 
in different studies with patients in different phases of treatment for cancer and 
caregivers, and shows that the scale is sensitive to change in levels of fatigue over 
time [32-34]. The internal consistency of the subscale is good (α=0.88) [30].
Statistical analyses
Analyses were performed using Statistical Package for the Social Sciences software 
version 20 (SPSS Inc. Chicago, IL, USA). When the data of the patient and/or the 
caregiver were incomplete at any time point, the dyad was excluded for analyses. 
For sample characteristics, descriptive statistics were used. For continuous variables 
Student’s t-tests (equal distribution expected between groups) or the Mann-
Whitney U test (equal distribution unlikely) were used. For categorical variables, 
Chi-square tests or Fisher's exact test were performed. Characteristics of dyads 
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who dropped out during the study were compared with the dyads who completed 
all the measurements. This was performed for age, gender, marital status, level of 
education, patients’ and caregivers’ baseline fatigue, caregivers’ baseline burden 
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Figure 1. Research model for predicting factors contributing to burden and fatigue of informal 
caregivers after patients’ chemoradiotherapy
For our first exploratory aim, general linear model repeated measure analysis 
was performed to determine caregivers’ course of burden, using mean SPPIC 
scores on all measurement time points (T0, T1 and T2). For determining caregivers’ 
and patients’ course of fatigue, mean fatigue severity scores on all measurement 
time points (T0, T1 and T2) were used. Additionally, the same analyses were 
performed to determine caregivers’ fatigue in relation to patients’ fatigue, using 
mean scores on all the measurement time points (T0, T1 and T2). To explore the 
association between patients’ distress and caregivers’ burden and distress, Pearson 
correlations were performed. For our second exploratory aim, we designed an 
exploratory model, which is shown in Figure 1. Linear regression analyses (enter 
method) were conducted based on the exploratory model. Fatigue and burden on 
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T2 were used as dependent variables. Independent variables were age, gender, 
relation to the patient, patients’ HRQoL on T1, patients’ difference in HRQoL 
between T1 and T0, caregivers’ baseline burden and caregivers’ baseline fatigue. 
The adjusted R2 and Beta weights were used for interpretation of the model. The 
assumptions of linearity, constant error variance and normality were determined 
performing residual analysis. Statistical significance was determined based on a 
two-sided alpha of 0.05.
RESULTS
Caregivers’ and patients’ baseline characteristics
In total, 68 patients were eligible. Eight dyads decided not to participate. Reasons 
not to participate were that participating was perceived too burdensome (n=4), 
patient had caregivers, but no principal one (n=2), dyad was not recruited by 
accident (n=1) or reasons were unclear (n=1). After inclusion, three dyads withdrew 
from participation for unclear reasons and one patient passed away. The mean 
recruitment rate was three dyads every month. For analyses, complete data of 
56 dyads was available for T0, 49 dyads for T1 (withdrew n=3; incomplete data 
n=1; patient deceased n=1, recurrent disease n=1, reason unclear n=1), and 45 
dyads for T2 (recurrent disease n=2, logistic mistake (n=1), incomplete data n=1). 
Baseline characteristics are given in Table 1. For age, gender, marital status, level 
of education and baseline fatigue, no significant differences were found between 
caregivers who dropped out (n=11) and those who completed all assessments at all 
time points (n=45), except for baseline burden, which was significantly lower in the 
group who dropped out (mean rank 16.6) compared to the group who completed 
all measurements (mean rank 31.4; p=0.006). Patients who dropped out (n=11) 
showed no significant differences compared to the patients who completed all 
measurements (n=45), except for baseline HRQoL, which was significantly higher in 
the group of patients who dropped out (mean rank 37.6) compared to the patients 
who completed all measurements (mean rank 25.5; p=0.03). At T0, patients’ health-
related functioning was significantly better and disease-related symptoms were 
significantly less when compared with data of the EORTC manual reference values 
(stage III/IV head and neck cancer) [35]. Details are outlined in Table 2.
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Table 1. Sample characteristics 
Characteristics   Caregiver, n (%) Patient, n (%)
Participants   56 56
Gender Female, n (%) 42 (75) 19 (34)
  Male, n (%) 14 (25) 37 (66)
Median age, years (ICR)   58 (44-64) 58 (53-63)
Education level (ISCED) Lower education ≤ 4, n (%) 44 (80) 43 (78)
  Higher education > 4, n (%) 11 (20) 12 (22)
Relation to patient Partner, n (%) 39 (70) -
  Parent, n (%) 5 (9) -
  Child, n (%) 7 (13) -
  Friend, n (%) 3 (5) -
  Other, n (%) 2 (4) -
Employment status Employed (paid), n (%) 32 (58) 26 (47)
Unemployed, n (%) 0 (0) 7 (13)
  Housekeeper, n (%) 12 (22) 8 (14.5)
  Disablement insurance act, n (%) 2 (4) 6 (11)
  Retired, n (%) 9 (16) 8 (14.5)
Duration of treatment Weeks, median (IQR) - 5.5 (5–6)
Chemoradiotherapy (CRT) Postoperative CRT (%) - 42.9
Primary CRT (%) - 57.1
HPV status Positive, n (%) - 5 (8.9)
ISCED = International Standard Classification of Education 2011; ≤ 4: secondary, non-tertiary 
education level, > 4: tertiary education level (bachelor, master or doctoral level); HPV = human 
papilloma virus
Caregivers’ course of burden and fatigue and patients’ course of fatigue, distress 
and HRQoL 
Caregivers’ mean scores on burden and the distribution of the level of burden are 
given in Table 3. Caregivers’ mean scores of burden changed significantly over time 
(p=0.006), and showed a peak at T1. At T2 after chemoradiotherapy, burden was 
significantly lower when compared to burden at T0 and T1 (p=0.024 and p=0.001, 
respectively). Caregivers’ mean scores on fatigue and the proportion of severely 




Table 2. EORTC mean scores of sample, compared to reference data [35]
QLQ-C30 Reference data (n=1722); head and 





Global health-related QoL 63.1 (22.4) 73.3 (19.7) <0.001a
Physical functioning 81.2 (20.2) 87.0 (14.0) 0.004a
Role functioning 78.8 (27.9) 72.2 (29.8) 0.111
Emotional functioning 71.2 (24.1) 78.2 (17.5) 0.005a
Cognitive functioning 86.4 (19.1) 89.8 (19.3) 0.198
Social functioning 82.2 (24.7) 77.8 (25.5) 0.208
Fatigue 27.6 (25) 21.8 (20.2) 0.04a
Nausea and vomiting 5.2 (13.3) 1.9 (7.0) 0.001a
Pain 24.9 (26.3) 21.6 (26.4) 0.364
Dyspnoea 18.0 (26.6) 6.9 (16.5) <0.001a
Insomnia 28.5 (32.4) 26.5 (29.2) 0.625
Appetite loss 19.4 (29.3) 8.6 (20.7) <0.001a
Constipation 11.7 (23.2) 8.0 (18.2) 0.145
Diarrhoea 6.1 (16.7) 4.3 (13.0) 0.32
Financial difficulties 18.8 (30.2) 13.2 (13.0) 0.106
QLQ-HN-35      
Pain 29.9 (25.1) 21.3 (19.1) 0.002a
Swallowing 27.5 (26.1) 17.8 (23.8) 0.005a
Senses 20.0 (30.0) 9.8 (17.1) <0.001a
Speech 27.1 (27.2) 16.9 (19.7) <0.001a
Social eating 23.9 (26.7) 13.0 (14.4) <0.001a
Social contact 13.2 (19.1) 7.7 (13.0) 0.004a
Sexuality 32.3 (36.1) 28.1 (21.8) 0.31
Teeth 27.8 (35.0) 10.2 (21.7) <0.001a
Opening mouth 22.4 (31.9) 30.1 (33.2) 0.099
Dry mouth 31.1 (34.2) 19.2 (23.2) 0.001a
Sticky saliva 32.4 (35.4) 20.9 (24.0) 0.001a
Coughing 34.9 (32.1) 17.7 (26.1) <0.001a
Felt ill 21.7 (29.2) 10.3 (19.3) <0.001a
Pain killers 52.8 (49.9) 61.5 (49.1) 0.205
Nutritional supplements 27.0 (44.4) 28.9 (45.7) 0.772
Feeding tube 18.3 (38.7) 7.6 (26.7) 0.005a
Weight loss 41.3 (49.2) 34.6 (48.0) 0.32
Weight gain 25.9 (43.8) 36.5 (48.6) 0.121
a Statistically significant difference
Informal caregivers’ burden and fatigue during patients’ treatment for LAHNC
39
2
Table 3. Mean scores for caregivers’ burden and fatigue and distribution on individual level 
(> cutoff)
Time point T0 (n=56) T1 (n=47) T2 (n=45) 
Mean scores (SD)      
Fatigue 24.3 (13) 27.5 (12.4) 22.4 (11.8)
Burden 4.1 (2.4) 4.6 (2.4) 3.2 (2.4)
Score > cutoff n (%)      
Fatigue 10 (19) 14 (30) 9 (21) 
Burden 
Low 30 (53.6) 20 (42.6) 30 (66.7)
Moderate 20 (35.7) 17 (63.2) 10 (22.2)
High 6 (10.7) 10 (21.3) 5 (11.1) 
There was no statistically significant difference for caregiver found between groups 
for HPV positivity on all three time points for burden (T0: mean rank 40.6 versus 
27.3, p=0.079; T1: mean rank 27.2 versus 23.6, p=0.578; T2: mean rank 32.2 versus 21.9, 
p=0.093) and fatigue (T0: mean rank 35.3 versus 26.7, p=0.243; T1: mean rank 26.2 
versus 23.7, p=0.704; T2: mean rank 29.7 versus 20.9, p=0.144). 
Patients’ mean scores on fatigue, distress and global health are shown in Table 
4. Patients’ fatigue increased significantly from T0 to T1 (p<0.001), and decreased 
significantly from T1 to T2 (p<0.001). Patients’ levels of fatigue were significantly 
higher at T2 compared to T0 (p=0.026). Patients’ distress changed over time 
(p=0.012), and showed a peak at T1. Distress increased between T0 and T1 (p=0.02), 
and decreased again between T1 and T2 (p=0.03), down to baseline levels. There 
was no difference in distress at T0 and T2. Patients’ HRQoL decreased from T0 to T1 
(p<0.001), and recovered from T1 to T2 (p<0.001), up to baseline levels. Moreover, a 
clinically relevant decrease in HRQoL was observed from T0 to T1 (>10 points; from 
73.3 to 54.3; range 0-100), and this was restored from T1 to T2 (> 10 points; from 54.3 
to 72.0; range 0-100). 
Comparing the course of caregivers’ fatigue to patients’ fatigue, patients were 
significantly more fatigued than their caregivers (F[1,81] = 5.245, p=0.025). Fatigue 
peaked for both patients and caregivers at T1 (F[1,81] = 39.153, p<0.001). Patients’ 




Table 4. Mean scores of patients’ fatigue, distress and HRQoL and proportion of patients’ 
fatigue severity and distress. 
Time point T0 (n=56) T1 (n=47) T2 (n=45)
Mean scores (SD)
Fatigue 23.7 (12.1) 37.8 (12.7) 28.1 (12.7)
Distress 10.4 (7.3) 13.2 (9.0) 10.7 (6.8)
Global health 73.3 (19.7) 54.3 (25.0) 72.0 (15.7)
Score > cutoff n (%)
Fatigue 9 (16) 31 (65) 14 (33)
Distress 25 (46) 26 (54) 25 (56)
Correlations
At baseline, caregivers’ burden was significantly correlated to patients’ fatigue, distress 
and HRQoL (r=0.28, p=0.04 and r=0.32, p=0.02 and r=-0.331, p=0.02, respectively). At T1, 
caregivers’ burden was significantly correlated to patients’ distress and HRQoL (r=0.47, 
p=0.001 and r=-0.44, p=0.002). At T2, burden was significantly correlated to patients’ 
distress and HRQoL at T2 (r=0.411, p=0.005 and r=-0.413, p=0.005). 
At baseline, caregivers’ fatigue was significantly correlated to patients fatigue 
at T0 (r=0.31, p=0.03). Patients’ fatigue at T0 was significantly correlated to distress 
and HRQoL at T0 (r=0.452, p=0.001 and r=-0.657, p < 0.001, respectively), T1 (r=0.623, 
p<0.001 and r=-0.723, p<0.001, respectively) and T2 (r=0.314, p=0.04 and r=-0.616, 
p<0.001, respectively).
Patients’ distress was significantly correlated to their HRQoL at T0, T1 and T2 
(r=-0.564, p<0.001, r=-0.725, p<0.001 and r=-0.508, p<0.001, respectively). Caregivers’ 
fatigue on T0, T1 and T2 was significantly correlated at all time points (r=0.43, p=0.001, 
r=0.51, p<0.001 and r=0.54, p<0.001, respectively). 
Exploration of risk factors for burden and fatigue after chemoradiotherapy
Table 5 shows the results of the regression analysis. Twenty-seven percent of the 
variance in scores for burden on T2 could be explained by the independent variables. 
There was no significant attribution of one individual independent variable. However, 
all seven variables together, i.e. younger age, spousal and female caregivers, higher 
levels of fatigue and burden on baseline within caregiver and greater difference in 
decline in HRQoL within the patient, were found to contribute significantly (p=0.012). 
Burden and fatigue at baseline contributed most to burden three months after 
chemoradiotherapy (13% of the 27%), followed by gender, patients’ global HRQoL 
at T1, and relation to the patient. Age and the change in global HRQoL between T1 
and T0 contributed less. 
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Thirty-four percent of the variance in fatigue scores was explained by the 
independent variables. Caregivers’ fatigue at baseline contributed significantly 
to caregivers’ fatigue on T2 (p<0.01). Caregivers’ care-related characteristics (i.e. 
burden and fatigue) at baseline contributed most to the explained variance of 
fatigue scores three months after chemoradiotherapy (29% of 34%). 
Table 5. Determinants of burden and fatigue among caregiver of patients with LAHNC, 3 
months after completing chemoradiotherapy; final ß weight and adjusted R2 (n=41)
Caregiver characteristics Burden Fatigue
Gender (male=0; female=1) 0.234 0.067
Age 0.059 0.065
Relation to patient (non-spouse=0; spouse=1) 0.218 -0.023
Adjusted R2 0.08 0.01
Patient characteristics - treatment related
EORTC GH T1 -0.222 0.023
EORTC GH T1-T0 0.058 0.25
∆Adjusted R2 0.06 0.04
Caregiver care-related characteristics
Baseline burden 0.267 -0.009
Baseline fatigue 0.262 0.609a
∆ Adjusted R2 0.13 0.29
Total R2 27% 34%
a p<0.01
DISCUSSION
This prospective, observational pilot study of patients with LAHNC and their 
caregivers is one of the few studies to focus on the course of burden and fatigue 
of caregivers in relation to patients fatigue, distress and global HRQoL. It contributes 
to the existing knowledge about risk factors for burden and fatigue in caregivers of 
patients short after patients’ end of treatment with chemoradiotherapy. 
This study adds valuable knowledge for the identification of caregivers at 
risk for burden when patients have finished chemoradiotherapy. Female spouses 
with higher baseline levels of burden and fatigue, and caring for patients with 
lower levels of global HRQoL seem at higher risk for burden after end of the 
intensive treatment of chemoradiotherapy. Adelman and colleagues describe 
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risk factors for caregiver burden, which resemble our findings, such as female 
sex and cohabitation with the care recipient [11]. They describe caregivers who 
suffer from sleep deprivation are at higher risk, which seems to be in line with 
our finding that caregivers’ baseline fatigue contribute to higher levels of burden 
after end of chemoradiotherapy. Longacre and colleagues describe in a review 
the psychological health of caregivers of patients with head and neck cancer [15]. 
They do not find a consistency on the caregivers' risk on higher levels of burden 
in relation to the female gender. The need for psychological help, however, is 
higher among women. Furthermore, they found a relation between treatment-
related factors and caregiver burden. No association was found between 
caregiver distress and patient type of treatment and their functional impairment. 
They conclude that often no consistency is found in factors contributing to 
poorer mental health among caregivers, which could be a consequence of 
different methodology (small sample sizes and lack of longitudinal study design) 
and terminology (the definition of caregivers, for example). 
This study adds valuable knowledge to the literature about the course of 
caregiver burden. The available data of caregivers’ course of burden during 
and after treatment is limited and mostly regarding caregivers’ burden during 
treatment. Nightingale and colleagues reported an increase in burden during 
radio- and/or chemotherapy, which remained high up to end of treatment 
[36]. Badr and colleagues reported constant levels of burden, up to 6 weeks 
after initiating treatment (radiotherapy alone, and / or in combination with 
prior surgery and / or chemotherapy) [6]. A recent pilot study of Nightingale 
and colleagues showed that caregivers of patients receiving radiotherapy, 
reported higher levels of burden during and one month after ending therapy 
[37]. Our study showed an increase in burden one week after chemoradiotherapy 
and a decrease to baseline levels three months after chemoradiotherapy. In 
order to prevent this rise in caregiver burden and the risk for burden after 
treatment, support for caregivers at risk for burden may be focused at the start 
of patient’s treatment. Higher levels of burden and fatigue of the caregiver at 
the start of patients’ treatment seem to contribute most to their burden after 
chemoradiotherapy. Based on this study, no conclusions can be drawn about 
determinants of baseline burden and fatigue and what kind of support for 
caregivers is needed. This should be determined with future research. 
A main risk factor for caregivers’ severe fatigue after patients finish 
chemoradiation is baseline fatigue. Fatigue is considered an important 
determinant for general health and levels of fatigue were higher among caregivers 
when compared to the general working population [38,39]. Additionally, fatigue 
severity was in the range of caregivers of patients in the palliative phase [33]. 
Informal caregivers’ burden and fatigue during patients’ treatment for LAHNC
43
2
One could imagine that the intensive treatment with chemoradiotherapy, with 
daily visits to the hospital, and the impact of treatment-related side effects and 
their specific care demands may play an important role in caregivers’ fatigue. 
Caregivers have to combine support for the patient with their own personal life. 
In this study, more than half of the caregivers combine their role as caregiver 
with work. It is known that being employed while caring for a significant other is 
challenging and can negatively influence caregivers’ well-being, especially when 
caring demands flexibility while the caregivers’ work demands otherwise [40]. 
Caregivers’ fatigue, where a peak was found one week after chemoradiotherapy, 
is different from the constant levels reported by caregivers of patients in the 
palliative phase [33]. In order to support caregivers of patient with LAHNC coping 
with their own fatigue, it is important to know what causes fatigue before starting 
treatment. Our study shows that fatigue at baseline could be associated with 
patients’ fatigue, distress and HRQoL. However, it remains unclear whether this 
causes caregivers’ fatigue and therefore could be a focus for future research. 
Although this study adds valuable knowledge, limitations should be 
considered. The predefined model for these exploratory analyses, based on 
clinical observations and supported by theory, contained a large number of 
predictors in a small sample size. Nevertheless, the exploratory model offers a 
direction for future studies with a larger sample size to identify caregivers at risk 
for burden and fatigue [41]. Furthermore, we may question the generalizability of 
our study for other LAHNC patients and their caregivers. Since the sample size is 
small, it is possible that our findings are too optimistic; the HRQoL of our sample 
in comparison to the reference group was significantly better at baseline. A 
possible explanation could be that the reference group represents stadium III 
and IV head and neck cancer patients, whereas our study only included patients 
with LAHNC without metastases (i.e. stages III, IVa, IVb). On the other hand, it is 
possible that our findings are more pessimistic; caregivers with lower levels of 
burden and patients with higher levels of HRQoL dropped out. An explanation for 
the latter could be that the caregivers with lower levels of burden and patients 
with higher levels of HRQoL, decided to withdraw from the study since they 
could not identify themselves with the purpose of the study. 
In conclusion, burden of caregivers of LAHNC patients receiving 
chemoradiotherapy is determined by multiple variables and follows patients’ 
peak in distress, fatigue and diminished HRQoL. Female, spousal caregivers 
who are burdened and fatigued at baseline are important to identify before 
a patient starts treatment in order to prevent burden after patients’ ending 
of chemoradiotherapy. Where burden seems to be determined by multiple 
aspects, caregivers’ fatigue after patients’ curative treatment for LAHNC seems 
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predominantly caused by caregivers’ fatigue at baseline. Fatigue is an important 
problem to identify, since it is an important determinant of a person’s general 
health and ability to participate in society. Lastly, problems as a consequence 
of patients’ treatment for LAHNC are likely to influence both the well-being of 
caregivers and patients. Therefore, it seems justified to involve both patients and 
caregivers when designing interventions addressing aforementioned issues. 




1. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, 
Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human 
papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363 (1):24-35. 
doi:10.1056/NEJMoa0912217
2. Argiris A, Karamouzis MV, Raben D, Ferris RL (2008) Head and neck cancer. Lancet 371 
(9625):1695-1709. doi:10.1016/S0140-6736(08)60728-X
3. Bottomley A, Tridello G, Coens C, Rolland F, Tesselaar ME, Leemans CR, Hupperets P, Licitra 
L, Vermorken JB, Van Den Weyngaert D, Truc G, Barillot I, Lefebvre JL (2014) An international 
phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on 
behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group. Cancer 120 
(3):390-398. doi:10.1002/cncr.28392
4. Verdonck-de Leeuw IM, Eerenstein SE, Van der Linden MH, Kuik DJ, de Bree R, Leemans 
CR (2007) Distress in spouses and patients after treatment for head and neck cancer. The 
Laryngoscope 117 (2):238-241. doi:10.1097/01.mlg.0000250169.10241.58
5. Lydiatt WM, Moran J, Burke WJ (2009) A review of depression in the head and neck cancer 
patient. Clinical advances in hematology & oncology : H&O 7 (6):397-403
6. Badr H, Gupta V, Sikora A, Posner M (2014) Psychological distress in patients and caregivers 
over the course of radiotherapy for head and neck cancer. Oral oncology 50 (10):1005-1011. 
doi:10.1016/j.oraloncology.2014.07.003
7. Folkman S, Lazarus RS, Dunkel-Schetter C, DeLongis A, Gruen RJ (1986) Dynamics of a 
stressful encounter: cognitive appraisal, coping, and encounter outcomes. J Pers Soc Psychol 
50 (5):992-1003
8. Pot AM, van Dyck R, Deeg DJ (1995) [Perceived stress caused by informal caregiving. 
Construction of a scale]. Tijdschrift voor gerontologie en geriatrie 26 (5):214-219
9. Nijboer C, Triemstra M, Tempelaar R, Sanderman R, van den Bos GA (1999) Determinants of 
caregiving experiences and mental health of partners of cancer patients. Cancer 86 (4):577-588
10. Zarit SH, Todd PA, Zarit JM (1986) Subjective burden of husbands and wives as caregivers: a 
longitudinal study. The Gerontologist 26 (3):260-266
11. Adelman RD, Tmanova LL, Delgado D, Dion S, Lachs MS (2014) Caregiver burden: a clinical 
review. JAMA : the journal of the American Medical Association 311 (10):1052-1060. doi:10.1001/
jama.2014.304
12. Haj Mohammad N, Walter AW, van Oijen MG, Hulshof MC, Bergman JJ, Anderegg MC, van 
Berge Henegouwen MI, Henselmans I, Sprangers MA, van Laarhoven HW (2015) Burden of 
spousal caregivers of stage II and III esophageal cancer survivors 3 years after treatment with 
curative intent. Supportive care in cancer: official journal of the Multinational Association of 
Supportive Care in Cancer 23 (12):3589-3598. doi:10.1007/s00520-015-2727-4
13. Vickery LE, Latchford G, Hewison J, Bellew M, Feber T (2003) The impact of head and neck 
cancer and facial disfigurement on the quality of life of patients and their partners. Head & 
neck 25 (4):289-296. doi:10.1002/hed.10206
14. Ostroff J, Ross S, Steinglass P, Ronis-Tobin V, Singh B (2004) Interest in and barriers to 
participation in multiple family groups among head and neck cancer survivors and their 
primary family caregivers. Family process 43 (2):195-208
Chapter 2
46
15. Longacre ML, Ridge JA, Burtness BA, Galloway TJ, Fang CY (2012) Psychological functioning 
of caregivers for head and neck cancer patients. Oral oncology 48 (1):18-25. doi:10.1016/j.
oraloncology.2011.11.012
16. Stenberg U, Ruland CM, Miaskowski C (2010) Review of the literature on the effects of caring 
for a patient with cancer. Psycho-oncology 19 (10):1013-1025. doi:10.1002/pon.1670
17. Baghi M, Wagenblast J, Hambek M, Radeloff A, Gstoettner W, Scherzed A, Spaenkuch B, Yuan 
J, Hornung S, Strebhardt K, Knecht R (2007) Demands on caring relatives of head and neck 
cancer patients. The Laryngoscope 117 (4):712-716. doi:10.1097/mlg.0b013e318031d0b4
18. Romito F, Goldzweig G, Cormio C, Hagedoorn M, Andersen BL (2013) Informal caregiving for 
cancer patients. Cancer 119 Suppl 11:2160-2169. doi:10.1002/cncr.28057
19. Blood GW, Simpson KC, Dineen M, Kauffman SM, Raimondi SC (1994) Spouses of individuals 
with laryngeal cancer: caregiver strain and burden. Journal of communication disorders 27 
(1):19-35
20. Nijboer C, Tempelaar R, Sanderman R, Triemstra M, Spruijt RJ, van den Bos GA (1998) Cancer 
and caregiving: the impact on the caregiver’s health. Psycho-oncology 7 (1):3-13. doi:10.1002/
(SICI)1099-1611(199801/02)7:1<3::AID-PON320>3.0.CO;2-5
21. Kim Y, Given BA (2008) Quality of life of family caregivers of cancer survivors: across the 
trajectory of the illness. Cancer 112 (11 Suppl):2556-2568. doi:10.1002/cncr.23449
22. Northouse LL, Mood D, Templin T, Mellon S, George T (2000) Couples’ patterns of adjustment 
to colon cancer. Social science & medicine 50 (2):271-284
23. Kim Y, van Ryn M, Jensen RE, Griffin JM, Potosky A, Rowland J (2014) Effects of gender and 
depressive symptoms on quality of life among colorectal and lung cancer patients and their 
family caregivers. Psycho-oncology. doi:10.1002/pon.3580
24. Patterson JM, Rapley T, Carding PN, Wilson JA, McColl E (2013) Head and neck cancer and 
dysphagia; caring for carers. Psycho-oncology 22 (8):1815-1820. doi:10.1002/pon.3226
25. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta psychiatrica 
Scandinavica 67 (6):361-370
26. Vodermaier A, Millman RD (2011) Accuracy of the Hospital Anxiety and Depression Scale as 
a screening tool in cancer patients: a systematic review and meta-analysis. Supportive care 
in cancer : official journal of the Multinational Association of Supportive Care in Cancer 19 
(12):1899-1908. doi:10.1007/s00520-011-1251-4
27. Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM (1997) A 
validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of 
Dutch subjects. Psychological medicine 27 (2):363-370
28. Bjordal K, de Graeff A, Fayers PM, Hammerlid E, van Pottelsberghe C, Curran D, Ahlner-Elmqvist 
M, Maher EJ, Meyza JW, Bredart A, Soderholm AL, Arraras JJ, Feine JS, Abendstein H, Morton 
RP, Pignon T, Huguenin P, Bottomly A, Kaasa S (2000) A 12 country field study of the EORTC 
QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in 
head and neck patients. EORTC Quality of Life Group. European journal of cancer 36 (14):1796-
1807
29. Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes 
in health-related quality-of-life scores. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 16 (1):139-144
30. Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G (1994) 
Dimensional assessment of chronic fatigue syndrome. Journal of psychosomatic research 38 
(5):383-392
Informal caregivers’ burden and fatigue during patients’ treatment for LAHNC
47
2
31. Worm-Smeitink M, Gielissen M, Bloot L, van Laarhoven HWM, van Engelen BGM, van Riel P, 
Bleijenberg G, Nikolaus S, Knoop H (2017) The assessment of fatigue: Psychometric qualities 
and norms for the Checklist individual strength. Journal of psychosomatic research 98:40-46. 
doi:10.1016/j.jpsychores.2017.05.007
32. Goedendorp MM, Gielissen MF, Verhagen CA, Bleijenberg G (2013) Development of fatigue in 
cancer survivors: a prospective follow-up study from diagnosis into the year after treatment. 
J Pain Symptom Manage 45 (2):213-222. doi:10.1016/j.jpainsymman.2012.02.009
33. Peters ME, Goedendorp MM, Verhagen SA, Smilde TJ, Bleijenberg G, van der Graaf WT (2014) 
A prospective analysis on fatigue and experienced burden in informal caregivers of cancer 
patients during cancer treatment in the palliative phase. Acta oncologica:1-7. doi:10.3109/028
4186X.2014.953254
34. Prinsen H, van Dijk JP, Zwarts MJ, Leer JW, Bleijenberg G, van Laarhoven HW (2015) The role 
of central and peripheral muscle fatigue in postcancer fatigue: a randomized controlled trial. 
J Pain Symptom Manage 49 (2):173-182. doi:10.1016/j.jpainsymman.2014.06.020
35. Scott NW FP, Bottomley A (2008) EORTC QLQ-C30 Reference Values Manual. EORTC Quality 
of Life Group publications: Brussels, Belgium. . 
36. Nightingale CL, Lagorio L, Carnaby G (2014) A prospective pilot study of psychosocial 
functioning in head and neck cancer patient-caregiver dyads. J Psychosoc Oncol 32 (5):477-
492. doi:10.1080/07347332.2014.936649
37. Nightingale CL, Curbow BA, Wingard JR, Pereira DB, Carnaby GD (2016) Burden, quality of 
life, and social support in caregivers of patients undergoing radiotherapy for head and neck 
cancer: A pilot study. Chronic illness 12 (3):236-245. doi:10.1177/1742395316644305
38. Northouse L, Williams AL, Given B, McCorkle R (2012) Psychosocial care for family caregivers 
of patients with cancer. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology 30 (11):1227-1234. doi:10.1200/JCO.2011.39.5798
39. Beurskens AJ, Bultmann U, Kant I, Vercoulen JH, Bleijenberg G, Swaen GM (2000) Fatigue 
among working people: validity of a questionnaire measure. Occupational and environmental 
medicine 57 (5):353-357
40. Swanberg JE (2006) Making it work: informal caregiving, cancer, and employment. J Psychosoc 
Oncol 24 (3):1-18. doi:10.1300/J077v24n03_01
41. Ogundimu EO, Altman DG, Collins GS (2016) Adequate sample size for developing prediction 




Informal caregiver well-being during and 
after patients’ treatment with adjuvant 
chemotherapy for colon cancer:
a prospective, exploratory study 
Simone  M.C.H. Langenberg , Hanneke  Poort , Anke  N.M. Wymenga , 
Jan Willem de  Groot , Erik  W. Muller, Winette  T.A. van  der Graaf, 
Judith  B. Prins, Carla  M.L. van  Herpen
Supportive  Care  in  Cancer (2020) 29 (5): 2481-2491
ABSTRACT
Introduction: Caring for a significant other during cancer treatment can be 
demanding. Little is known about the well-being of informal caregivers of patients 
with colon cancer. This study aims to examine informal caregiver well-being during 
adjuvant chemotherapy for colon cancer.
Material and methods: This exploratory longitudinal, prospective study measured 
the course of informal caregiver burden (Self-Perceived Pressure of Informal Care), 
distress (Hospital Anxiety and Depression Scale), health-related quality of life 
(RAND-36), marital satisfaction (Maudsley Marital Questionnaire), social support 
(Social Support List – Discrepancies), fatigue (Abbreviated Fatigue Questionnaire), 
and self-esteem (Caregiver Reaction Assessment) before (T0), during (T1), and after 
(T2) patients’ treatment.
Results: Baseline data of 60 out of 76 eligible dyads (79%) were analysed. Mean 
levels of informal caregiver burden and distress improved significantly over time, 
as did their health-related quality of life and perceived social support. At baseline, 
30% and 26.7% of informal caregivers reported moderate-to-high levels of burden 
and clinically relevant levels of distress, respectively, which changed to 20% and 
18.8% at T2. Informal caregiver burden and distress at baseline were the strongest 
predictors of informal caregiver burden and distress during and following patients’ 
treatment, respectively. 
Conclusion: When informal caregivers and patients experience problems before 
start of adjuvant chemotherapy, problems seem to improve over time. Approximately 
20% of informal caregivers remain burdened and distressed after patients’ end of 
treatment. Paying attention to baseline distress and burden seems indicated, as 
these were strong predictors of informal caregivers’ wellbeing during and after 
treatment.




Colon cancer is a common cancer among men and women [1]. In 2018, colon cancer 
accounted for 6% of all new cancer cases and 551,269 people died as a consequence 
of colon cancer worldwide [1]. In 2018, 9555 people were newly diagnosed with colon 
cancer in The Netherlands [2]. After diagnosis and staging, treatment plans are made 
according to (inter)national guidelines. When a patient is diagnosed with high-risk 
stage II or III colon cancer, surgical resection alone results in a 5-year survival rate of 
60–80% for stage II and 30–60% for stage III disease [3]. To further improve survival, 
patients receive adjuvant chemotherapy containing fluoropyrimidines and oxaliplatin 
(i.e., 5FU/leucovorin with oxaliplatin (FOLFOX) or capecitabine with oxaliplatin 
(CAPOX)), or capecitabine monotherapy when oxaliplatin is contra-indicated [4, 5]. 
Common side effects of this regimen are nausea, vomiting, hand-foot syndrome, and 
sensory, peripheral neuropathy. Being diagnosed with cancer and receiving cancer 
treatment impact the patient and can cause psychological distress [6]. 
After a cancer diagnosis and during cancer treatment, support by a significant 
other is indispensable. Informal caregivers support patients both practically 
and emotionally [6, 7]. These tasks can cause burden and distress, which may 
impact an informal caregiver’s ability to support the patient during treatment [8, 
9]. Informal caregiver burden can be experienced on several dimensions and be 
related to emotional, social, physical, spiritual functioning, and/or practical and 
financial problems [7]. The National Cancer Institute defined distress as “emotional, 
social, spiritual or physical pain or suffering that may cause a person to feel sad, 
afraid, depressed, anxious or lonely” [10]. Previous studies identified burden 
and distress as important problems for informal caregivers [6, 9]. Patients and 
informal caregivers cope with cancer as a dyad and informal caregivers’ distress 
may sometimes exceed patients’ distress [11, 12]. Informal caregiver burden and 
distress are interrelated and share risk factors, such as female gender, younger 
age, and perceived patient distress [7, 9]. Importantly, informal caregiver burden and 
distress may also negatively influence the informal caregivers’ physical health and 
social functioning [6–9]. Little is known about the course of well-being of informal 
caregivers of patients treated with adjuvant chemotherapy for colon cancer. 
This prospective, observational study had four exploratory aims. First, we aimed 
to examine the course of informal caregiver well-being. Second, we intended to 
explore the clinically relevant levels of informal caregiver burden and distress. Third, 
we aimed to identify baseline risk factors for higher informal caregiver burden and 
distress during and after a patient’s treatment. Fourth, we explored the association 
between informal caregiver burden and distress and patient distress before, during, 





We conducted a prospective, observational study between October 2013 and 
September 2017 in four hospitals in The Netherlands. We recruited patients 
aged 18 or older, proficient in Dutch, who were scheduled to receive adjuvant 
chemotherapy (CAPOX or capecitabine monotherapy) after surgery for colon 
cancer, and their informal caregivers, for participation in this study. 
Procedure
The attending physician or the nurse practitioner approached the patient and 
their informal caregiver for study participation after informing them about 
starting adjuvant chemotherapy. Written informed consents were obtained from 
both patient and informal caregiver. The study included completion of paper-
and-pencil questionnaires at home at three time points: (1) baseline, before 
starting adjuvant chemotherapy (T0), (2) between the second and third cycle (T1), 
and (3) 3 months after ending adjuvant chemotherapy (T2). We asked patients 
and informal caregivers to complete questionnaires separately. The study was 
approved by the local medical ethics committee of the Radboud university 
medical center (registration number 2013/393).
Measures
Sociodemographic and clinical factors
Patients and informal caregivers self-reported their age, sex, level of education 
(categorized using the International Standard Classification of Education), and 
employment (paid work, housekeeper, disablement insurance act, retired, volunteer, 
study) at baseline. Informal caregivers completed a general questionnaire on the 
nature of their relation to the patient (partner, child, sibling, friend), whether they 
lived together with the patient (yes/no) and the extent of their caregiving tasks 
(hours of caring, independency of the patient, caring for more than patient alone), 
as well as their needs during caring for their significant other (practical and/or 
emotional support from social support system and/or professionals, information 
services from hospital and/or general practitioner, and/or better communication 
with physician/nurses/general practitioner). Furthermore, we inquired whether the 
treatment side effects of cancer treatment had a negative influence on informal 
caregiver well-being (no/ yes, somewhat/yes). 
Patients self-reported whether they had a colostomy after surgery, the 
total number of cycles of adjuvant chemotherapy, and experienced toxicity 
(T1 and T2). Patients also reported what sort of complications they had after 
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surgery. The attending medical oncologist provided information which adjuvant 
chemotherapy (CAPOX versus capecitabine monotherapy) was prescribed. 
We used the Self-administered Comorbidity Questionnaire (SCQ) to assess 14 
common medical conditions in both patients and informal caregivers, and additional 
comorbidities could also be reported [13]. For each condition, patients and informal 
caregivers indicated whether it was present, being treated, or imposed functional 
limitations. For the present study, we used data on whether a comorbidity was 
present and causing functional limitations. 
Informal caregiver well-being
Informal caregivers completed the 9-item Self-Perceived Pressure from 
Informal Care (SPPIC) [14]. Items are scored on a 5-point scale ranging from 0 
(no!) to 5 (yes!). We dichotomized scores to 0 (“no!” and “no”) and 1 (“yes!,” “yes,” 
and “more or less”). Total scores range from 0 to 9, and higher scores indicate 
higher levels of perceived informal caregiver burden. In accordance with other 
studies [15–17], we classified informal caregivers into low (0–3), moderate (4–6), 
and high levels of burden (7–9) based on their total score. Patients and informal 
caregivers each completed the Hospital Anxiety and Depression Scale (HADS) 
to measure distress [18]. 
The HADS consists of 14 items assessing symptoms of anxiety and depression 
during the past week. Items are scored on a 4-point Likert scale ranging from 0 to 3. 
Total scores range from 0 to 42, and higher scores indicate more distress. We used 
the 36-item RAND-36 Health Survey to assess functional status, well-being, and 
general health [19]. Scores on each of the eight subscales are transformed into a 
range from 0 to 100; higher scores indicate higher levels of functioning, well-being, 
and general health. 
The Social Support List – Discrepancies (SSL-D) is a 34-item questionnaire 
assessing discrepancies between an individual’s need for social support and their 
perceived social support [20, 21]. The questionnaire assesses six types of social 
support, namely emotional interactions, problem-focused emotional support, 
esteem support, instrumental interactions, social companionship, and informational 
support. The score on every item is transformed into a sum score ranging from 34 
to 136. Higher scores indicate more unmet needs for social support. 
We used the “marital satisfaction” subscale of the Maudsley Marital Questionnaire 
(MMQ) to assess marital satisfaction [22]. This is a 10-item questionnaire, answered 
on a 9-point scale (0–8), ranging from 0 to 80. Higher scores indicate decreased 
marital satisfaction. We instructed participants to complete this questionnaire if 
they had a partner relationship. 
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We administered the Abbreviated Fatigue Questionnaire (AFQ), a validated 
4-item questionnaire to measure fatigue [23, 24]. The AFQ is an abbreviated version 
of the subscale fatigue severity of the Checklist Individual Strength. Items are 
scored on a 7-point scale ranging from “no, that’s not correct” (score 1) to “yes, 
that’s correct” (score 7). The total score on the 4-item questionnaire ranges from 4 
to 28. Higher scores indicate greater levels of fatigue. 
Informal caregiver self-esteem was measured by the subscale caregiver self-
esteem of the Caregiver Reaction Assessment Scale (CRA) [25]. The subscale 
consists of 7 items, scored on a 5-point Likert scale. The total score reflects a 
mean score of 7 items and ranges between 1 and 5; a higher score indicates more 
self-esteem. 
Statistical analysis
Descriptive statistics were used for baseline characteristics of the patients and 
informal caregivers. Chi-square and Fisher’s exact tests were performed to examine 
the relation between categorical variables. Independent-samples t tests and 
Mann-Whitney U tests were used to compare continuous variables. We analysed 
informal caregiver burden, distress, health-related quality of life, marital satisfaction, 
discrepancies in social needs, fatigue, and informal caregiver self-esteem with one-
way ANOVA with repeated measure. Next, we applied the same statistical analyses 
for patient distress, health-related quality of life, marital satisfaction, discrepancies 
in social needs, and fatigue. We applied the Greenhouse-Geisser correction 
when the assumption of sphericity was violated. Post hoc tests with Bonferroni’s 
correction were used to identify which specific means differed. To identify cases 
of clinically significant distress, we applied a HADS total clinical cutoff score of ≥ 11 
to identify patients with clinically significant distress [26] and a cutoff score of ≥ 12 
for informal caregivers [27]. To identify possible cases of depression (HADS-D) and 
anxiety (HADS-A), we used the cutoff score of ≥ 8 [26, 27]. McNemar’s tests were 
carried out to determine whether the proportion of patients or informal caregivers 
exceeding the cutoff for clinically relevant distress differed between baseline and 
T2. We used multiple linear regression to predict informal caregiver burden and 
distress at T1 and T2 from informal caregiver gender, age, burden, distress, fatigue, 
and patient distress at baseline (method: enter). For the linear regression analyses, 
we used the continuous variables of burden, distress, and fatigue. All data analyses 
were performed using the statistical package for the social sciences (SPSS, version 
24.0). Statistical significance was determined based on a two-sided alpha of 0.05. 




Of 76 eligible patients and their informal caregivers, 62 (82%) dyads enrolled in the 
study, and 14 (18%) declined participation, mostly because participation was considered 
too burdensome. Of the 62 dyads that provided consent, 2 dyads withdrew consent 
after enrollment. Thus, T0 was completed by 60 (79%), whereas T1 by 58 (76%) and T2 
by 51 dyads (67%). Baseline, caregiving, and treatment characteristics are provided 
in Table 1. Table 2 displays an overview of what support informal caregivers need 
before, during, and after a patients’ treatment with adjuvant chemotherapy. When 
informal caregivers reported they need support, it seemed most needed before 
starting chemotherapy and focused on practical support and receiving information. 
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Negative influence of patients’ side effects on caregiver well-








































































Reason for modification treatment (n=26)
Discontinuation oxaliplatin only
Discontinuation oxaliplatin and capecitabine
13/26 (50%)
13/26 (50%)
Toxicity 3 months after ending adjuvant treatment
No
Yes, suffered from side effect, but disappeared
Yes, suffered from side effects, now barely noticeable 


































































SD = standard deviation; ISCED = International Standard Classification of Education 2011; ≤ 4: 
secondary, non-tertiary education level, > 4: tertiary education level (bachelor, master or doctoral 
level); T0 = baseline, T1 = between 2nd and 3rd cycle of adjuvant chemotherapy, T2 = 3 months after 
ending adjuvant chemotherapy; CAPOX = capecitabine with oxaliplatin
a Multiple answers possible; b One missing answer; c Two missing answers
Table 2. Informal caregivers’ needs for support before, during and after adjuvant chemotherapy
Baseline
(n=60)
After second Tx 
cycle (n=57)
Three months after 
completing Tx (n=51)
No support needed 
Practical support
From social support system
From professional
Emotional support
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Course of burden, distress, health-related quality of life, marital satisfaction, 
discrepancies in social needs, fatigue over time, and informal caregiver self-
esteem. 
Table 3 shows mean scores for informal caregiver well-being over time. Mean scores 
for informal caregiver burden (F[2,94] = 4.465; p=0.014), distress (F[1.773,81.574] = 5.497; 
p=0.008), role emotional limitations (F[2,94] = 8.814; p<0.0001), mental health (F[2,94] 
= 4.949; p=0.009), social functioning (F[2,98] = 3.985; p=0.022), and discrepancies in 
social support (F[2,66] = 3.466; p=0.037) differed significantly between time points. 
Post hoc analyses indicated an improvement of all scores over time; i.e., burden, 
distress, and role emotional limitations decreased, whereas mental health and 
social functioning increased. Discrepancies in social support decreased during 
and increased after ending adjuvant chemotherapy. Post hoc analyses are shown 
in Table 4. 
Table 5 displays patients’ mean scores for health-related quality of life, marital 
satisfaction, discrepancies in social needs, and fatigue over time. Mean patient 
distress (F[1.771,79.706] = 5.224; p=0.010), role physical limitations (F[2,94] = 9.551; 
p<0.0001), vitality (F[2,96] = 5.295; p=0.007), social functioning (F[2,96] = 9.157; 
p<0.0001), general health (F[2,92] = 6.672; p=0.002), marital satisfaction (F[2,54] = 
5.395; p=0.007), and fatigue (F[2,92] = 11.393; p<0.0001) changed significantly over 
time. Post hoc analyses revealed an overall decrease of distress and increase in role 
physical limitations and social functioning. Vitality and general health decreased 
during and increased after ending adjuvant chemotherapy. Marital satisfaction 
decreased over time. Fatigue increased during and decreased after ending adjuvant 
chemotherapy. Post hoc analyses are shown in Table 6. 
Clinically relevant levels of informal caregiver burden and distress
Moderate or high levels of burden of informal caregivers were found in 17.2% 
(n=10/58) and 12.1% (n=7/58) at baseline, 19.3% (n=11/57) and 10.5% (n=6/57) at T1, 
and 12% (n=6/50) and 8% (n=4/50) at T2, respectively. A HADS total score exceeding 
the cutoff for clinically relevant distress was found in 26.7% (n=16/60) at baseline, 
22.8% (n=13/57) at T1, and 18.8% (n=9/48) at T2. Clinically relevant levels of informal 
caregiver depressive symptoms (HADS-D) were 15% at baseline, 10.5% at T1, and 
12.2% at T2. Clinically relevant levels of informal caregiver anxiety (HADS-A) were 
21.7% at baseline, 21.1% at T1, and 12.2% at T2.
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Table 3. Informal caregivers’ course of burden, distress, health-related quality of life, marital 
satisfaction, fatigue and self-esteem
Population norm scores T0 T1 T2 Sign
Mean (SD) Mean (SD) Mean (SD) Mean (SD) p-value
Burden (SPPIC) [14,15] a 2.90 (2.44) 2.82 (2.38) 2.04 (2.25) 0.014*
Distress (HADS) [27] 8.4 (6.3) 8.96 (6.91) 7.57 (6.32) 6.64 (7.15) 0.008*
Health-related quality of life (RAND 36) [19]
Physical functioning 81.90 (23.20) 91.04 (10.47) 90.94 (13.90) 87.81 (16.24) 0.153
Role limitations due to physical health 79.40 (35.50) 79.89 (23.20) 87.50 (22.82) 84.78 (30.95) 0.253
Role limitations due to emotional problems 84.10 (32.30) 63.88 (41.73) 81.25 (34.32) 86.11 (30.62) <0.0001*
Vitality 67.40 (19.90) 67.29 (14.73) 71.98 (15.04) 71.88 (20.39) 0.067
Mental health 76.80 (18.40) 73.00 (14.16) 77.08 (12.83) 78.33 (14.41) 0.015*
Social functioning 86.90 (20.50) 80.00 (20.52) 84.75 (18.09) 87.00 (15.14) 0.022*
Pain 79.50 (25.60) 92.00 (12.98) 89.63 (15.63) 88.30 (17.17) 0.173
General health 72.70 (22.70) 74.56 (16.68) 75.56 (16.42) 73.33 (20.83) 0.430
Marital satisfaction (MMQ) [22,38] 13.58 (10.79) 9.76 (9.94) 10.37 (10.80) 11.66 (11.53) 0.189
Social support discrepancies (SSL-D) [21] 43.6 (10.3) 41.18 (9.09) 38.38 (5.68) 39.06 (6.63) 0.037*
Fatigue (AFQ) [24] b 10.02 (2.65) 10.49 (6.30) 10.55 (7.26) 0.748
Self Esteem (CRA) [39] 4.19 (0.41) 4.32 (0.54) 4.32 (0.49) 4.23 (0.48) 0.181
SPPIC = Self-Perceived Pressure of Informal Care, HADS = Hospital Anxiety and Depression Scale, 
MMQ = Maudsley Marital questionnaire, SSL-D = Social Support List – Discrepancies, AFQ = 
Abbreviated Fatigue Questionnaire, CRA = Caregiver Reaction Assessment; T0 = baseline, T1 = 
between 2nd and 3rd cycle of adjuvant chemotherapy, 
T2 = 3 months after ending adjuvant chemotherapy; * p-values represent significant changes in 
mean scores over time; references given in this table refer to population norm scores; a Scores 
for levels of burden: 0-3 low, 4-6 moderate, 7-9 high; b Scores for level of fatigue: low = 4, below 
average = 4, average = 5-8, above average = 9-14, high ≥ 15
Table 4. Post-hoc analyses of courses of informal caregiver variables which differed significantly
Measure Burden Distress Role emotional limitations Mental health Social functioning Social support discrepancies
































T2 versus T1 -0.085 -0.942 0.771 1.000 -1.383 -2.899 0.133 .085 17.361 1.975 32.747 .022* 4.083 -0.327 8.494 .078 4.750 -0.980 10.480 .136 2.794 -5.629 0.041 .054
T3 versus T1 -0.862 -1.642 -0.099 .022* -2.319 -4.349 -0.290 .020* 22.222 7.784 36.660 .001* 5.333 0.058 10.609 .047* 7 0.190 13.810 .042* -2.118 -4.803 0.567 .165
T3 versus T2 -0.777 -1.521 -0.033 .038* -0.936 -2.596 0.724 .503 4.861 -6.428 16.150 .871 1.250 -2.045 4.545 1.000 2.250 -3.991 8.491 1.000 0.676 -2.178 3.531 1.000
∆ = mean difference; CI = confidence interval; T0=before starting adjuvant chemotherapy; 
T1=between 2nd and 3rd cycle; T2=three months after ending chemotherapy; sign.= significance; 
*significant mean difference
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Table 3. Informal caregivers’ course of burden, distress, health-related quality of life, marital 
satisfaction, fatigue and self-esteem
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T2 versus T1 -0.085 -0.942 0.771 1.000 -1.383 -2.899 0.133 .085 17.361 1.975 32.747 .022* 4.083 -0.327 8.494 .078 4.750 -0.980 10.480 .136 2.794 -5.629 0.041 .054
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Table 5. Patient course of distress, health-related quality of life, marital satisfaction, fatigue 
and self-esteem
Population norm scores T0 T1 T2 Significant difference over time
Mean (SD) Mean (SD) Mean (SD) Mean (SD) p-value
Distress (HADS) [27] 8.4 (6.3) 7.22 (6.04) 7.37 (5.41) 5.54 (4.31) 0.010*
Health-related quality of life (RAND 36) [19]
Physical functioning 81.90 (23.20) 76.35 (19.76) 76.15 (20.78) 79.52 (20.85) 0.168
Role limitations due to physical health 79.40 (35.50) 31.77 (40.52) 33.33 (38.71) 59.36 (45.44) <0.0001*
Role limitations due to emotional problems 84.10 (32.30) 65.93 (44.66) 74.81 (40.92) 85.19 (33.75) 0.061
Vitality 67.40 (19.90) 64.59 (17.61) 58.16 (18.33) 64.90 (19.59) 0.007*
Mental health 76.80 (18.40) 79.92 (14.64) 70.49 (14.33) 82.45 (11.07) 0.344
Social functioning 86.90 (20.50) 68.37 (19.45) 72.45 (20.41) 82.14 (19.76) <0.0001*
Pain 79.50 (25.60) 74.90 (23.06) 74.82 (22.63) 80.42 (20.56) 0.285
General health 72.70 (22.70) 63.51 (19.33) 60.00 (18.44) 68.62 (20.50) 0.002*
Marital satisfaction (MMQ) [38] 13.58 (10.79) 5.79 (6.85) 6.86 (8.37) 9.00 (9.58) 0.007*
Social support discrepancies (SSL-D) [21] 43.2 (10.7) 36.86 (4.90) 36.19 (3.03) 36.06 (3.18) 0.445
Fatigue (AFQ) [24] a 12.36 (6.61) 16.21 (7.23) 12.85 (6.37) <0.0001*
HADS = Hospital Anxiety and Depression Scale, MMQ = Maudsley Marital questionnaire, SSL-D = 
Social Support List – Discrepancies, AFQ = Abbreviated Fatigue Questionnaire; T0 = baseline, T1 
= between 2nd and 3rd cycle of adjuvant chemotherapy, 
T2 = 3 months after ending adjuvant chemotherapy; * p-values represent changes in mean scores 
over time; references given in this table refer to population norm scores; a Scores for level of 
fatigue: low = 4, below average = 5-12, average = 13-21, above average = 22-27, high ≥ 28
Table 6. Post-hoc analyses of courses of patient variables which differed significantly 
Patient Distress Role physical limitations Vitality Social functioning General health Marital satisfaction   Fatigue





































T2 versus T1 0.152 1.473 1.777 1.000 1.563 -16.955 20.080 1.000 -6.429 -12.227 -0.630 .025* 4.082 -5.245 13.409 .849 -3.511 -8.551 1.529 .271 1.071 -1.141 3.284 .681 3.851 1.722 5.980 <.0001*
T3 versus T1 -1.674 -3.423 0.075 .065 27.604 12.563 42.645 <.0001* 0.306 -5.220 5.832 1.000 13.776 6.090 21.461 <.0001* 5.106 -0.802 11.015 .111 3.214 0.370 6.059 .023* 0.489 -1.606 2.585 1.000
T3 versus T2 -1.826 -3.087 -0.565 .002* 26.042 7.019 45.065 .004* 6.735 0.676 12.793 .025* 9.694 2.223 17.165 .007* 8.617 1.989 15.245 .007* 2.143 -0.392 4.677 .120 -3.362 -5.678 -1.045 .002*
∆ = mean difference; CI = confidence interval; T0=before starting adjuvant chemotherapy; 
T1=between 2nd and 3rd cycle; T2=three months after ending chemotherapy; sign.= significance; 
*significant mean difference
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In patients, 22.4% (n=13/58) exceeded the cutoff at baseline for clinically 
relevant levels of distress, 31.5% (n=17/54) at T1, and 18.0% (n=9/50) at T2. Clinically 
relevant levels of patient depression were 12.1% at baseline, 16.1% at T1, and 7.8% 
at T2. Clinically relevant levels of patient anxiety were 17.2% at baseline, 13.0% at 
T1, and 7.8% at T2. There was no significant difference between the proportions of 
informal caregivers (p=0.289) or patients (p=0.508) with clinically relevant levels of 
distress at baseline and T2. 
Predictors of informal caregiver distress and burden at T1 and T2
Informal caregiver gender, age, burden, distress, fatigue, and patient distress at 
baseline predicted informal caregiver self-perceived burden at T1 (F[6,53] = 4.493, 
p=0.001, R2 = 0.365) and T2 (F[6,46] = 4.523, p<0.001, R2 = 0.404). Only informal 
caregiver burden at baseline added significantly to the prediction at T1 (p=0.002) 
and T2 (p=0.002). The multivariate regression model was also used to predict 
distress at T1 (F[6,53] = 12.305, p<0.0001, R2 = 0.611) and T2 (F[6,44] = 7.204, p<0.0001, 
R2 = 0.532). Only baseline informal caregiver distress (p<0.001) added significantly 
to the prediction at T1 (p<0.001) and T2 (p=0.001). Details are displayed in Table 7. 
Table 7. Multivariate regression analyses to explore associations with informal caregiver 
burden and distress during and after patients’ treatment with adjuvant chemotherapy 











Age 0.021 0.862 -0.134 0.290 -0.028 0.761 -0.066 0.876
Gender -0.082 0.497 -0.032 0.799 -0.008 0.931 0.042 0.819
Burden T0 0.440 0.002* 0.478 0.002* -0.011 0.917 0.002 0.988
Distress T0 0.294 0.065 0.100 0.533 0.716 0.000* 0.544 0.001*
Fatigue T0 -0.056 0.720 0.115 0.472 0.119 0.335 0.275 0.063
Patient characteristics                
Distress T0 0.014 0.909 0.037 0.777 -0.110 0.258 -0.105 0.395
R2 37%   40%   61%   53%  
* Statistically significant
Interaction between informal caregivers and patients
Generally, informal caregivers reported higher distress levels (T0 mean 8.47 (SD=6.83); 
T1 M=7.42 (SD=6.34); T2 M=6.50 (SD=7.14)) compared with patients (T0 M=7.02 (SD 
5.80); T1 M=7.20 (SD=5.93); T2 M=5.56 (SD=4.69)), but these differences did not reach 
statistical significance (T0 mean difference 1.45, p=0.217; T1 mean difference 0.22, 
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p=0.853; T2 mean difference 0.94, p=0.445). We did not find significant correlations 
between informal caregiver and patient distress at baseline (r=0.134, p=0.315), T1 
(r=0.263, p=0.054), or T2 (r=0.121, p=0.424). In addition, informal caregiver burden and 
patient distress did not correlate significantly at T1 (r=0.209, p=0.129) or T2 (r=0.205, 
p=0.167). However, at baseline, informal caregiver burden was significantly, but 
weakly correlated with patient distress (r=0.261, p=0.05). 
DISCUSSION
The present longitudinal study explored the course of informal caregiver well-being, 
clinically relevant levels of informal caregiver burden and distress, and baseline 
risk factors for higher levels of burden and distress during and after a patients’ 
adjuvant chemotherapy for colon cancer. We found that informal caregivers 
seem to report more mental problems before and during chemotherapy, whereas 
patients report more physical problems. Additionally, 20–30% of informal caregivers 
report relevant levels of burden and distress, between, before, during, and after a 
patients’ treatment. Baseline burden and distress are risk factors for burden and 
distress during and after a patients’ adjuvant treatment. 
Informal caregivers reported more mental than physical problems after a 
patient’s cancer diagnosis and during treatment, and social functioning seemed 
to be influenced negatively. This was also found in another study on the impact of 
colorectal cancer on patients and their partners [30]. This study of Traa et al. showed 
that both partners and patients suffer mentally and in social functioning, which is 
in line with our findings. Furthermore, a study of Law et al. showed that informal 
caregivers’ social functioning changed due to fear of burdening others, and when 
informal caregivers do get support, this support is perceived insufficient and not 
what they need on that moment [31]. Also, informal caregivers report that family and 
friends become avoidant in their contact with the patient and informal caregiver, 
which challenges their social interactions [32]. In contrast to the findings of Traa et al. 
who found a stabilization in mental well-being and social functioning, we observed 
an improvement over time. A possible explanation could be that in the study of Traa 
et al., 60% had an colostomy after surgery compared with only 13% in our study. 
Having a colostomy is known to cause distress for the patient and their informal 
caregiver and may impact social activities and increase social isolation [32–35].
Before starting adjuvant chemotherapy, almost 30% of informal caregivers 
reported moderate-to-high levels of burden and clinically relevant distress, which 
decreased to 20% 3 months after the end of adjuvant treatment. Ohlsson-Nevo 
et al. pointed out that partners’ lives are turned upside down after colorectal 
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cancer diagnosis, being confronted with how fragile life is [33]. They had to deal 
with new and other unwanted responsibilities at home that they felt compelled 
to fulfill [33]. Northouse et al. found that during patients’ treatment for cancer, 
informal caregivers experienced worries about the effectiveness of the treatment, 
accompanied by difficulties managing side effects [6]. For informal caregivers who 
still experienced burden and distress after the patient’s completion of adjuvant 
chemotherapy, a possible contributing factor could be the ongoing treatment 
toxicity, which was reported by 61% of the patients in our study. Although toxicity 
can diminish over time, there is a group of patients for which the toxicity, in 
particular peripheral neuropathy, remains a limiting factor in a patients’ life [36], 
and thereby also influences the life of their significant others. Fortunately, there 
are new insights for treating stage III colon cancer, namely a shift from 6 to 3 
months CAPOX, which is non-inferior in terms of survival and induces less toxicity 
[36]. Our study was performed when these data were not available yet. Since the 
number of cycles will be reduced and thereby also the associated cumulative 
toxicity, this may ultimately also positively impact the informal caregiver [36]. 
Another contributing factor for ongoing burden and distress can be fear of cancer 
recurrence. This is found in patients, and van de Wal et al. found that partners 
report the same levels of fear of recurrence as well. [37] 
When thinking of ways to support informal caregivers in need, it could be 
particularly helpful to predict who is in need of support and when. In our study, we 
found that informal caregiver burden and distress at baseline predicted informal 
caregiver burden and distress both during adjuvant chemotherapy and 3 months 
after completion of treatment. Jansen et al. reported that informal caregivers of 
patients with different types of cancer with higher baseline levels of burden remained 
burdened over the following years [38]. It is possible that informal caregivers who 
remain burdened and distressed have more difficulties coping, as negative coping 
skills are associated with higher levels of burden and distress [39]. Further research 
with ongoing assessment of burden and distress due to the dynamic nature of 
these constructs, with a focus on what causes and maintains burden and distress, 
is recommended. Especially it is known that long-term burden and distress cause 
serious general health problems [7]. Additionally, our study shows that informal 
caregivers’ distress exceeds patients’ distress. This finding is consistent with those 
of other studies [6, 30]. Based on these findings, we recommend to pay attention 
and offer support when informal caregiver burden and distress are observed before 
starting adjuvant chemotherapy, or even earlier, shortly after diagnosis. More 
specifically, repeated assessment of informal caregiver needs for more practical 
support or other informational services from care professionals is recommended. 
Importantly, the management of treatment side effects deserves special attention 
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as 60% of informal caregivers report that their well-being is negatively influenced 
by patients’ side effects during treatment. Additionally, based on our inquiry of 
informal caregiver needs, the general practitioner may be particularly well-suited 
for providing support to the informal caregiver, as leading practitioner in informal 
caregiver care. 
Our exploratory longitudinal study adds significantly to the scarce literature on 
informal caregiver burden and distress during adjuvant treatment of colon cancer. 
However, it is important to take into account several limitations. First, the sample 
size is relatively small which prevented us from studying additional predictors 
of informal caregiver burden and distress, such as the influence of a patient’s 
colostomy. Second, patients and informal caregivers who declined participation 
in this study often refused because participation was perceived too burdensome. 
This may limit the generalizability of our findings and our conclusion on burden and 
distress to the larger population of informal caregivers, and our findings may be an 
underestimation. Third, although we assessed statistical significance of changes 
in informal caregiver wellbeing over time, we were unable to determine clinical 
relevance due to the lack of established minimally clinically important differences 
(MCID) for the measures that we used. Future research assessing MCIDs for among 
informal caregiver population is warranted. 
In conclusion, before and during adjuvant chemotherapy, informal caregivers 
report more mental problems whereas patients report more physical problems. 
When informal caregivers and patients experience problems before start of 
adjuvant chemotherapy, problems seem to improve over time. Nevertheless, 
approximately 20% of informal caregivers remain burdened and distressed after 
patients’ end of treatment, and remarkably informal caregivers’ distress exceeds 
patients’ distress. Additionally, informal caregivers’ baseline burden and distress 
seem to be risk factors for ongoing burden and distress after treatment. Therefore, 
it is of great importance to identify burden and distress among informal caregivers 
of patients treated with adjuvant chemotherapy for colon cancer and offer them 
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ABSTRACT
Introduction: TKIs are a long-term treatment for GIST, and may have an impact on 
caregivers.
Material and Methods: For this cross-sectional study, patients and caregivers were 
both included when patients had been treated with TKIs for at least six months. 
Caregivers completed questionnaires including demographics, distress (Hospital 
Anxiety and Depression scale), burden (Self-Perceived Pressure from Informal 
Care) general health (RAND-36), comorbidity (Self-administered Comorbidity 
Questionnaire), social support (Social Support List – Discrepancies) and marital 
satisfaction (Maudsley Marital Questionnaire). Patients completed similar 
questionnaires, without ‘burden’. We conducted analyses to explore differences 
between caregivers with low/moderate versus high levels of burden and low 
versus high levels of distress.
Results: Sixty-one out of seventy-one eligible couples (84%) were included in the 
analysis. The median age of the caregivers was 60 years; 66% were female and 
78% were the patients’ spouse. The median age of the patients was 66 years; 43% 
were female. Caregivers experienced high levels of burden and distress in 10% 
and 23%, respectively. Caregivers with high levels of burden perceived significantly 
lower mental health, less vitality, lower general health and high levels of distress. 
Significantly higher levels of burden were found in non-spouses, caregivers of 
patients with more treatment-related side effects, caregivers who spent more hours 
caring, and those caring for more than one person. For distress, caregivers with high 
levels of distress perceived significantly more burden, lower social functioning, 
more role physical and emotional problems, lower mental health, less vitality and 
lower general health. Furthermore, high levels of distress were found in caregivers 
of more dependent patients and those caring for more than one person.
Conclusions: Caregivers of the patients with GIST treated with TKI are managing 
well. There is a small, vulnerable group of caregivers with high levels of burden 
and/or distress, who show more health-related problems, both physical and 
mental, and require adequate support.




Gastro-intestinal stromal tumours (GIST) belong to the rare and heterogeneous 
group of soft tissue sarcomas. Curative treatment consists of radical surgery, in 
high risk tumours combined with (neo) adjuvant imatinib [1]. Currently, the duration 
of adjuvant therapy is three years [2]. Until 2000, the treatment of GIST was limited, 
as GIST are resistant to chemo- and radiotherapy. In 2000, imatinib, a tyrosine 
kinase inhibitor (TKI), was introduced as the first targeted treatment for metastatic 
GIST. This significantly improved median overall survival from <1 year to >5 years 
nowadays, causing a change in life perspective for these patients [2]. Imatinib in 
GIST has been a successful, often prolonged, targeted treatment for GIST, both in 
the adjuvant and metastatic setting. More attention has recently been given to the 
chronicity of the disease, including the need for treatment with other TKIs when 
resistance to imatinib develops. This had led to the so called Sword of Damocles, 
fear of recurrence or progression [3]. The approach to GIST patients and their 
caregivers and their needs had therefore evolved [4]. Chronic oral treatment may 
be accompanied by side effects, such as, fatigue, diarrhoea, nausea, periorbital 
oedema, muscle cramps and skin rash [5]. These adverse events, frequent 
radiological evaluations and related uncertainties may have an impact on patients’ 
personal lives. We previously demonstrated that around one third of GIST patients 
on TKIs experience high levels of fear of cancer recurrence or progression. They 
also experience high levels of distress, functional impairment (emotional, social, 
cognitive) and have difficulties making plans for the future [3]. 
In a study of prostate cancer patients, treated with curative intent, we found 
that fear of cancer recurrence did not only adversely affect patients, but also their 
caregivers [6]. Little is known about how GIST and its (chronic) treatment may impact 
informal caregivers, while chronic fatigue, nausea and diarrhoea may conceivably 
impact the partner or the family. Studies have shown that cancer not only affects the 
individual patient and caregiver separately, but also their intertwined life as a couple 
[7,8]. Patients’ longer-term mechanisms for coping with cancer and its treatment 
are influenced by difficulties experienced by their caregivers. Caregivers may even 
perceive levels of burden, distress, anxiety and decreased social support that are 
greater than the patient during the cancer treatment trajectory [8]. 
Burden is defined by Zarit et al., and mentioned in the review of Adelman et 
al., as ‘the extent to which caregivers perceive that caregiving has had an adverse 
effect on their emotional, social, financial, physical and spiritual functioning’ [9,10]. 
This definition shows that burden is a multidimensional experience. Known risk 
factors for higher levels of perceived burden are diverse, but most well recognized 
are demographic factors, such as being female and living with the recipient of care, 
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psychosocial factors (especially depression), fewer coping strategies and social 
isolation [10]. Furthermore, patient distress, spending more hours caring for the 
patient, financial stress, a lack of choice in becoming a caregiver and discontinuation 
of their own employment are risk factors [10]. High levels of burden may negatively 
interfere with the caregivers’ general health, both physical and mental [11,12]. 
Distress, defined by the National Cancer Institute as ‘emotional, social, spiritual of 
physical pain or suffering that may cause a person to feel sad, afraid, depressed, 
anxious or lonely’, is an important psychological morbidity, which often coincides 
with burden [10,13]. Risk factors for distress are wide ranging, however worry about 
treatment efficacy, managing side effects, social isolation, lack of preparation in 
caring for a significant other and complexity of care are identified as more specific 
for caregivers of patients on active treatment for cancer [13]. 
With this cross-sectional study, we aim to explore the well-being of caregivers 
of patients with chronic TKI treatment, by measuring burden, distress, general 
health, discrepancies in social support and marital satisfaction. Furthermore, we 
will explore whether there are the differences in caregivers experiencing high levels 
of burden and distress versus caregivers with low/moderate levels of burden and 
low levels of distress. To the best of our knowledge, this is the first study exploring 
well-being of caregivers of patients with GIST treated with TKIs, and is also one of 




The cross-sectional study was conducted between June 2013 and May 2014 
in the Departments of Medical Oncology at three hospitals in different regions 
of the Netherlands; two university medical centres and one regional hospital. 
Inclusion criteria for patients were: age older than 18 years, able to communicate 
in Dutch language, TKI treatment for at least six months in either the adjuvant or 
palliative setting, having an informal caregiver. Exclusion criteria for the patients 
were: prognosis of less than 12 weeks, able to communicate in Dutch language, 
no informal caregiver. A caregiver was defined as a person who cared for a patient 
during their chronic treatment with a TKI for GIST. This included a spouse, sibling, 
friend or other relative. Inclusion criteria for caregivers were: age older than 18 years. 
Exclusion criteria for caregivers were: not able to communicate in Dutch language. 
When either the patient or the caregiver met the one of the exclusion criteria, both 
were excluded. 




The study was approved by the local medical ethical committee (Radboud University 
Medical Centre 2013/278). All patients in the database of the Departments of Medical 
Oncology of the attending hospitals were systematically assessed for their eligibility 
by their attending physician. The attending physician approached the patient and 
their caregiver during an outpatient follow-up visit or by telephone. When the 
patient and the informal caregiver gave their verbal informed consent, they were 
included. They were both asked to a single complete self-report questionnaires, 
independently of each other. Completing the paper and pencil questionnaire took 
between 45 and 60 min. Data were analysed anonymously.
Questionnaires
Demographics
Demographic characteristics were obtained with a questionnaire, including 
gender, age, nationality, education, employment and relationship with each other 
(spouse, sibling, offspring, friend). We inquired whether the patient experienced 
side effects of TKI treatment (answer possibilities: ‘no, I do not experience side 
effects’, ‘yes, I do experience side effect, but they are not bothersome’, ‘yes, I 
do experience side effects and they are bothersome’, ‘yes, I do experience side 
effects and they are extremely bothersome’) and whether the patient experienced 
difficulties enduring long-term TKI treatment (answer possibilities: ‘no’, ‘yes, a little 
bit’, ‘yes’, ‘yes, it is very difficult’). The caregiver answered questions regarding 
caregiving-related topics, including patients’ independence, hours of caring, 
caring for more people than the patient, change in own health as a consequence 
of giving care, and neglecting own health as a consequence of being a caregiver. 
Duration and setting ((neo-) adjuvant or palliative) of treatment was reported by 
the attending physician.
Questionnaires assessing general health
The RAND-36 Health Survey is a validated, 36-item questionnaire assessing 
functional status, well-being and general health on eight subscales: (1) physical 
functioning (i.e., activities of daily living; 10 items), (2) social functioning (i.e., 
limitations in normal social functioning due to physical and emotional functioning), 
(3) role-physical (i.e., limitations in work and activity of daily living due to physical 
problems), (4) role-emotional (i.e., limitations in work and activity of daily living due 
to emotional problems), (5) mental health (i.e., regarding feelings of sadness and 
anxiety), (6) pain (i.e., experience of pain and limitations of activities of daily living 
as a consequence of pain), (7) vitality (i.e., feelings of energy and tiredness) and (8) 
general health (i.e., subjective evaluation of personal general health). Scores on 
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each subscale are transformed into a range from 0 to 100. Higher scores indicate 
higher levels of functioning, well-being and general health. The Dutch version 
of the questionnaire has been validated and showed sufficient to good internal 
consistency (Cronbach’s a 0.71–0.92) [14]. 
The Self-administered Comorbidity Questionnaire is a questionnaire, assessing 
whether comorbidity is present, and if so, is treated and/or leads to impairments 
in daily functioning. The questionnaire consists of 14-items with defined medical 
conditions and three blank spaces to complete when a medical condition is present, 
but not defined in the 14-items [15]. 
Questionnaires assessing mental health and social support
The Hospital Anxiety and Depression Scale (HADS) is a validated, 14-item self-
assessment questionnaire to assess psychological distress [16,17]. Total scores 
range between 0 and 42. Each item is rated on a scale from 0 (not at all) to 3 (very 
much). Higher scores indicate higher levels of distress. To identify high levels of 
distress on an individual basis, for patients we used the validated cutoff score for 
cancer patients of 11 or higher [18]. For caregivers, a cutoff score of 12 was used. 
This cutoff score is validated in several Dutch populations and used in other clinical 
studies in with cancer caregivers in the Netherlands [16,19].
The Social Support List – Discrepancies (SSL-D) contains 34-items to assess 
discrepancies between an individual’s’ need for social support and their perceived 
social support. The questionnaire assesses six types of social support, namely 
emotional interactions, problem-focused emotional support, esteem support, 
instrumental interactions, social companionship and informational support. The 
main question is ‘Does it ever occur that people…’, which is followed by a statement, 
for example ‘offer you mental support’ or ‘offer you good advice’ or ‘offer you 
constructive feedback’. The answer possibilities are (1) ‘I miss this, I would like to 
receive this more often’, (2) I do not miss this, but it would be fortunate to receive 
this more often, (3) The support meets my needs exactly, (4) This happens too often, 
it would be fortunate when it happens less. The score on every item is transformed 
to scores ranging from 34 to 136, with higher scores indicating more unmet need 
for social support [20,21]. 
Marital satisfaction was measured with the ‘marital satisfaction’ subscale of 
the Maudsley Marital Questionnaire (MMQ), a validated questionnaire to assess 
marital satisfaction. This is a 10-item questionnaire, answered on a 9-point scale 
(0–8), ranging from 0 to 80. Higher scores indicate decreased marital satisfaction 
[22]. We instructed participants of this study only to complete this questionnaire if 
they were a couple. 
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Questionnaire assessing giving care to a significant other
The Self-Perceived Pressure from Informal Care (SPPIC) is a Dutch, validated 
questionnaire to assess caregivers’ self-perceived stress as a reaction to providing 
informal care. In the Netherlands, the questionnaire is often used among cancer 
caregivers to measure their perceived burden during patients’ treatment. The 
questionnaire assesses how perceived pressure as a consequence of giving care 
to a significant other interferes with caregivers’ personal interests, where ‘personal 
interest’ is defined as the possibility to have own thoughts, activities and/or other 
roles they want to fulfil in life. Examples of questions are ‘As a consequence of the 
situation of my significant other, less time is available managing my personal life’ 
or ‘Combining the responsibility for my significant other and my family and work 
is challenging’. It consists of a nine-item, five-point Rasch scale. According to the 
questionnaire manual, the scores are dichotomized to 0 (‘no!’ and ‘no’) and 1 (‘yes!’, 
‘yes’ and ‘more or less’). The total scores range from 0 to 9, with higher scores 
indicating high levels of burden [23]. Total scores on the scale were defined as low 
(0–3), moderate (4–6) and high levels of burden. (7–9) This was in accordance with 
a study performed among caregivers of patients with oesophageal cancer [24]. 
Statistical analyses
Analyses were performed using SPSS software version 20 (SPSS Inc. Chicago, IL, 
USA). For analysis, incomplete dyads were excluded. Descriptive statistics were used 
for sample characteristics. To explore the association between patients’ distress 
and caregivers’ burden and distress, Pearsons correlations were performed. For the 
analysis of low/moderate versus high levels of burden and low versus high levels of 
distress, we performed independent-samples T-test for continuous variables when 
equal distribution of the number of participants between group was expected. The 
Mann–Whitney U test was performed when normal distribution was not met between 
groups. For categorical variables, Chi-square tests were performed and Fisher's  exact 
test was conducted when the condition of a maximum of 20% with ≤ 5 expected counts 
was not met. We explored whether there was a difference between low/moderate 
(score 0–6) versus high levels (7–9) of burden for the following variables: age, gender, 
relation to patient (spouse versus non-spouse), employment (yes/no), independence 
patient (yes/no), caring for more people than the patient with GIST (yes/no), hours 
of caring (<8h/>8 h), duration of TKI use (months), setting of TKI use (adjuvant versus 
palliative), side effects of TKI use (yes/no), caregivers’ comorbidity (yes/no), distress 
(HADS), discrepancies in social support (SSL-D), general health (RAND-36) and marital 
satisfaction (MMQ). We applied all the same variables to explore differences between 
high and low levels of distress, where distress (HADS) was replaced for burden (SPPIC). 




Caregivers’ and patients’ characteristics
Seventy-one couples were eligible, of whom 61 (84%) couples participated by 
returning the completed questionnaires. Reasons for not participating in the study 
were the expectation that filling out the questionnaires was too confronting (two 
couples) and unknown reason (eight couples). Table 1 shows caregivers’ and 
patients’ demographic characteristics, patients’ treatment-related characteristics 
and caregiving-related characteristics. The median age of caregivers’ was 60 years; 
66% were female and 78% were the patient’s’ spouse. The median age of patients 
was 66 years, and 43% were female. The mean duration of patients’ treatment with 
a TKI was 44 months (SD=34). 
Table 1. Caregivers’ and patients’ characteristics (n=61)




Gender Female 40 (66) 26 (43)
Age, median Years (IQR) 60 (51-68) 66 (55-75)
Educational level a Lower education (ISCED < 4) 36 (60) 41 (67)
Higher education (ISCED > 4) 24 (40) 20 (33)




Employment status c Paid work 28 (47) 12 (20)
Housekeeper 8 (13) 14 (23)
Voluntary work 5 (8) 7 (12)
Disablement insurance act 3 (5) 11 (18)
Retired 22 (37) 27 (44)
TKI treatment duration Month (SD) 44 (34)
TKI treatment Adjuvant, n (%) 12 (20)
Palliative, n (%) 49 (80)
Side effects treatment No, n (%) 5 (9)
Yes, minimal, n (%) 24 (41)
Yes, bothersome, n (%) 25 (42)
Yes, severe, n (%) 5 (9)








Difficulties enduring TKI treatment No, n (%) 40 (66)
Yes, somewhat, n (%) 12 (20)
Yes, n (%) 7 (12)
Yes, serious, n (%) 1 (2)
Hours of caregiving (weekly), n (%) < 8, n (%) 47 (84)
8-16, n (%) 5 (9)
16-24, n (%) 0 (0)
>24, n (%) 4 (7)
Patients’ independence, n (%) Completely independent 42 (69)
Mostly independent 14 (23)
Partly independent, partly 
dependent
4 (6)
Mostly dependent 1 (2)




General health changed as a 




Neglecting own health as a 




Number of comorbidities 0 18 (30) 13 (21.3)
1 19 (31) 15 (24.6)
2 13 (21) 18 (29.5)
3 5 (8) 6 (9.8)
4 3 (5) 2 (3.3)
5 1 (2) 4 (6.6)
6 1 (2) 3 (4.9)
7 1 (2) 0 (0)
IQR = interquartile range; ISCED = International Standard Classification of Education; SD = standard 
deviation; a One missing; b two missing; c more than one option possible
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Caregivers’ general health (RAND-36), comorbidities (SCQ), burden (SPPIC), 
distress (HADS), marital satisfaction (MMQ) and discrepancies between need 
for social support and perceived social support (SSL-D) 
Overall, scores on the RAND-36 showed that caregivers’ general health was not 
significantly different from values of normative comparatives, except for pain, 
which was significantly worse (p<.001). Details are shown in Table 2. The number 
of comorbidities affecting caregivers ranged from 0 (29.5%) to 7 (1.6%), with most 
between 0 and 2 (84%); 70% had one or more comorbidit(y)(ies). An overview of the 
number of comorbidities is given in Table 1. An overview of the nature and treatment 
of comorbidities, is shown in Table 3. 
The mean score for burden was 2.4 (SD=2.3; range 0–9). Seventy-four percent 
(n=45) reported low, 16% (n=10) moderate and 10% (n=6) high levels of burden. Of the 
caregivers who reported low levels of burden, 18% (n=11) experienced no burden at 
all. The mean level of distress was 8.1 (SD=5.7; range 0–42) and 23% of the caregivers 
experienced high levels of distress. Discrepancies in social support showed a mean 
score of 39.2 (SD=6.7; range 34–136). Mean score for marital satisfaction was 9.3 (SD 
9.3; range 0–80). 
Caregivers’ burden was significantly correlated with their own distress (r=0.584, 
p<0.01) and patients’ distress (r=0.442, p<0.01). Furthermore, caregivers’ distress was 
significantly correlated with patients’ distress (r=0.375, p<0.01).
Table 2. RAND-36 Health Survey outcomes of caregivers and patients in relation to healthy 
population [14]






Physical functioning 87.6 (19.9) 69 (21.2) * 81.9 (23.2)
Social functioning 83.5 (16.7) 77.5 (24.8) * 86.9 (20.5)
Role physical 83.2 (30.1) 63 (43.4) * 79.4 (35.5)
Role emotional 87.9 (28.4) 69.4 (42.6) * 84.1 (32.3)
Mental health 77.2 (15.8) 76.3 (15.7) 76.8 (18.4)
Pain 49.1 (5.4) * 48.1 (7.6) * 79.5 (25.6)
Vitality 70.1 (17.5) 61 (19.1) * 67.4 (19.9)
General health 72.7 (17.8) 49.4 (20.9) * 72.7 (22.7)
RAND = Rand-36 Health Survey; SD = standard deviation; * Significantly different from healthy 
population at p<0.01 level 
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n (% of total)
Impairments in daily 
functioning, n (% of total)
Heart disease 7 (12) 7 (100) 4 (57)
Stroke 0 (0) 0 (0) 0 (0)
Hypertension 12 (20) 10 (83) 0 (0)
Asthma, chronic bronchitis, COPD 4 (7) 2 (33) 1 (25)
Diabetes 1 (2) 1 (100) 0 (0)
Stomach ulcer 0 (0) 0 (0) 0 (0)
Kidney disease 0 (0) 0 (0) 0 (0)
Liver disease 0 (0) 0 (0) 0 (0)
Anaemia or other blood diseases 0 (0) 0 (0) 0 (0)
Cancer 2 (3) 1 (50) 0 (0)
Thyroid disease 2 (3) 2 (100) 1 (50)
Depression 4 (7) 1 (25) 3 (75)
Arthrosis 17 (28) 6 (40) 8 (57)
Back pain 15 (25) 5 (36) 8 (57)
Rheumatoid arthritis 3 (5) 1 (33) 1 (50)
Other 23 (37) 13 10
COPD = chronic obstructive pulmonary disease
Patients’ general health (RAND-36), comorbidities (SCQ), distress (HADS), marital 
satisfaction (MMQ) and discrepancies between need for social support and 
perceived social support (SSL-D)
Patients’ general health was significantly different to normative comparatives for 
every dimension measured, except for mental health, which was comparable. 
Details are shown in Table 2. The number of comorbidities affecting patients 
ranged from 0 (21.3%) to 6 (4.9%), with the most between 0 and 3 (85.2%); 78.7% 
had one or more comorbidit(y)(ies). Details are given in Table 1. Overall, the mean 
level of patients’ general distress was 9.6 (SD=6.8; range 0–42) and 34% of patients 
experienced high levels of distress. Discrepancies in social support showed a mean 
score of 38.7 (SD=6.2; range 34–136). For marital satisfaction patients reported a 
mean score of 9.3 (SD=10.0; range 0–80). 
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Exploring caregivers’ high levels of burden and distress
When the caregivers who experienced high burden (n=6, 10%) were compared to 
caregivers with low and moderate burden (n=55, 90%), the caregivers with high 
levels of burden experienced significantly more distress (p=0.003), lower mental 
health (p=0.033), less vitality (p=0.019) and lower general health (p=0.038). High 
levels of burden were found in non-spouses (p=0.017), caregivers of patients 
experiencing more treatment side effects (p=0.016), those who spent more hours 
caring (p=0.046) and those who were caring for more than one person (p=0.038). All 
caregivers with high levels of burden, had one of more comorbidit(y)(ies). Details 
are shown in Table 4. 
Table 4. Overview of demographical, treatment-related, care-related and health-related 
variables of caregivers stratified for low/moderate levels versus high levels of burden 







Gender Male, n (%) 20 (95.2) 1 (4.8) 0.654
Female, n (%) 35 (87.5) 5 (12.5)
Relation to patient Spouse, n (%) 45 (95.7) 2 (4.3) 0.017*
Non spouse, n (%) 9 (69.2) 4 (30.8)
Employment Yes, n (%) 25 (89.3) 3 (10.7) 1.000
No, n (%) 29 (90.6) 3 (9.4)
Side effects Yes, n (%) 22 (81.5) 5 (18.5) 0.016*
No, n (%) 32 (100) 0 (0)
Setting TKI use Adjuvant, n (%) 12 (100) 0 (0) 0.588
Palliative, n (%) 43 (87.8) 6 (12.2)
Independence patient Yes, n (%) 52 (92.9) 4 (7.1) 0.071
No, n (%) 3 (60) 2 (40)
Hours of caring < 8 hours, n (%) 44 (93.6) 3 (6.4) 0.046*
> 8 hours, n (%) 6 (66.7) 3 (33.3)
Caring for more than one 
person
Yes, n (%) 6 (66.7) 3 (33.3) 0.038*
No, n (%) 48 (94.1) 3 (5.9)
Comorbidity caregiver Yes, n (%) 37 (86) 6 (14) 0.167
No, n (%) 18 (100) 0 (0)
Age Years 31.2 29.5 0.827
Duration TKI treatment Months 29.2 42.8 0.085
HADS total (caregiver) Mean ranks 28.9 50.1 0.003**











SSL-D Mean ranks 26.9 36.9 0.137
MMQ – marital satisfaction Mean ranks 23.2 30.5 0.450
RAND physical functioning 
caregiver
Mean ranks 29.9 30.2 0.977
RAND social functioning 
caregiver
Mean ranks 31.5 21.3 0.156
RAND role physical caregiver Mean ranks 29.9 25.2 0.458
RAND role emotional 
caregiver
Mean ranks 30.2 22.6 0.162
RAND mental health 
caregiver
Mean ranks 31.1 15.7 0.033*
RAND vitality caregiver Mean ranks 31.2 14.5 0.019*
RAND pain caregiver Mean ranks 30.0 24.2 0.483
RAND general health 
caregiver
Mean ranks 31.1 16.0 0.038*
TKI = tyrosine kinase inhibitor; HADS = Hospital Anxiety and Depression Scale; SSL-D = Social 
Support List – Discrepancies; RAND = Rand-36 Health Survey; MMQ = Maudsley Marital 
Questionnaire; *Statistically significant values at p<0.05 level; ** Statistically significant values at 
p<0.01 level; continuous variables were tested with Mann-Whitney U, mean ranks are reported; 
categorical variables were tested with Fisher's exact, numbers and percentages are reported. 
When caregivers with high levels of distress (n=14, 23%) were compared to caregivers 
with low levels of distress (n=47, 77%), the caregivers with high levels of distress 
experienced significantly more burden (p=0.001), lower levels of social functioning 
(p=0.016), more role physical problems (p=0.007), more role emotional problems 
(p=0.043), lower levels of mental health (p<0.001), less vitality (p<0 .001), lower 
levels of general health (p=0.006). Furthermore, high levels of distress were found 
in caregivers of patients who were perceived as less independent (p=0.008) and in 
caregivers caring for more than one person (p=0.025). For caregivers with high levels 
of distress 79% had one or more comorbidit(y)(ies), but there was no difference in 
whether the caregiver had comorbidities (yes/no) between groups with low versus 
higher levels of distress. Details are shown in Table 5. The duration of treatment 
and setting in which the treatment was given (adjuvant or for metastatic GIST) did 
not differ between caregivers with high or low/moderate levels of burden, nor high 
and low levels of distress.
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Table 5. Overview of demographical, treatment-related, care-related and health-related 
variables of caregivers stratified for low versus high levels of distress







Gender Male, n (%) 19 (90.5) 2 (9.5) 0.109
Female, n (%) 28 (70) 12 (30)
Relation to patient Spouse, n (%) 37 (78.7) 10 (21.3) 0.478
Non spouse, n (%) 9 (69.2) 4 (28.6)
Employment Yes, n (%) 23 (82.1) 5 (17.9) 0.547
No, n (%) 24 (75) 8 (25)
Side effects Yes, n (%) 19 (70.4) 8 (29.6) 0.224
No, n (%) 27 (84.4) 5 (15.6)
Setting TKI use Adjuvant, n (%) 9 (75) 3 (25) 1.000
Palliative, n (%) 38 (77.6) 11 (22.4)
Independence patient Yes, n (%) 46 (82.1) 10 (17.9) 0.008**
No, n (%) 1 (20) 4 (80)
Hours of caring < 8 hours, n (%) 37 (78.7) 10 (21.3) 0.206
> 8 hours, n (%) 5 (55.6) 4 (44.4)
Caring for more than one person Yes, n (%) 4 (44.4) 5 (55.6) 0.025*
No, n (%) 42 (82.4) 9 (17.6)
Comorbidity caregiver Yes, n (%) 15 (83.3) 3 (16.7) 0.525
No, n (%) 32 (74.4) 11 (25.6)
Age Years 30.3 33.2 0.595
Duration TKI treatment Months 31.4 29.7 0.757
SPPIC Mean ranks 26.8 45.1 0.001**
SSL-D Mean ranks 27.2 30.7 0.475
MMQ – marital satisfaction Mean ranks 21.9 29.2 0.131
RAND physical functioning caregiver Mean ranks 31.5 25.1 0.205
RAND social functioning caregiver Mean ranks 33.4 21.0 0.016*
RAND role physical caregiver Mean ranks 32.1 20.6 0.007**
RAND role emotional caregiver Mean ranks 31.2 24.1 0.043*
RAND mental health caregiver Mean ranks 35.3 11.3 0.000**
RAND vitality caregiver Mean ranks 34.1 15.1 0.000**
RAND pain caregiver Mean ranks 29.9 28.0 0.669
RAND general health caregiver Mean ranks 31.1 16.0 0.006**
TKI = tyrosine kinase inhibitor; HADS = Hospital Anxiety and Depression Scale; SSL-D = Social 
Support List – Discrepancies; RAND = Rand-36 Health Survey; MMQ = Maudsley Marital 
Questionnaire; *Statistically significant values at p<0.05 level; ** Statistically significant values at 
p<0.01 level; continuous variables were tested with Mann-Whitney U, mean ranks are reported; 
categorical variables were tested with Fisher's exact, number and percentages are reported. 




The goal of this study was to explore caregivers’ burden and distress during the 
patients’ long-term treatment with TKI for GIST. Overall, caregivers of patients 
treated for GIST seem to manage well, as their levels of perceived burden and 
distress are low, their perceived general health is good and similar to the healthy 
population, their marital satisfaction seems good and they do not seem to 
experience discrepancies in social support. Fortunately, 90% of caregivers in this 
study perceived low to moderate levels of burden, of whom 18% did not perceive 
any burden at all. The burden of caregivers of the patients with cancer differ, but 
hardly any studies are performed in caregivers of patients treated with long-term 
TKIs. In a study by Haj Mohammed et al., where caregivers of oesophageal cancer 
patients were studied for burden approximately 3 years after being treated with 
curative intent with neo-adjuvant chemoradiotherapy followed by resection, the 
percentage of low and moderate burden was 81% [24]. In a study by Hsu et al., 
exploring caregivers’ burden of patients treated for cancer in early stage of disease 
(30%) or advanced disease (70%) for haematological and solid malignancies, low and 
moderate burden was found in 75% of caregivers [25]. Additionally, the multivariate 
analyses in the study by Hsu et al. showed that caregivers who were employed and 
providing support for activities of daily living, were at greater risk of high levels of 
burden [25]. According to the caregivers in our study, 84% of the caregivers spent 
less than 8 h weekly providing care to the patient and 92% of GIST patients function 
independently of their caregivers in daily life, although the questionnaire did not 
define exactly what is meant by functioning independently. This may explain why 
the levels of burden in caregivers is perceived as low. Another reason may be that 
caregivers in our study experience low levels of discrepancies between their need 
for social support and their perceived social support. It is known that social support 
is vital in preventing high levels of burden [10]. Furthermore, it is known that good 
copings skills may protect caregivers from overstretching themselves [10]. As the 
average duration of treatment of the patients in our sample was 44 months, this 
may have given caregivers time to adjust to patients’ disease and treatment. On 
the other hand, our study showed that there was no difference between the groups 
of low/moderate and high levels of burden and low and high levels of distress 
according to the duration of treatment. This may also suggest that there is a group 
of caregivers that is not able to adjust over time. 
Overall, we found that levels of distress were low. Distress in caregivers of 
patients on active treatment can arise due to worries about the efficacy of treatment, 
management of side effects, social isolation, lack of experience when caring for 
a significant other and complexity of care [13]. Considering these risk factors, 
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caregivers in our study experienced low levels of unmet needs for social support 
and the majority of the caregivers spent a low number of hours of providing care, 
which might protect them from distress. On the other hand, 50% of the patients 
in this study reported bothersome or severe side effects of treatment and 34% of 
the patients experienced high levels of distress. The latter was associated with 
caregivers’ levels of distress and burden. This, together with the need for continuous 
treatment, anxiety about computed tomography (CT) scans and results, may have 
contributed to high levels of distress in 23% of caregivers. 
It is vital that attention is given to caregivers with high levels of distress and 
burden, as active treatment for patients with GIST is at least three years in the 
adjuvant setting and may be much longer with metastatic GIST. We identified a 
group of caregivers with high levels of burden (10%) or distress (23%), and compared 
them to the group of caregivers with low/moderate levels of burden or low levels 
of distress. Caregivers with high levels of burden, had significantly lower levels 
of mental health (i.e., feelings of sadness and anxiety), vitality (i.e., tiredness and 
lower levels of energy) and general health (i.e., perception of lower quality of 
personal general health). It is known that high levels of burden are associated with 
depressive symptoms, or even depression as an outcome, and our findings are 
therefore consistent with other studies [10,13]. Regarding their general health, 100% 
of the caregivers with high levels of burden had one or more comorbidities, which 
is higher than the average for the Dutch population (between 42 and 52% above 
55 years) [26]. Nevertheless, there was no significant difference in the number of 
comorbidities between the group with low/moderate and high levels of burden. 
This may be explained by the fact that most of the comorbidities reported by 
caregivers did not cause limitations in daily functioning, except for arthrosis, back 
pain and rheumatoid arthritis. The latter may explain why caregivers, overall, 
had significantly higher pain scores on RAND-36 compared with their normative 
comparatives. Nevertheless, only 2% reported they experienced a decline in their 
health as a consequence of caring for their significant other. 
Caregivers who perceived high levels of burden spent significantly more hours 
caring for their significant other and were more likely to care for more people other 
than the GIST patient alone. Adelman et al. described in their review that spending 
more hours caring is a risk factor for burden and Northouse et al. described that 
it is associated with disruption to their own lifestyle and interference with their 
own social activities causing social isolation [10,11]. The latter may on its own 
contribute to distress, as we found that caregivers with high levels of distress had 
significantly more problems with social functioning. It may be that what normally 
protects caregivers against overstraining, such as moving on with their own life, their 
employment and social interaction, is insufficient and may lead to (serious) health 
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problems, as found in other studies [10,13,27]. Furthermore, caregivers experiencing 
high levels of burden were shown to care for patients who had significantly more 
treatment-related side effects. An important TKI-related side effect is severe 
fatigue, which was studied by Poort et al. This study showed that 30% of patients 
treated with a TKI for GIST were severely fatigued and this influenced their quality 
of life and impaired their overall functioning [28]. Pitceathly et al. described that 
caregivers’ distress increases when a patient has more physical complaints [27]. It 
is conceivable that side effects may influence many aspects of a patient’s life and 
therefore also interfere with the well-being of caregivers, as they cope with the 
disease and its treatment as a couple [7,8]. 
This study had a number of limitations. Firstly, as far as we know, there are no 
validated cutoff points for measuring burden and distress in caregivers with the 
SPPIC and HADS, respectively. The SPPIC is a validated instrument to measure 
burden and is often used in clinical settings to measure cancer caregivers’ burden. 
However, no reference data are available and there are no studies performed 
establishing validated cutoff scores. Nevertheless, for clinical practice, mean scores 
are often more difficult to interpret and during consultation it is useful to evaluate 
whether a caregiver experiences moderate or high levels of burden, in order to 
prioritise the need for support. Therefore, we decided to dichotomise with low 
and moderate versus high levels of burden, as with the study performed by Haj 
Mohammed et al. [24] Using this, we tried to identify the most vulnerable group of 
caregivers and explore risk factors for high levels of burden. Future studies could 
also focus on the group with moderate levels of burden or decide to combine 
moderate and high levels of burden, since moderate levels of burden could be of 
importance for caregivers of patients on long-term treatment. The HADS is also a 
validated questionnaire and often used to screen for distress among caregivers in 
clinical practice in the Netherlands. As for burden, to evaluate whether a caregiver 
experiences distress, a cutoff score could be helpful, however, there are no 
established cutoff scores to measure higher levels of caregivers’ distress. Therefore, 
we adopted a cutoff score of 12, which is often used when screening for distress 
in general practice, and seems to have a satisfactory sensitivity for the total HADS 
scale, important for preventing too many false negatives [16]. We acknowledge 
that the HADS is especially useful as a first screening for distress and we want to 
emphasize that it is important to explore the cause of distress further when finding 
cases using cutoff scores. 
In order to explore differences between low/moderate and high levels of 
burden and low and high levels of distress, we used multiple separate tests. 
With these tests we can only explore whether there were differences between 
the groups, without drawing conclusions about its cause or associations between 
Chapter 4
90
variables. To determine association between the variables and possible causes 
of burden and distress, a multiple regression analysis would be of added value. 
Due to our small sample size we did not perform multiple regression analyses. 
The generalizability of this study may also be limited due to the small sample 
size. Future studies could perform these analyses with a larger sample size in 
order to prevent type II error. These studies could focus on this association to 
better understand burden and distress in this group of caregivers, using multiple 
regression analyses. This was a cross-sectional study and therefore, we cannot 
draw firm conclusions about causality. We also included both patients receiving 
curative, i.e., adjuvant, and palliative treatment, however this did not translate in 
differences in perceived burden and distress. We only studied a group of patients 
who were on TKI treatment for at least six months and had a prognosis of >12 weeks. 
Therefore, our results cannot be generalised to caregivers of patients at the start 
of TKI treatment or caregivers of GIST patients in the terminal phase of their lives. 
Our sample also did not include caregivers who were under the age of 18 years and 
were not able to communicate in the Dutch language. These caregivers could be 
another interesting group of caregivers and it would be interesting to study them 
in the future. Lastly, there were two couples who did not want to participate as 
they felt that the questionnaires were too confronting. It is conceivable that these 
patients and/or caregiver may suffer from burden and/or distress. It is therefore 
possible that the levels of distress and burden might be even higher than observed 
in this study. 
In conclusion, caregivers of patients on long-term treatment for GIST with 
TKIs appear to manage well. Nevertheless, it is important to recognise caregivers 
who have high levels of burden and distress, associated with physical and mental 
health-related problems. Interestingly, the stage of disease for which the patient 
was treated, and the duration of the treatment, did not seem to impact the burden 
and distress, however treatment-related side effects and more hours of caring were 
related. Healthcare professionals currently aim to involve caregivers in patient care 
through providing adequate information on how to deal with patients’ treatment. 
Awareness of caregivers’ health problems should be improved. Recognizing the 
burden and distress is an important initial step, however management may be 
challenging. Future research could focus on how to implement screening for 
caregivers’ burden and distress, how to identify caregivers at high risk for burden and 
distress, and how to work with other professionals, including general practitioners, 
in caring for the caregiver.
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ABSTRACT
Introduction: The aims of the study were to (1) describe the prevalence of fear 
of cancer recurrence (FCR) in partners of prostate cancer (PCa) survivors; (2) to 
compare the proportions of high FCR in partners with high FCR in PCa survivors; (3) 
to explore partners’ demographic and survivors’ clinical characteristics associated 
with high FCR in partners; and (4) to identify the relationship between high FCR and 
health-related quality of life (HRQoL) in partners.
Methods: Questionnaires were sent to partners of disease-free PCa survivors. 
Outcomes included FCR severity (Cancer Worry Scale [CWS]) and HRQoL (RAND-
36). The t and chi-square tests were used to compare partner FCR with survivor 
FCR. Regression analyses were performed to determine if demographic and clinical 
characteristics were significantly associated with partner FCR. The multivariate 
analysis of variance identified differences in HRQoL between partners with high 
and low FCR. 
Results: Questionnaires were completed by 168 partners. Mean levels of FCR 
were comparable between partners and survivors (p=0.144). Thirty-five percent of 
partners reported high FCR (CWS≥14) compared to 38% of PCa survivors (CWS≥13) 
(p=0.542). Higher survivor FCR and younger partner age were significantly associated 
with higher partner FCR. Partners with high FCR scored significantly lower on social 
functioning, emotional role functioning, mental health, general health, and vitality 
than those with low FCR (all p<0.05). 
Conclusions: Findings from this study illustrate that FCR is a significant concern 
for partners of PCa survivors. Clinicians should be aware of partner FCR when 
delivering care to men with PCa.




Cancer survivorship comes with emotional and physical challenges for the cancer 
survivor and may also affect their carers and family, especially partners [1]. Most 
partners adjust well to the stress of cancer after treatment has been completed, 
but a minority faces difficulties [2,3]. For instance, there is some evidence that 
female partners of cancer survivors perceive more psychological distress and a 
lower quality of life than male partners [4,5]. Partners may experience a significant 
physical and emotional care burden such as heightened distress, fatigue, or the 
worry that the cancer may come back [6,7]. 
Fear of cancer recurrence (FCR) is the fear, worry, or concern about cancer 
returning or progressing [8]. The current literature suggests that FCR is a common 
concern for those who have survived cancer, with moderate to high FCR affecting 
on average 49% of cancer survivors [9]. For partners of prostate cancer (PCa) 
survivors, it was found that a third (36%) of them reported high FCR [10]. While FCR 
has primarily been regarded as a patient concern, partners may also worry about 
the risk of cancer recurrence or the possibility of losing their loved one to a potential 
disease recurrence [11]. As no partner-specific FCR models have been proposed, 
more general FCR models may be suitable for partners as well. For instance, the 
conceptual FCR model by Lee-Jones et al [12] explains FCR as a multidimensional 
construct that includes cognitive and emotional processing systems that influence 
the perception of FCR and lead to behavioural and emotional FCR responses. Also, 
certain structural characteristics (personality, history) may predispose persons to 
higher levels of worry or FCR. Partners’ psychological reactions to disease and 
treatment are believed to follow the same underlying processes and Lee-Jones’s 
model may be applicable to them as well [12]. 
In cancer survivors, high levels of FCR do not improve spontaneously with 
time [13] and are associated with adverse outcomes of emotional functioning, 
experienced distress [9], greater utilization of health care [14], and poorer health 
behaviours (smoking, lower activity levels) [15]. For partners, potential consequences 
of FCR are less well understood, but given its association with negative outcomes 
in cancer survivors, it is reasonable to expect a comparable impact on partner 
well-being. 
Currently, there is a paucity of research on what FCR entails in partners of 
cancer survivors and only 1 study has assessed high levels of fear of progression 
(FoP) in partners of PCa patients [16]. This study reported that half (51%, n=24) of 
all partners experienced high FoP at an average of 8.9 months postdiagnosis; 
especially partners of PCa patients whom had a relapse. This study’s sample size 
was relatively small, and an unreported number of patients had experienced a 
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recurrence that limits generalizability. The few studies that have addressed FCR in 
partners of non-PCa survivors often found similar or even greater FCR in partners 
(or carers) than in survivors themselves [17-21]. Also, help in managing concerns 
about cancer returning was one of the top 3 cited unmet needs by partners and 
caregivers of both short and long-term cancer survivors [22,23] with, respectively, 
18% and 10% reporting FCR to be an unmet need at 6 and 24 months post survivor 
diagnosis [23]. Fear of cancer recurrence appeared to be a consistent and core 
unmet need for many. Furthermore, greater knowledge of factors associated with 
FCR in partners can be used to guide improvement of care for partners. 
The aims of this cross-sectional study were to (1) describe the prevalence of 
high FCR in partners of PCa survivors; (2) to compare the proportions of partners 
with high FCR with the proportion of survivors with high FCR; (3) to explore 
partners’ demographic and survivors’ clinical characteristics associated with high 
FCR in partners; and finally, (4) to identify the relationship between high FCR in 
partners and their health-related quality of life (HRQoL). It was hypothesized that 
(1) partners experience similar mean levels of FCR as PCa survivors and that (2) an 
equal proportion of partners and cancer survivors report high FCR. On the basis 
of the available literature,8,24 we expect that (3) a younger age to be significantly 




Sample size calculation is based on identifying high FCR in partners. A database 
with 740 PCa survivors was available for partner invitation (exact number of partners 
unknown). Assuming an equal proportion of high FCR in cancer survivors and 
partners, the estimated proportion of partners with high FCR is set to 37% (range 
34%-40%) [10,25]. To measure this proportion in current exploratory study with a 
7% margin of error, we estimate that we will need approximately 173 partners to 
complete the questionnaires. 
Respondents and procedure
The only eligibility criterion was that the partner was identified as being in 
committed relationship with a disease-free PCa survivor. Partners were invited 
to participate via a letter from the treating urologist that was sent between June 
and August 2013 to PCa survivors listed in an existing database. This database 
included 740 PCa survivors who were curatively treated between 1992 and 2012 at 
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the sites’ Department of Urology. As it was unknown how many PCa survivors were 
in a committed relationship, all were asked if they and (if applicable) their current 
partner would be willing to participate in a questionnaire study. Therefore, it was 
not possible to ascertain exact response rates for partners because they were 
not contacted directly for confidentiality reasons. Results from the PCa survivor 
study have already been reported elsewhere (their response rate was 43%; for more 
details, see Van de Wal et al) [10]. 
By having the partner return a participation form, 311 indicated willingness to 
participate and 75 refused participation. Reasons for nonparticipation are displayed 
in Figure 1. Questionnaires were completed and returned by 219 partners. Because 
of incompleteness (<50% competed, n=8), false inclusion (PCa survivor not disease 
free, n=12) or survivor disease status unknown (n=31), 51 questionnaires were 
excluded from analysis resulting in n=168. Ethical approval was given by the Medical 
Ethics Committee, Radboud university medical center. 
   
  

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    
 
     
Figure 1. Flow diagram
Measures
Demographics and clinical characteristics of partners
Variable selection was guided by the theoretical model of FCR by Lee-Jones et 
al [12] plus past literature. Partner demographics (age, education, children [yes/
no], and years as a couple) and the variable cancer history were gathered by self-
report. Gender was not asked. Educational level was operationalized as lower 
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(elementary school and/or lower secondary education), secondary (general 
secondary education and intermediate vocational schooling), or tertiary (higher 
vocational schooling and/or university). 
Partners of prostate cancer survivor information
Partners of prostate cancer survivors’ information was retrieved from an existing 
dataset and linked to partner information in the current study. Survivor information 
included clinical characteristics (treatment modality, time since diagnosis and 
surgery) and demographics (age, education, and children [yes/no]). Furthermore, 
survivors’ Cancer Worry Scale (CWS) scores were also available. 
Fear of cancer recurrence
The FCR scores (measured by the CWS) were available for both PCa survivors 
and partners. The PCa survivors had completed the original CWS26 in a previous 
study [10], whereas partners completed a modified version in the current study. 
For partners, the wording of the original 8-item CWS was adjusted to make the 
questionnaire more suitable for their situation. For instance, the original item 
“How often have you thought about your chances of getting cancer (again)?” 
was changed to “How often have you thought about the chances of your partner 
getting cancer (again)?” Responses to all items were provided on a 4-point Likert 
scale ranging from “never” to “almost always”. Scores range from 8 to 32, a 
higher score indicating more worries about a recurrence. A CWS score of ≥14 was 
found to differentiate between low and high FCR in breast and colorectal cancer 
survivors (sensitivity 77%/86%, specificity 81%/87%); however, a cutoff point of 
≥13 was found optimal for making this differentiation in PCa survivors (sensitivity 
86%, specificity 84%) [10,25,27]. The modified CWS has not been validated in 
partners of cancer survivors yet. To detect high FCR in (female) partners, two 
options to define high FCR in this group were possible. The first was using the 
validated CWS cutoff point of ≥13 that was found for PCa survivors. However, 
research in couples coping with chronic diseases has shown that women report 
more burden regardless of whether they are the patient or caregiver [28,29]. This 
suggests that there is a gender rather than role effect (i.e. patient versus partner) 
whereby women experience more burden or distress than men. Therefore, it 
seemed more logical to use the validated female breast cancer survivor cutoff 
score of CWS ≥ 14, rather than the cutoff for male PCa patients. In the current 
study, reliability of the CWS was sufficient for both PCa survivors and partners 
(α = 0.88 and 0.87). Incomplete items for the CWS (5%, n=9) were imputed using 
mean substitutions.
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Health-related quality of life in partners
The HRQoL in partners was assessed using the RAND-36 [30]. The RAND-36 
data were not available for survivors. The RAND-36 measures 4 physical health 
concepts and 4 mental health concepts: physical functioning, role limitations 
caused by physical health problems, pain, general health perceptions, emotional 
well-being, role limitations caused by emotional problems, social functioning, 
and energy/vitality. The internal consistency of subscales ranged from α=0.80 
to 0.90 in the present sample. All scale scores were transformed linearly to a 0 
(worst health) to 100 (best health) range. Missing data were handled according 
to the scoring manual that recommends use of mean substitution for handling of 
missing data [31]. If more than 50% of the items were missing on a subscale, the 
subscale score was not computed and was regarded as missing. The RAND-36 
has sufficient psychometric properties whereby the alpha values for the subscales 
vary between 0.71 to 0.92 and for the test-retest reliability between 0.58 to 0.82 
over a 2-month period [30,31]
Statistics
SPSSv20 was used to analyse the data. Descriptive statistics are provided as 
a frequency breakdown of categorical variables and medians (or means) with 
dispersion statistics for continuous variables. Unless otherwise specified, all 
analyses were tested at ≤0.05 level of significance. Mean levels of FCR were 
computed for partners and survivors and compared with t tests. Associations 
between survivors’ and partners’ mean CWS scores were explored using Pearson 
correlation. For all subsequent analyses, the CWS cutoff score was used to group 
partners according to low or high FCR (low≤13; high≥14). Chi-square tests were 
used to assess differences in proportions of high FCR between partners and 
survivors. A multiple linear regression analysis (enter method) of age at survey, 
partner (yes/no), cancer history (yes/no), education (dummy coded with lower 
education as the referent), children (yes/no), time since diagnosis, treatment 
modality, and survivors’ CWS score on partner FCR was conducted. Differences in 
HRQoL between partners with low vs high FCR were compared with multivariate 





Demographics and clinical characteristics of partners and PCa survivors are shown 
in Table 1. A total of 168 partners of PCa survivors participated. Partners had a 
median age at survey of 67.4 years (range 40-86) and PCa survivors 70.1 years 
(range 54-89). Survivors were on average 7.5 years postdiagnosis (range 0.9-20). 
Couples had been together an average of 3 years (range 8-57). Twenty-two partners 
(13%) reported being examined with cancer in the past (mostly breast cancer; 41%). 
Table 1. Demographics (n=168 partner-patient dyads)
Partners, n (%) PCa survivors, n (%)
Age at survey
Median (range) 64.7 (40-86) 70.1 (54-89)
Education
Lower 94 (56) 35 (24)
Secondary 46 (27) 40 (27)
Tertiary 28 (17) 70 (48)
Children
Yes 155 (92) 151 (94)
No 14 (8) 9 (6)
Years a couple
Median (range) 43.0 (8-57) n.a.
History of cancer
Yes 22 (13) 174 (100)
No 147 (87) n.a.
Time since diagnosis (years)
Median (range) n.a. 7.5 (0.9-20.0)
Time since surgery (years)
Median (range) n.a. 5.9 (0.8-19.2)
Treatment modality
Surgery only n.a. 126 (75)
Surgery + RT n.a. 41 (25
PCa = prostate cancer; RT = radiotherapy; n.a. = not applicable.
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The prevalence of high FCR in partners and PCa survivors 
Partners’ mean rating of FCR was 12.6 (SD=3.5), which is similar to mean levels of 
FCR reported by PCa survivors, M=12.0 (SD = 3.8), t=−1.465, p=0.144, 95% confidence 
interval (CI) [−1.366 to 0.200]. A significant moderate positive correlation was found 
between partners’ and survivors’ mean levels of FCR (r=0.44, p<0.001). 
When using a CWS cutoff score of ≥13 for PCa survivors and the more 
conservative female breast cancer survivor cutoff score of ≥14 for partners, no 
significant difference in the percentage of high fearful survivors (38%) or partners 
(35%) was found, χ2(1, n=326) = 0.372, p=0.542. Fifty-seven of the high fearful partners, 
compared to 28% of the low fearful partners, were in a relationship with a high 
fearful PCa survivor, χ2(1, n=168) = 13.084, p<0.001. Twenty-one percent of the 
couples consisted of both a survivor and partner with high FCR. 
Further exploratory analysis using the same cutoff for both (CWS≥13) found 
significantly more partners reported high FCR (49% partners vs 38% survivors, 
p=0.03). 
Demographic and clinical associates of high FCR (CWS≥14) in partners
The overall model for regression was significant (p<0.001) and explained 21% (R2) 
of partner FCR. Only higher survivor FCR (β 0.310; p<0.001) and younger age of the 
partner (β −0.304; p=0.008) were significantly associated with higher FCR in partners 
(Table 2). 
The HRQoL correlates of FCR in partners
Compared to partners with low FCR, partners with high FCR (CWS≥14) scored 
significantly worse on social functioning, emotional role functioning, mental health, 
vitality, and general health (Table 3). Compared to scores of a normative female 
population (Table 3) partners with high FCR reported significantly worse social 
functioning and general health (both p<0.05).
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Table 2. Regression analysis of factors associated with partner FCR (n=159)
Variable B SE(B) β t Sig. (p-value)
Partner variables
Age at survey -0.129 0.048 -0.295 -2.706 0.008*
Years a couple 0.045 0.033 0.140 1.368 0.173
Cancer history (yes/no) 0.220 0.729 0.022 0.302 0.763
Education secondary vs. lower -0.749 0.600 -0.096 -1.249 0.214
Education tertiary vs. lower -1.212 0.714 -0.134 -1.698 0.092
Children (yes/no) -0.465 1.032 -0.037 -0.450 0.653
Survivor variables
Time since diagnosis 0.043 0.060 0.064 0.719 0.477
Treatment modality 0.827 0.594 0.106 1.392 0.166




CWS = Cancer Worry Scale; *p<0.05 and **p<0.001.
Table 3. Health-related quality of life in partners with high FCR vs. partners with low FCR and 
a normative population










Physical functioning 81.8 (18.9) 76.7 (24.8) 0.151 80.7 (23.6) 0.260
Social functioning 88.5 (16.8) 77.6 (19.1) <0.001** 68.1 (20.9) 0.003**
Physical role functioning 75.7 (37.3) 71.7 (38.6) 0.529 78.3 (36.5) 0.207
Emotional role functioning 88.4 (27.9) 76.1 (37.8) 0.023* 82.5 (33.5) 0.185
Mental health 82.0 (12.0) 74.0 (13.5) <0.001** 75.5 (18.9) 0.571
Vitality 71.8 (14.5) 66.4 (16.8) 0.038* 66.3 (19.6) 0.971
Pain 84.2 (19.7) 81.4 (21.8) 0.428 80.0 (25.4) 0.696
General health 70.0 (17.0) 63.9 (20.1) 0.042* 71.5 (21.8) 0.014*
a Normative sample, Dutch female general population (n=691) RAND-36 manual [31]; *p<0.05 
and **p<0.001.




This study demonstrated that FCR is not restricted to cancer survivors but affects 
partners as well. Amongst partners, who were on average 7.5 years post-survivor 
diagnosis, approximately one-third (35%) scored above the cutoff for high FCR. 
Using the conservative CWS cutoff score to define high FCR, the proportion of 
high fearful partners in the current study is lower than reported by Zimmermann et al 
[16] where 51% of partners of PCa survivors (n=24) scored above the cutoff for clinical 
fear of progression. Reasons for differences in percentages of high FCR could be 
that the studies differed in respect certain partner characteristics, for instance, our 
sample did not include partners of survivors who had experienced a recurrence. 
Also, different questionnaires were used and the sample by Zimmermann et al [16] 
was relatively small, which makes it hard to generalize their findings. Our finding 
that even 7.5 years after diagnosis that a number of partners continue to experience 
high FCR is concerning and indicates that FCR is not restricted to the period around 
disease and treatment. The Dutch prostate cancer guideline advises semi-annual 
or annual hospital follow-ups up to 5 years postdiagnosis.32 This, together with 
the fact that partners do not always join the patient during medical consultations, 
makes high FCR in partners a problem that can remain undetected, especially in 
the period beyond 5 years postdiagnosis. 
Partners reported a mean CWS score of 12.6. As there is no comparison data 
available of healthy persons or partners of cancer survivors, we compared it with 
the mean CWS score (12.4) found amongst family members of patients with Lynch 
Syndrome (HNPCC) and found no significant difference [26]. In accordance with 
previous studies and our hypothesis, we found that equal mean levels of FCR were 
reported between PCa survivors and their partners. For instance, Cohee et al [19] 
reported equivalent mean FCR scores between young breast cancer survivors 
and male partners. Three studies that have addressed FCR in caregivers (partners 
and relatives combined) showed equal mean levels of FCR between patients and 
caregivers [20] or reported that caregivers experienced higher levels of FCR [17,18]. 
Furthermore, in our study, partners with high FCR were more often partnered with 
a high fearful survivor than partners with low FCR. Also, there was a significant 
moderate correlation between PCa survivors’ and partners’ FCR. Overall, this study 
provides early evidence that high FCR is not only a common problem amongst 
partners but also that it is related to survivors’ FCR as well. Future studies could 




We identified demographic and clinical factors associated with higher FCR 
in partners. Survivor FCR was the strongest significant contributor to partner 
FCR, further contributing to the evidence that FCR is a dyadic concern. The 
only other significant predictor was partners’ younger age, which is in line with 
our hypothesis. Mellon et al [17] also found that younger age in caregivers was 
related to elevated FCR levels in caregivers. Reasons why a younger age has been 
linked to higher FCR are still speculative. It could be that those who are younger 
experience a greater life disruption caused by cancer. Those who are older may 
have had more exposure to stressful life events leaving them more resilient to 
FCR [33]. However, Cohee et al [19] did not find an association between age and 
FCR in male partners of young breast cancer survivors. In the latter study, the 
only demographic characteristic significantly related to higher FCR was lower 
education. Regarding survivors’ time since diagnosis and treatment modality, we 
did not find a significant association with partner FCR. Our results indicate that 
partners experience FCR at different stages of the cancer continuum, directly after 
cancer treatment but also in the long-term cancer survivorship phase (>10 years 
post-survivor diagnosis). Because of an insufficient number of published studies, 
there is no clear consensus on which demographic or patient factors, except for a 
younger age, strongly contribute to partner FCR. This remains an important topic 
for future studies to address. 
Finally, the relationship between high FCR in partners and their HRQoL 
was explored. Compared to HRQoL scores found in the Dutch healthy female 
population, those with high FCR scored significantly lower on social functioning 
and general health whereas all domain scores for those with low FCR were equal 
to those by the healthy norm population [31]. This is in line with our expectations 
and corroborates the results of many previous studies amongst cancer survivors 
that reported an association between high FCR and poorer emotional wellbeing 
[9,10,27]. One study [20] reported higher caregiver FCR to be related to poorer 
mental health. We did not find any differences in physical (role) functioning or 
pain between partners with low or high FCR. 
Our results have important implications for clinical practice because 
they demonstrate that FCR is a significant concern for many partners of PCa 
survivors. A subgroup of partners might benefit from interventions designed to 
help them manage FCR. Most interventions or supportive care for partners of 
PCa survivors have focused on emotional distress (in which FCR is sporadically 
addressed) and sexual intimacy [34-36]. To date, none have focused exclusively 
on FCR in partners (or couples). In a review by Wooten et al [34], the efficacy 
of psychosocial interventions for the well-being of PCa survivors’ partners 
remained inconclusive, although psycho-educational interventions and cognitive 
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behavioural interventions showed some promising results. As partners often 
have unmet needs in multiple areas, tailored generic interventions with multiple 
targets (eg, sexual intimacy, FCR) might be more suitable than a symptom-specific 
intervention. 
Also, there is limited but growing evidence that FCR interventions for cancer 
survivors are a promising approach in managing high FCR [37,38] and it would be 
interesting to see if these might be adapted for treatment of partners with high 
FCR. Future studies should delineate the most appropriate methods to offer high 
fearful partners help with FCR. 
Several limitations of this study warrant attention. Firstly, because of the cross-
sectional design, causality and directionality cannot be implied. Prospective research 
is needed to identify the longitudinal trajectory of FCR in partners over time. Secondly, 
in the study information, we asked all partners to participate regardless of level of 
FCR. Unfortunately, one of the most common reasons for partner nonparticipation 
(21%) was no interest to participate because of absence of FCR. The percentage 
of partners experiencing high FCR could therefore be overestimated because of 
self-selection bias. On the other hand, there were also some partners who declined 
study participation because they perceived it as too confronting. Thirdly, it was also 
unknown (1) how many survivors invited their partners to participate and (2) how many 
survivors had a partner. Therefore, the participation rate of partners could not be 
precisely calculated. Nonparticipation bias has been found to be a problem in other 
couple-based and partner studies [39,40]. Finally, while we assume most partners 
to be female, gender was not explicitly asked. 
The aforementioned factors limit the generalizability of our findings. As there are 
currently no validated questionnaires available to assess FCR in partners of cancer 
survivors, we chose to use an adapted version of the Dutch CWS to measure FCR 
and decided (on theoretical grounds) to define high FCR with the more conservative 
score (≥14) on this instrument. Nevertheless, we encourage the development and 
validation of strategies to identify partners (and caregivers) with high FCR who 
could potentially benefit from additional supportive care and/or intervention. 
In conclusion, findings from this study illustrate that FCR is a significant concern 
for partners of PCa survivors. Partners with high FCR reported a worse mental and 
general health when compared with those who experienced low FCR. Our findings 
support the need for increased awareness of the presence of FCR in partners and 
better methods of screening for high FCR in partners (and caregivers). Furthermore, 
as partners with high FCR may benefit from help in managing their fears, more 
research on possible partner or couple interventions is encouraged. Clinical health 
professionals should be aware that FCR is not solely a patient affair but a problem 
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ABSTRACT
Introduction: It can be assumed that patients’ participation in a phase I study will 
have an important impact on their partners’ life. However, evaluation of partners’ 
experiences while patients are undergoing experimental treatment and of their 
well-being after the patient’s death is lacking. We aimed to explore partners’ 
experience of patients’ participation in phase I studies and to investigate their well-
being after a patient’s death.
Methods: This was an observational study conducted after the patient’s death. 
Partners of deceased patients who had participated in a phase I study completed 
a questionnaire designed by us for experience evaluation and the Beck Depression 
Inventory for Primary Care, the Hospital Anxiety and Depression Scale, the Inventory 
of Traumatic Grief, and the RAND-36 Health Survey.
Results: The median age of the 58 participating partners was 58 years (range: 
51–65), and 67% was female. Partners reported negative effects on patients’ quality 
of life, but only 5% of partners regretted patients’ participation. Approximately 
two years after the patients’ death, 19% of partners scored for depression, 36% 
for psychological distress, and 46% for complicated grief, and partners generally 
scored significantly lower on social and mental functioning compared to normative 
comparators.
Conclusion: Although partners reported negative consequences on patients’ 
quality of life, most did not regret patients’ participation in the phase I studies. 
Prevalence of depression, psychological distress, and complicated grief seemed 
important problems after a patient’s death, and these must be considered when 
shaping further support for partners of patients participating in phase I trials.




Patients with cancer enrolled in a phase I trial have no remaining standard 
treatment options, but they are still in good enough clinical condition to receive 
experimental treatments. Along with a limited chance of benefit, experimental 
treatment may lead to significant side effects and more visits to the hospital [1]. 
This may burden a patient during the vulnerable end-of-life phase [2]. Critics 
have stated their concerns about patients’ voluntariness, considering the risk/
benefit ratio and the informed consent procedure for phase I oncological trials. 
The decision to participate will most often be a consequence of a misconception, 
coercion, or blurred judgment caused by the urgency of the patient’s condition 
[3]. On the other hand, the well-informed patient is aware of the alternatives 
to enrolment, does not suffer from coercion, and is determined to fight their 
cancer no matter what the cost [4]. Regarding studies performed related to the 
ethical basis of experimental treatment, most take the point of view of the care 
professional or patient [3,5]. Since the partner may suffer due to the patient’s 
burden during and following participation, the partner’s point of view is at least 
as important, but usually not actively sought. There is increasing awareness that 
care for a patient with cancer has a significant impact on the partner’s life [6,7]. 
They are not prepared and educated to provide specialized care for a patient with 
cancer during the often dynamic and protracted illness trajectory [8,9], and they 
have to integrate their role as caregiver into their own personal life, including their 
employment, household, and social life [10,6]. They can experience unmet needs 
while providing care, which bring on negative consequences for their general 
health [6,8]. As we noted that partners face special difficulties assisting the patient 
during experimental treatment, we retrospectively (1) explored the partner’s point 
of view on patient participation in a phase I study and (2) determined their well-
being after the patient’s death, assessing depression, psychological distress, 
complicated grief, and health-related quality of life. 
Our results could ultimately lead to improved support for partners during the 
phase of experimental therapy and after the death of patients. To our knowledge, 
this is the first study on the experience of partners of patients participating in phase 





This study was conducted between January of 2009 and July of 2010 and consisted 
of completion of validated questionnaires. Partners of deceased patients who 
participated in phase I studies at the Radboud university medical center between 
2007 and 2009 were recruited. Some 74 partners were deemed eligible and were 
approached between six months and two years after a patient’s death. 
Although this study did not fall under the Medical Research Involving Human 
Subjects Act, the advice of the local medical ethical committee was requested, since 
the partners were regarded as a vulnerable group. Permission to conduct the study 
was obtained. For recruitment, a research nurse (MEWJP) contacted partners by 
telephone. Information was provided within a structured format in order to transmit the 
needed information most completely. Partners were asked to consider participation 
and were offered additional written information and time for consideration. Some gave 
oral informed consent instantly and agreed to receive the questionnaires, which were 
sent by mail, together with an enclosed return envelope. Some requested additional 
written information and needed further time to consider. After one to two weeks they 
were again contacted. If they decided to participate and gave oral informed consent, 
they received the questionnaires immediately. Completing the paper-and-pencil 
questionnaires took between 45 and 60 minutes. 
Measurements 
A general questionnaire was designed by us to obtain demographic characteristics 
and more specific details on a partner’s experience during the patient’s participation 
in a phase I study. A partner’s experience was investigated using seven main 
questions (listed in Table 2). Answers to these questions were categorized in a 
multiple-choice format, using a 3-to-5-point Likert-type scale. Our questionnaire 
also assessed changes in the partner’s personal situation due to patient illness 
and treatment, including financial problems, employment, relationship with the 
patient, and general health. We also evaluated the partner’s experience regarding 
the patient’s terminal phase and death, the personal situation after the death, 
including having received professional grief counselling, current marital status, 
housing, employment, and whether other important life events took place during 
the previous year. 
For determination of partners’ well-being during bereavement we used four 
validated questionnaires. The Beck Depression Inventory for Primary Care (BDI–
PC) is a 7-item screening instrument for depression. The questions are extracted 
from the Beck Depression Inventory–II, which reflects DSM–IV criteria for major 
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depressive disorders. Each item has a 4-point scaling system, ranging from 0 to 
3, and is scored by summing all scores for the 7 items. Higher scores indicate 
symptoms of depression. This instrument has a high internal consistency (Cronbach’s 
α 0.85–0.88). For determination of cases, we used a cutoff score of 4 [11,12]. 
The Hospital Anxiety and Depression Scale (HADS) is a 14-item self-assessment 
questionnaire measuring psychological distress, with two 7-item subscales 
measuring anxiety and depression. Based on the current discussion, and considering 
the reliability of the use of the HADS subscales, only the total score was employed 
to measure psychological distress [13]. Total score ranges from 0 to 42. Each item 
is rated on a scale from 0 (not at all) to 3 (very much), with higher scores indicating 
higher levels of distress. This scale has been translated and validated for different 
age groups within the general Dutch population (Cronbach’s α 0.84– 0.90). When 
the total score on the questionnaire is 12 or higher, manifest distress is likely [14]. 
The Inventory of Traumatic Grief (ITG) (Dutch version) is a validated (Cronbach’s 
α 0.94) 29-item self-report questionnaire that measures maladaptive symptoms of 
grief. It is scored on a 5-point scale, ranging from 0 (never) to 4 (always). Summation 
of individual item scores yields an indication of the severity of maladaptive grief 
symptoms. A cutoff score of 39 or higher indicates complicated grief [15]. 
The RAND-36 Health Survey (RAND-36) is a validated 36-item questionnaire 
that assesses general health, well-being, and functional status on nine subscales: 
physical functioning, role physical, role emotional, mental functioning, social 
functioning, pain, vitality, health, and health changes. Subscale scores are 
transformed to a range from 0 to 100, with higher scores representing higher levels 
of functioning and health. The questionnaire is validated against a healthy random 
sample in the Netherlands and has been shown to be sufficient in terms of internal 
consistency (Cronbach’s α 0.71–0.92). Scores for healthy normative comparators are 
documented in the Dutch version of the RAND manual [16]. 
Statistical Analyses
Statistical analysis was conducted using IBM SPSS statistics software (v. 20). 
Descriptive statistics with frequencies were employed to summarize the data 
obtained from the general questionnaire. To compare subgroups, a chi-squared 
test was utilized for categorical variables, and an independent sample t test was 
used for continuous variables. A one-sample t test was employed to compare 
mean scores for the sample on the RAND-36 with normative comparators. The 





Of the 89 deceased patients who received experimental treatment between 2007 
and 2009 in the Radboud university medical center, 12 lacked a partner and 3 
partners were untraceable. Of the 74 deceased patients with a partner, 4 refused 
to participate in the study, 1 was not able to participate due to health problems, 
and 6 others refused without citing a clear reason. Finally, 63 partners (85%) were 
included, of whom 60 (81%) returned the questionnaires. Two partners returned the 
questionnaire without filling it out due to emotional difficulties brought on by the 
assessment process. Data from 58 (78%) partners were thus available for analysis. 
The characteristics of participating partners are given in Table 1. 
Table 1. Partners’ characteristics, n=58.
Age, median (IQR) 58 (51-65)




Duration marriage with patient, n (%)
1-5 years 2 (3)
6-10 years 1 (2)
11-20 years 7 (12)
>20 years 48 (83)
Marital satisfaction, n (%)
Exceptionally happy 30 (52)
Happier than average 23 (40)
A bit happier than average 2 (3)
Average 3 (5)
A bit-/ certainly-/ much less happier than average 0 (0)
Months from the patients’ death up to receiving the completed 
questionnaire, median (IQR)
25 (19-28)
Minimum - maximum, months 7-45
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Partner’s Experiences During Patient’s Treatment 
Participation in a Phase I Study
The specifics of partners’ experiences during patient participation in a phase I 
study are shown in Table 2. Some 33% of partners reported “somewhat negative 
effects” and 24% “negative effects” on patients’ quality of life due to phase I study 
participation. “Some hindrance” or “hindrance” to the patient due to side effects 
were reported by 50 and 36% of partners, respectively. Outpatient control visits were 
reported “somewhat burdensome” and “burdensome” in 41 and 28% of partners, 
respectively. In contrast, 88% of partners supported patient participation and 41% 
reported positive effects on patient quality of life. Though a substantial number of 
partners regarded patient participation with mixed feelings (59%), only 5% deemed 
such participation regrettable. 
Table 2. Experiences of the patients’ participation in a phase I study from the partners’ 
point of view
Question Partners, n (%)
Before enrolment, how did you regard participation in a phase I study?
I stood behind it 51 (88)
I had some difficulties with it 6 (10)
I did not support it 1 (2)





Did participation in a phase I study have a negative effect on your 




How do you reflect on side-effects your partner experienced, due to 
experimental treatment?
He/she had hindrance due to the side-effects 21 (36)
He/she had some hindrance due to side-effects 29 (50)
He/she had hardly any side-effects 4 (7)




Question Partners, n (%)
Did you consider the extra control visits to the outpatient clinic 








How do you look back on your partner’s participation in a phase I study?
With good feelings 21 (36)
With mixed feelings; there were good moments 21 (36)
With mixed feeling; it was tough 13 (23)
With regrets 3 (5)
a One missing value
Patients’ Terminal Phase 
During the terminal phase (i.e., during the last weeks of life), 64% of patients were 
free from hospital admissions, whereas 26% of patients were admitted once and 
10% more than once. Some 83% of patients died at home, 12% in the hospital, and 
5% in a hospice. Satisfaction with the final farewell was reported by 76% of partners, 
while 17% regarded the farewell unsatisfactorily, and 7% were still not able to think 
about it. Op een nieuwe regel: Changes in partners' personal situation
Changes in partners' personal situation 
Table 3 shows the changes in partners’ personal situations due to patient illness 
and treatment. Of the 58 participating partners, an important number reported no 
changes in their employment (70%), no financial problems (89%), and no changes 
in their general health (85% reported the same general health compared to before 
the patient’s illness; 74% experienced no health changes during bereavement 
compared to the period of patient illness). 
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Table 3. Changes in personal situation partner due to patients’ illness.
Changes n (%)
Employment a
No changes 39 (70)
Worked less 13 (23)
Stopped working 4 (7)
Financial problems
No problems 52 (89)
Yes, but solved 5 (9)
Yes, but not solved 1 (2)
Relationship with partner
No change 25 (43)
We became closer 29 (50)
Became more difficult 4 (7)
General health during patients’ illness/treatment compared to period before
No change, same as before illness 49 (85)
Better than before illness 1 (2)
Worse than before illness 8 (13)




a Two missing values
Well-Being After Patient Death 
Depression, Distress, and Complicated Grief
The scores for depression, distress, and complicated grief are presented in 
Table 4. The mean scores for the total sample on the questionnaires showed no 
abnormalities compared to cutoff points. On an individual level, 19% of partners 
scored for depression, 36% for psychological distress, and 46% for complicated 
grief. No significant differences for gender were found. The concomitant prevalence 
of complicated grief and depression was 29%. 
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Table 4. Descriptives of validated questionnaires – mean scores and caseness on depression 
(BDI-PC), distress (HADS) and complicated grief (ITG)
Questionnaire Total Total score, 
mean (SD)
Total > cutoff 
(% of total)
Female score, mean 
(SD)
Female > cutoff (% of 
total > cutoff)
Male score, mean 
(SD)
Male > cutoff (% of 
total > cutoff)
Depression (BDI-PC) 58 2 (2) 11 (19) 2.2 (2.1) 9 (82) 1.6 (1.6) 2 (18)
Distress (HADS total) 58 9.5 (6.7) 21 (36) 10.5 (6.9) 15 (71) 7.5 (6) 6 (29)
Complicated grief (ITG) 57a 36.9 (18.3) 26 (46) 39.7 (18.6) 19 (73) 31.2 (16.7) 7 (27)
a One missing value (female partner)
Health-Related Quality of Life
The data for health-related quality of life are given in Table 5. Three outcomes 
are outlined herein. The mean scores of partners in the age group 35–44 years 
were lower than their normative comparators on all RAND-36 subscales, except for 
“physical functioning.” The mean scores for the total sample showed that partners 
scored significantly higher on subscales “physical functioning” (p=0.001) and “pain” 
(p=0.039) compared to normative comparators. Partners scored significantly lower 
on subscales “social functioning” (p=0.010) and “mental functioning” (p=0.007). No 
significant differences for gender were found. 
Table 5. Descriptive RAND-36 – mean scores for age groups and differences in sample mean 
scores compared to normative comparatives.
RAND-36 
subscales





Physical 56 89.1 (15.7) 81.9 (23.2) p=0.001
35-44 4 90 (13.5) 90.0 (14.4)
45-54 17 94.7 (9.1) 79.9 (24.7)
55-64 22 84.8 (20.2) 72.7 (24.4)
65-75 10 90.5 (9.6) 66.7 (26.0)
75-85 3 83.3 (24.7) 56.0 (29.7)
Role emotional 55 81.8 (35.6) 84.1 (32.3) p=0.637
35-44 4 33.3 (47.1) 82.2 (33.5)
45-54 17 98.0 (8.1) 83.6 (34.1)
55-64 22 77.3 (40.4) 90.1 (24.5)
65-75 9 77.8 (37.3) 82.9 (33.8)
75-85 3 100.0 (0) 73.7 (40.4)
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Table 4. Descriptives of validated questionnaires – mean scores and caseness on depression 
(BDI-PC), distress (HADS) and complicated grief (ITG)
Questionnaire Total Total score, 
mean (SD)
Total > cutoff 
(% of total)
Female score, mean 
(SD)
Female > cutoff (% of 
total > cutoff)
Male score, mean 
(SD)
Male > cutoff (% of 
total > cutoff)
Depression (BDI-PC) 58 2 (2) 11 (19) 2.2 (2.1) 9 (82) 1.6 (1.6) 2 (18)
Distress (HADS total) 58 9.5 (6.7) 21 (36) 10.5 (6.9) 15 (71) 7.5 (6) 6 (29)
Complicated grief (ITG) 57a 36.9 (18.3) 26 (46) 39.7 (18.6) 19 (73) 31.2 (16.7) 7 (27)
a One missing value (female partner)
Health-Related Quality of Life
The data for health-related quality of life are given in Table 5. Three outcomes 
are outlined herein. The mean scores of partners in the age group 35–44 years 
were lower than their normative comparators on all RAND-36 subscales, except for 
“physical functioning.” The mean scores for the total sample showed that partners 
scored significantly higher on subscales “physical functioning” (p=0.001) and “pain” 
(p=0.039) compared to normative comparators. Partners scored significantly lower 
on subscales “social functioning” (p=0.010) and “mental functioning” (p=0.007). No 
significant differences for gender were found. 
Table 5. Descriptive RAND-36 – mean scores for age groups and differences in sample mean 
scores compared to normative comparatives.
RAND-36 
subscales





Physical 56 89.1 (15.7) 81.9 (23.2) p=0.001
35-44 4 90 (13.5) 90.0 (14.4)
45-54 17 94.7 (9.1) 79.9 (24.7)
55-64 22 84.8 (20.2) 72.7 (24.4)
65-75 10 90.5 (9.6) 66.7 (26.0)
75-85 3 83.3 (24.7) 56.0 (29.7)
Role emotional 55 81.8 (35.6) 84.1 (32.3) p=0.637
35-44 4 33.3 (47.1) 82.2 (33.5)
45-54 17 98.0 (8.1) 83.6 (34.1)
55-64 22 77.3 (40.4) 90.1 (24.5)
65-75 9 77.8 (37.3) 82.9 (33.8)









Role physical 55 82.3 (34.6) 79.4 (35.5) p=0.540
35-44 4 62.5 (47.9) 82.9 (32.0)
45-54 17 83.8 (33.0) 78.9 (37.0)
55-64 22 86.4 (32.5) 76.5 (38.1)
65-75 9 75.0 (43.3) 69.1 (42.5)
75-85 3 91.7 (14.4) 60.1 (43.1)
Social 58 79.1 (22.4) 86.9 (20.5) p=0.010
35-44 4 68.8 (37.5) 88.0 (17.6)
45-54 17 80.9 (20.3) 86.1 (21.8)
55-64 23 78.8 (24.3) 86.6 (21.4)
65-75 10 78.8 (20.5) 83.2 (23.7)
75-85 4 84.4 (12) 82.0 (24.9)
Mental 58 70.8 (16.2) 76.8 (18.4) p=0.007
35-44 4 58.0 (26.4) 76.9 (18.0)
45-54 17 75.5 (13.3) 76.7 (19.6)
55-64 23 70.4 (15.4) 77.1 (18.7)
65-75 10 68.0 (17.2) 75.9 (17.3)
75-85 4 73.0 (18.3) 76.9 (14.3)
Vital 58 63.9 (17.9) 67.4 (19.9) p=0.139
35-44 4 48.8 (21.4) 67.1 (18.9)
45-54 17 63.5 (19.7) 67.5 (20.3)
55-64 23 64.1 (16.6) 67.0 (21.3)
65-75 10 68.5 (13.1) 64.2 (22.0)











Pain 58 85.5 (21.7) 79.5 (25.6) p=0.039
35-44 4 80.6 (32.3) 83.8 (21.7)
45-54 17 92.4 (18.3) 80.5 (26.7)
55-64 23 82 (24.1) 74.7 (25.0) 
65-75 10 89 (16.6) 74.8 (28.0) 
75-85 4 73 (20.4) 72.0 (30.3)
Health 58 71.9 (20.9) 72.7 (22.7) p=0.771
35-44 4 52.5 (29.0) 74.0 (20.7)
45-54 17 79.7 (19.2) 71.6 (23.0)
55-64 23 66.5 (21.3) 64.4 (22.2)
65-75 10 76.5 (16.3) 60.1 (23.9)
75-85 4 77.5 (14.4) 59.0 (21.2)
Health change 58 55.6 (22) 52.4 (19.4) p=0.272
35-44 4 50.0 (35.4) 55.4 (17.7)
45-54 17 58.8 (19.6) 51.9 (19.8)
55-64 23 51.1 (21.9) 48.7 (15.4)
65-75 10 67.5 (20.6) 46.8 (20.5)
75-85 4 43.8 (12.5) 45.1 (18.7)
Personal Situation and Care After Patients’ Death 
Professional help for grief was received by 31% of partners, of whom 50% scored for 
complicated grief. A general practitioner was most often consulted (56%), followed 
by a psychologist (22%), a vicar (22%), a welfare worker (17%) and/or specialized 
bereavement support (17%). Satisfaction with grief-related care was reported by 44% 
of partners, 44% was neutral, and 11% were not satisfied. Table 6 presents partners’ 
personal situation after a patient’s death. Of the bereaved partners, 21% had a new 
relationship (men significantly more often than women; p<0.01). 
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Table 6. Partners’ personal situation after patients’ death. 
Personal situation n (%)
Marital status
New partner total 12 (21)
Male 8 (67)
Female 4 (33)




Paid work  38 (66)
Unpaid work 3 (5)
Housekeeper 19 (33)
No work 6 (10)
Sickness Benefits Act 3 (5)
Voluntary work 3 (5)
Housing 
Single 34 (59)
Single, living with children 16 (28) 
With new partner 3 (5)
Removal to parents/children/other family members 5 (8)
Important life-events last year a 44 (76) 
New employment 6 (14)
Retirement 2 (5)
Wedding child 2 (5)
Becoming grandparent 12 (27)
Illness of beloved (other than patient) 16 (36)
Death of beloved (other than patient) 22 (50)
Removal 3 (7)
Other 11 (25)




To the best of our knowledge, this is the first study to report on partners’ experiences 
of patients’ participation in a phase I study. A substantial number of partners 
reported that participation went according to their expectations, and they did not 
regret the patient’s participation, though they reported hindersome side effects, 
burdensome augmentation of visits to the outpatient clinic, and negative effects 
on patient quality of life. These findings may expand on the criticism of phase I 
study participation at the end of life in the literature [3], and may also contribute to 
our ability to provide partners more information on what a patient’s participation 
might imply for that partner, since experimental treatment has consequences for 
partners as well. 
Depression, psychological distress, and complicated grief are frequently 
noted during bereavement [17]. Their prevalence in this sample was 19, 36, and 
46%, respectively. The incidence of complicated grief reported in other studies in 
general populations is 2.4% in Japan, 3.7% in Germany, and 4.8% in the Netherlands, 
with a mean duration of bereavement of 13.3 years, 10 years, and 6.7 months, 
respectively [18-20]. For the significant others of deceased patients who suffered 
from cancer, the prevalence of complicated grief ranges between 18 and 40% 
[21-23]. In addition, the prevalence of complicated grief in bereaved individuals 
diminished over time in one study, with a decline from 40% at 6 months to 27% at 18 
months [21]. A possible explanation for the relatively high incidence of complicated 
grief in our sample might be found in the combination of (1) the spousal relationship, 
(2) caring for the patient at the end of life (since most patients in this sample died 
at home), and (3) loss of another person in their inner circle, which was the case 
for 50% of our partners. These three factors have been identified as risk factors for 
complicated grief [24,23,25]. It can also be considered whether the reported high 
marital satisfaction contributed to more problems during bereavement. 
Symptoms of complicated grief are closely related to symptoms of depression 
and psychological distress [25]. Their coincidence is frequently found, as is 
worsening of depressive symptoms due to complicated grief [17,25]. In our sample, 
the prevalence of depression was 19% about 2 years after the patient’s death, which 
is high comparable to another study with 11% moderate to severe depression 
within bereaved family cancer caregivers at 18 months following loss [21]. Though 
the compared studies for depression and complicated grief employed different 
measurement tools at different timepoints with different sample characteristics, our 
findings emphasize that the psychological problems of caregivers during a patient’s 
treatment and during bereavement merit more attention. Moreover, according to 
the definition of the World Health Organization [26], palliative care includes support 
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for family members and bereavement care. However, no consensus has been 
reached on the amount of support for the wide range of difficulties in a patient’s 
terminal phase and during bereavement [21]. With regard to the number of partners 
with complicated grief receiving professional help after a patient’s death, this was 
only 50% in our sample, and the help they received was scattered. 
Our study can promote the consideration of depression, psychological distress, 
and complicated grief as three important aspects that need to be assessed in 
the partners of cancer patients with respect to participation in experimental 
treatment trials. Further research should focus on the extent to which experimental 
treatment can contribute to the severity of depression, psychological distress, and 
complicated grief experienced by partners.
On our questionnaire, a substantial number of partners reported stable general 
health during the patient’s treatment and following their death. This was supported 
by a general health-related quality of life assessment. The mean scores for the total 
sample were significantly higher on physical functioning and pain when compared 
to normative comparators. This might be explained by having to confront the 
patient’s physical limitations due to their illness and treatment. As a consequence 
they might value their physical functioning differently. Another explanation could 
be that partners of patients who participated in a phase I study were themselves 
in relatively good physical condition. One could expect that if a partner suffered 
from significant health problems, participation in a phase I study would not even 
be considered. It would be of added value to know if the partners suffered from 
comorbidities, something that was not assessed in our study. In contrast to the 
significantly higher scores for physical functioning, the significantly lower scores 
for social and mental functioning compared to normative comparators were 
remarkable. An association of these findings with the prevalence of depression and 
complicated grief in our sample could be an explanation, since these are associated 
with problems in social and mental functioning [25,17]. Whether problems related 
to social functioning could be a trigger for development of complicated grief and/
or depression or the other way around remains unclear as a consequence of our 
study design. 
Also with regard to our study design, it is important to consider that there is a 
possibility for recall bias, which can be related to the theory of cognitive dissonance. 
When confronted with incongruent or contradictory ideas or actions, which result 
in extreme mental stress, people try to reduce these conflicts with their beliefs [27]. 
Patients had made a decision to participate in a phase I trial, and partners most 
often supported them. After the patient’s death, in order to reduce this dissonance, 
partners perhaps answer according to their beliefs: so the patient made the right 
decision to participate. 
Chapter 6
132
Considering the amount of depression, psychological distress, and complicated 
grief among the partners in our sample, the 78% response rate is remarkable. It 
emphasizes partners’ willingness to help improve partner-related care during the 
patient’s experimental treatment. The restrictions on performing studies of this kind, 
where delicate topics are investigated in vulnerable individuals, is common, but 
not always necessary, as discussed in other work [28] and supported by our study 
regarding response rate. 
In conclusion, most partners of patients who participated in a phase I study 
supported their participation and did not regret it, though a significant number 
reported negative consequences for the patient’s quality of life at the end of life. 
It is unknown whether our findings regarding the high incidence of depression, 
psychological distress, and complicated grief about two years after the patient’s 
death are related to the experimental treatment. This will require further study 
and may perhaps ultimately lead to the required guidance for partners of patients 
participating in phase I oncological trials.
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A cancer diagnosis is a stressful event for patients and their families. Informal 
caregivers play an important role for patients diagnosed with and treated for 
cancer. Partners and other informal caregivers of a patient with cancer can 
experience a wide range of psychological problems which may impact their 
emotional health. The aim of this thesis was to gain more knowledge about 
informal caregivers’ functioning of a patient on active cancer treatment (part 1), 
after completion of treatment (part 2), or after a patients’ death (part 3). The final 
chapter summarizes and discusses all previous chapters. Moreover, it describes 
practical implications for clinical practice and formulate recommendations for 
future research. Table 1 shows an overview of the examined constructs used in 
the studies in this thesis. Table 2 to 5 shows an overview of mean and cutoff scores 
of burden and distress. 
PART 1: 
CARING FOR A PATIENT DURING 
THE TREATMENT PHASE
Informal caregivers of patients treated with curative intent
Concomitant chemoradiotherapy in locally advanced head and neck cancer 
(LAHNC) challenges both patients and their informal caregivers. Patients often 
experience fatigue, psychological distress (hereafter described as “distress”) and 
poor health-related quality of life (HRQoL), which in turn may burden informal 
caregivers. In Chapter 2, we described the course of informal caregiver burden 
and fatigue in relation to the patient’s fatigue, distress, and HRQoL. In addition, 
we identified risk factors for higher levels of informal caregiver burden and 
fatigue after completing chemoradiotherapy. Informal caregiver burden and 
fatigue peaked when patient fatigue and distress peaked, together with lowest 
patient HRQoL. One week after completion of chemoradiotherapy, informal 
caregiver burden and patients’ fatigued peaked. Three months later, these 
increased levels returned to baseline burden and fatigue. Female partners with 
higher baseline burden and fatigue, caring for patients with poor HRQoL were 
at higher risk for increased burden. With respect to fatigue, the main risk factor 




In chapter 3, we focused on informal caregiver burden and distress during and after 
completion of patients’ adjuvant chemotherapy for colon cancer. We examined 1) the 
number of informal caregivers having higher levels of burden and distress, and the 
course of informal caregiver burden and distress over time, 2) risk factors for developing 
higher levels of burden and distress during and after treatment, 3) associations between 
informal caregivers’ burden and distress and patients’ distress, and 4) the course of 
informal caregivers’ health-related quality of life over time and how this is associated 
with their own burden and distress, and with distress of the patient. Our findings showed 
that informal caregiver distress and burden was relatively low and reduced over time. 
At baseline, 27% (n=16/60) of caregivers reported clinically relevant levels of distress 
and 12% (n=7/58) reported high levels of burden. These percentages did not change 
over time. Informal caregiver burden and distress at baseline predicted their levels 
of burden and distress, respectively, both during adjuvant chemotherapy and three 
months after completion of treatment. Overall, informal caregiver burden and distress 
were not correlated with patient distress, with the exception of an association between 
informal caregiver burden and patient distress at baseline. 
Informal caregivers of patients on long-term treatment 
Long-term treatment with Tyrosine Kinase Inhibitors (TKIs) for Gastrointestinal 
Stromal Tumours (GIST) seems to be associated with burden and distress for the 
informal caregiver. However, details about the amount and severity of burden and 
distress are lacking. In chapter 4, we described the level of informal caregiver burden 
and distress during patients’ long-term treatment with TKIs, and the characteristics 
of those informal caregivers with high levels of distress and burden compared 
to their counterparts with low levels of distress and low/moderate perceived 
burden. Overall, informal caregivers of patients treated for GIST seemed to manage 
well. Perceived burden and distress were low in this group and their perceived 
general HRQoL was good and similar to the general population. In addition, marital 
satisfaction was good and they did not experience discrepancies in social support. 
On the other hand, 51% (n=30/61) of the patients in this study reported bothersome 
or severe side effects of treatment and 34% (n=21/61) experienced clinically relevant 
levels of distress. By comparison, 10% (n=6/61) of informal caregivers reported 
high levels of burden and 23% (n=14/61) had clinically significant levels of distress. 
Patients’ distress was associated with informal caregivers’ distress and burden. 
Informal caregivers with high levels of burden reported significantly poorer mental 
health, less vitality, lower general HRQoL and high distress. Significantly higher 
levels of burden were found in non-spouses, informal caregivers of patients with 
more treatment-related side effects, informal caregivers who spent more hours 




informal caregivers with high levels of distress perceived significantly more burden, 
lower social functioning, more role physical and emotional problems, poorer mental 
health, less vitality, and lower general HRQoL. Furthermore, high levels of distress 
were found in informal caregivers of more dependent patients and those caring for 
more than one person simultaneously.
PART 2: 
INFORMAL CAREGIVERS 
OF PATIENTS AFTER TREATMENT
Informal caregivers of patients in the survivorship phase 
Fear of cancer recurrence commonly affects cancer survivors. Partners of cancer 
survivors may also experience fear, which can impact their HRQoL. In chapter 5, we 
described 1) the rate of fear of cancer recurrence (FCR) among partners of patients 
with prostate cancer, 2) the relation between partners’ and patients’ FCR, 3) partners’ 
demographics and survivors’ clinical characteristics associated with high FCR, and 4) 
the relationship between high FCR and their HRQoL. Mean levels of FCR were similar 
between partners and survivors. Thirty-five percent (n=59/168) of partners reported 
high FCR compared to 38% (n=64/168) of prostate cancer survivors. Higher survivor 
FCR and younger partner age were significantly associated with higher partner FCR. 
Partners with high FCR scored significantly lower on social functioning, emotional 
role functioning, mental health, general health, and vitality than those with low FCR.
PART 3: 
BEREAVED INFORMAL CAREGIVERS
Bereaved partners of patients treated in a phase I study 
Chapter 6 describes the partners’ perspective of patients’ participation in an 
experimental, phase I clinical trial. Furthermore, we explored bereaved partners’ 
problems in terms of depression, distress, complicated grief, and HRQoL. Partners 
reported negative effects of phase I trial participation on patients’ HRQoL, but only 
5% (n=3/58) of partners regretted the patients’ participation. Approximately two 
years after the patients’ death, 19% (n=11/58) of partners scored high for depression, 
36% (n=21/58) for distress, and 46% (n=26/57) for complicated grief. In general, 




Table 1. Overview of examined constructs used in the studies reported in this thesis 
Construct Head&neck Colon GIST Prostate Phase I
Burden ● ● ●    
Distress   ● ●   ●
HRQOL   ● ● ● ●
Fatigue ● ●      
Complicated grief         ●
Depression         ●
FCR       ●  
Marital satisfaction   ● ●    
Social needs   ● ●    
HRQOL=health-related quality of life; FCR=fear of cancer recurrence  
Table 2. Informal caregivers’ burden mean scores between different studies reported in this 
thesis
Time points
Study T0 T1 T2
Head and neck, mean (SD) a 4.1 (2.4) 4.6 (2.4) 3.2 (2.4)
Colon, mean (SD) b 2.9 (2.44) 2.82 (2.38) 2.04 (2.25)
GIST, mean (SD) c 2.4 (2.3) - -
a Time points for head and neck: T0 = prior to start chemoradiotherapy (n=56), T1 = 1 week after 
ending chemoradiotherapy (n=49), and T2 = 3 months after the end of chemoradiotherapy (n=45); b 
Time points for colon: T0 = baseline, before starting adjuvant chemotherapy (n=60), T1 = between 
the second and third cycle (n=58), T2 = three months after ending adjuvant chemotherapy (n=51); 
c GIST: cross-sectional study, one measurement point only (n=61)
Table 3. Informal caregivers’ burden cutoff scores for high levels of burden
Time points
T0 T1 T2
Study Moderate High Total Moderate High Total Moderate High Total
Head and neck 36% 11% 47% 63% 21% 84% 22% 11% 33%
Colon a 17% 12% 28% 19% 11% 29% 12% 8% 20%
GIST b 16% 10% 26%
a Time points for head and neck: T0 = prior to start chemoradiotherapy (n=56), T1 = 1 week after 
ending chemoradiotherapy (n=49), and T2 = 3 months after the end of chemoradiotherapy (n=45); 
colon: T0 = baseline, before starting adjuvant chemotherapy (n=60), T1 = between the second and 
third cycle (n=58), T2 = three months after ending adjuvant chemotherapy (n=51); b GIST: cross-




Table 4. Informal caregivers’ distress mean scores between different studies reported in this 
thesis
Time points
Study T0 T1 T2
Colon, mean (SD) a 9.0 (6.9) 7.6 (6.3) 6.6 (7.2)
GIST, mean (SD) b 8.1 (5.7)
Phase I, mean (SD) 9.5 (6.7)
Studies cancer caregivers [1-3] 7.3 (4.3) – 17.5 (9.1)
General population [4-6] 7.6 (6.0) – 9.8 (5.9)
a Time points for colon: T0 = baseline, before starting adjuvant chemotherapy (n=60), T1 = between 
the second and third cycle (n=58), T2 = three months after ending adjuvant chemotherapy (n=51); 
b GIST: cross-sectional study, one measurement point only (n=61); c Phase I: cross-sectional study, 
one measurement point only (n=58)
Table 5. Informal caregivers’ distress cutoff scores for clinically relevant levels of distress
Time points
Study T0 T1 T2
Colon a 27% 23% 19%
GIST b 23%    
Phase I c 36%    
Studies with cancer caregivers [1] 20%    
General population [4,6] 12.6-30.2%    
a Time points for colon: T0 = baseline, before starting adjuvant chemotherapy (n=60), T1 = between 
the second and third cycle (n=58), T2 = three months after ending adjuvant chemotherapy (n=51); 
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Informal caregivers and their challenges in perspective 
Burden 
In our studies, informal caregiver burden was highest for those caring for patients 
with head and neck cancer (HNC) (33-84%), followed by those receiving longer-
term TKI treatment for GIST (26%) and those receiving adjuvant treatment for 
colon cancer (20-29%). Informal caregivers of patients with head and neck cancer 
were twice as likely to report moderate to high levels of burden (47%) compared 
to patients starting adjuvant treatment for colon cancer (28%) or those on long-
term treatment for GIST (26%). It is known that in head and neck cancer patients’ 
major depressive disorders are more prevalent when compared to other cancer 
patients [1]. This together with the intensity and side effects of concomitant 
chemoradiotherapy are factors that may distinguish these patients from other 
cancer patients and may challenge their informal caregivers more intensely. 
Additionally, Richardson et al. described that 19% of informal caregivers of patients 
with HNC suffered from a posttraumatic stress disorder (PTSD) approximately 6 
months after diagnosis [2]. Risk factors associated with informal caregivers’ PTSD 
were avoidant coping, many cancer symptoms and perception of low benefit of 
treatment. 
Increased burden can be regarded as a normal reaction to a major stressor and 
the course of burden described in this manuscript could reflect adaptation to a 
major event in the life of an informal caregiver, i.e. burden peaked during treatment 
and returned to pre-treatment levels after treatment. This echoes earlier findings, 
as does our finding that there is a group of informal caregivers who remained 
burdened after ending treatment [3-5]. Distinguishing between a normal reaction, 
where an informal caregiver will adapt, and a situation where an informal caregiver 
continues to suffer from high levels of burden is challenging. To help identify 
those informal caregivers at risk for higher levels of burden, we studied several 
sociodemographic, care-related and patient-related factors previously associated 
with burden. We found that risk factors for burden of informal caregivers of patients 
treated for head and neck cancer were multidimensional; female spouses with 
higher baseline levels of burden and fatigue, and caring for patients with lower 
levels of global HRQoL seemed at higher risk for burden after the end of the 
intensive treatment of chemoradiotherapy. For informal caregivers of patients with 
colon cancer baseline burden contributed significantly to burden during and after 
treatment. Having higher baseline problems causing burden later on was also found 
in other studies [3,6]. Teixeira et al. reviewed the underlying mechanisms of burden 
[7]. They concluded that problem-focused coping attributes to decreased informal 
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caregiver burden and that emotion-focused coping is associated with higher levels 
of general distress and posttraumatic stress disorder symptoms. They proposed 
multiple avenues for informal caregiver intervention, including the facilitation of 
improved coping strategies, improved emotion regulation skills, self-care, and 
family functioning [7]. 
Distress
In our study with informal caregivers of patients with colon cancer, 27% of informal 
caregivers experienced symptoms of distress before patients start of adjuvant 
treatment. Additionally, 23% of informal caregivers of patients on long-term palliative 
treatment for GIST reported symptoms of distress. When comparing the mean level 
of distress found in our studies to the general population and informal caregivers 
in other studies, these were similar [8-13]. 
Distress can be a normal response to a major stressor in the lives of informal 
caregivers of patients treated for colon cancer, which, when they find ways to adapt, 
improve over time. Similar to burden, there is need to identify informal caregivers at 
risk for longer-term distress. We found that informal caregivers with higher levels 
of distress, cared for more dependent patients and/or more than one individual at 
a time. More distress is experienced when caring for a significant other has higher 
impact on their day-to-day schedule [8,14,15]. Additionally, baseline distress is a risk 
factor for longer term distress, which has also been described in other studies [8,14,15]. 
It is important to understand the source of informal caregivers’ distress. Northouse 
et al. reviewed on the sources of emotional distress according to the phase of a 
patient’s illness. These authors described that in the diagnostic phase, caregivers 
experience unmet needs on different aspects, uncertainty how to address patients’ 
needs, feelings of being overwhelmed and powerless in combination with different 
care demands. During the treatment phase, informal caregivers lack experience and 
preparedness to perform (difficult) care tasks, manage juggling demands of others 
without help, and deal with feelings of social isolation. Furthermore, they worry 
about the effectiveness of patients’ treatment and experience difficulties how to 
manage side effects [14]. We also found that informal caregivers of patients treated 
for GIST were more burdened and distressed when patients experienced side effects. 
Furthermore, patients with GIST who reported fear of cancer progression also had 
high levels of distress [16], which will impact the informal caregiver as well [17].
Informal caregivers’ coping mechanism could play a role in adjusting to a 
major stressor in their lives. Perez-Ordóñez et al. described that distress of informal 
caregivers of patients on palliative treatment was related to dysfunctional coping 
(behavioural disengagement, denial, self-distraction, self-blame, substance 




mechanisms [18]. Together with more focus on informal caregivers’ coping, spiritual 
care deserves attention. It is known that spirituality functions as internal resource 
to cope with and forms a buffer for experiencing psychological distress [19]. Kim 
et al. found that informal caregivers who were highly spiritual, experienced less 
psychological distress, especially when giving care to a significant other was 
more challenging [19]. Selman et al. described in a qualitative study that informal 
caregivers have a wide range of spiritual questions and that their spiritual practices, 
beliefs and support from faith communities helped them cope with their role [20]. 
Depression and complicated grief
In our study with bereaved partners of patients who participated in a phase I study 
(i.e. received experimental treatment) in the last phase of their life, we found a 
high number of partners who experienced distress (36%), complicated grief (46%) 
and depression (19%), approximately 2 years after patients’ death. Symptoms 
of depression are closely related to symptoms of complicated grief and their 
coincidence is frequently found [21,22]. Reacting to bereavement varies between 
individuals as well as between cultures and ethnic groups [21]. The proportions we 
found are higher than in other studies of partners of deceased cancer patients at 
this point in time and when compared to the general population and other partners 
of deceased patients who suffered from cancer [23-28]. We observed that spousal 
relationship, being mainly responsible for caring for the patient at the end of life 
and another recent loss of a beloved one contributed to developing symptoms 
of complicated grief in our study. These findings are supported by other studies 
[22,28,29]. Another contributing factor could be that partners in our study suffered 
more from complicated grief due to a more avoidant coping strategy. Teixiera et 
al. and Perez-Ordóñez et al. describe that there is a difference in psychological 
health outcomes when informal caregivers have dysfunctional coping strategies 
[7,18]. Furthermore, patients’ low levels or even a total lack of acceptance of illness 
can contribute to feelings of distress in both patients and their partners, which 
will have influence on partners’ grief process. Moreover, patients’ acceptance 
is, amongst others, determined by the response to their illness by their relatives 
[30]. Continuing patients’ treatment during the last phase of their lives may have 
interfered with partners realisation and acceptance of their forthcoming loss. This 
may have complicated their grief after the patient’s death as well [22,31].
Exploring coping in relation to informal caregivers’ depression and grief and what 
their spiritual care needs are when a patients is treated in a phase I experimental 
study could be an interesting field of future research. Selman et al. described in a 
qualitative study that informal caregivers gave advise to further explore their spiritual 
care needs and they emphasized that this is also needed during bereavement. 
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Health-related quality of life and fatigue
In all our studies we found that informal caregivers with more problems, like 
higher levels of burden, distress and/or fear of recurrence, experienced more 
problems in social functioning and lower levels of general health, especially 
lower levels of mental health. It is known that mental health is intertwined 
with social functioning [14,32]. Pasek et al. described in a study with informal 
caregivers of patients on active curative treatment for cancer that informal 
caregivers’ sense of coherence, i.e. the degree of trust to comprehend, manage 
and find meaning in a challenging situation, was determined by the levels of 
perceived social support [30]. As informal caregivers’ sense of coherence is 
a resource in patients’ acceptance of illness, focusing on informal caregivers 
social functioning might benefit themselves and patients as well [30].
As part of exploration of informal caregivers’ general health, we also 
studied fatigue. Fatigue is a complex phenomenon. We found that fatigue is 
an important issue among informal caregivers, as their fatigue is higher than 
average, especially in informal caregivers of head and neck cancer patients. 
We also found that fatigue before treatment is a risk factor for fatigue after end 
of treatment. Traa et al. found that partners with more depressive symptoms 
were at risk for developing higher levels of fatigue [33]. Peters et al. found that 
caregiver fatigue was related to informal caregiver burden when patients were 
on palliative treatment [34].
These findings underline that mental and physical problems are related 
and that it seems important when we aim to improve their general health, 
both mental and physical, we need to pay attention to informal caregivers’ 
psychosocial functioning and focus on their social support system. It is known 
that better social support can improve the perception of burden and other 
mental health problems, which may also improve patients’ acceptance of their 
illness better [4,30,32]. 
Fear of cancer recurrence
We found that 35% of partners of prostate cancer survivors suffered from FCR 
and that the mean levels of FCR of partner and patients were comparable. 
The similarity in levels of FCR is in line with other studies [35,36]. Moreover, 
studies reported that informal caregivers’ FCR exceeded that of survivors [36,37]. 
We found that higher survivor FCR and younger partner age were significantly 
associated with higher partner FCR. Furthermore, partners with high FCR 
scored significantly lower on social functioning, emotional role functioning, 
mental health, general health, and vitality than those with low FCR. Mellon et 




development of FCR and that partners’ higher level of FCR was also associated 
with a negative influence on their HRQoL [38]. Cohee et al. found that cognitive 
processing mediates experiencing social constraints and increased levels of 
FCR. [39] Additionally, coping mechanisms, like avoidant coping, may also play 
a role in developing FCR [35-37,39]. 
Clinical implication & future research
Recognizing, acknowledging & resources
Based on the findings described in this thesis, it is clear that caring for a patient 
with cancer impacts the life of the informal caregiver, with possible negative 
consequences for their mental and physical health. In clinical practice three aspects 
are important to improve informal caregivers support: 1) healthcare professionals pay 
more attention to informal caregivers and recognize informal caregiver problems, 
2) informal caregivers acknowledge there is a problem and accept support, and 3) 
availability of resources to address the problems. 
First, it is important that attention is paid to informal caregivers. Counselling 
in general about the role as caregiver must be incorporated in patient information 
about their cancer treatment. Knowing that there is attention for informal caregiver 
functioning and normalizing their burden may help them lowering the threshold 
to ask for support. Together with counselling informal caregivers on their new 
role, it is advisable to screen for informal caregivers’ baseline problems, such as 
burden and distress. As the general practitioner serves as a family doctor and, 
according to the Medical Treatment Agreement Act, the general practitioner has 
a treatment relationship with the informal caregiver, it seems most suitable they 
facilitate screening and assessment what support suites the informal caregivers 
best. Offering support warrants healthcare professionals in the 1st line in care to join 
forces with healthcare professionals of the 2nd and 3rd line. 
In addition to the need for increased awareness by healthcare professionals 
of informal caregiver functioning, it is essential that the informal caregiver 
acknowledges if there is a problem, and accepts support. This remains a challenge 
in clinical practice. Informal caregivers often have the need to see their tasks 
alleviated, but on the other hand perceive difficulties in delegating their tasks. 
Therefore, it is essential to educate informal caregivers about their role and the 
possible consequences this may have for their own health, and how they can 
balance between taking good care of the patient and themselves as well. 
There is increasing knowledge that psychoeducation, supportive care/support 
interventions, mindfulness-based stress reduction and cognitive behavioural 
interventions are recommended to alleviate informal caregivers’ burden [40]. 
Unfortunately, a Cochrane review on the effectiveness of psychosocial interventions 
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for informal caregivers of patients with cancer described that studies on this subject 
show great heterogeneity, what makes it difficult to draw general conclusions about 
the effectiveness of psychosocial interventions on informal caregivers’ and patients’ 
quality of life [41]. Like the current shift in personalized patient care, this seems also 
applicable to support of informal caregivers. There is no “one size fits all” format to 
address informal caregivers’ problem, as their needs may range from practical to 
emotional. When problems do occur this warrants a multidisciplinary approach with 
psychologists, social workers and/or spiritual counsellors involved, depending on 
the source of their problem. 
Future research should focus on understanding how informal caregivers with 
high levels of burden and distress cope with a major stressor in their life and what 
could buffer burden and distress. There is a clear need for spiritual care reported by 
informal caregivers in a palliative care setting. In a study of Selman et al. informal 
caregivers emphasized to focus future research on educational interventions for 
healthcare professionals to improve their spiritual care skills, investigate suitability 
of spiritual care for diverse populations, including those without religious faith, 
improve assessment of informal caregivers’ spiritual needs, and study the impact 
of improved spiritual care, including during bereavement [20]. Additionally, it seems 
of added value to further study the positive aspect of giving care to a significant 
other. For a long time, it was thought that the burden and benefits were two ends of 
one continuum. Pendergrass et al. showed in a cross-sectional study that there is 
evidence that positive and negative effect of caregiving can co-occur and that the 
benefits of caregiving can buffer psychological distress [42]. However, there is need 
for longitudinal studies to further explore the possible buffering effects of caregiving 
informal cancer caregivers’ mental and physical health on the longer term. 
The current COVID-19 pandemic has a significant effect on a person’s well-
being and mental health, due to the measures taken, such as social distancing, 
self-isolation and quarantine. For informal caregivers this forms an even greater 
challenge as they are isolated from their social connections, and sometimes even 
from their loved ones, when they are admitted to the hospital [43]. As telehealth and 
phone check-ins are getting a more prominent place in care due to the COVID-19 
pandemic, this could also be an interesting field of research to further improve 
informal caregiver support [43].
Validated questionnaires & cut-off points for informal caregivers
A common challenge, aside from recognizing informal caregiver problems, is 
objectivating these problems. As described in this thesis, the problems of an 
informal caregiver faces are complex and the experience of burden is multi-




caregiver burden, like the Self-perceived pressure of informal care (SPPIC), the 
Caregiver Reaction Assessment (CRA) and The Zarit Burden Interview [44-46]. 
Applying these questionnaires in research delivered important information about 
informal caregiver functioning. However, for many other concepts and problems, 
such as distress, HRQoL and fatigue, there are no validated questionnaires and/
or cut-off points for informal caregivers of patients with cancer. This could be an 
interesting field of further research, to improve the quality of studies with informal 
caregivers of patients with cancer. In addition, in order to interpret clinically relevant 
changes of problems over time, there is need for the establishment of minimally 
clinically important differences (MCID), which could complement assessed 
statistical changes. This could support further research on interpreting effects of 
interventions to improve informal caregivers’ functioning.
Consequences of caregiving on caregivers’ physical health
In our study with informal caregivers of patients treated for GIST, we did not 
find that informal caregivers’ comorbidities were associated with high levels of 
burden and distress. Informal caregiver problems were especially determined by 
emotional challenges, which may impact physical health. Rohleder et al. found 
that in the year after patients’ cancer diagnosis, familial caregivers experienced 
marked changes in neurohormonal and inflammatory processes, with increasing 
inflammation and dysregulation of inflammatory control over time [47]. These 
inflammatory processes can be involved in the development of cardiovascular 
disease. A study of Lee et al. showed that high caregiving burden in spouses was 
an independent risk factor for coronary heart disease, after controlling for a range 
of behavioural, social, and physical factors [48]. Comprehending the impact of 
the role of caregiving on informal caregivers’ physical health would increase the 
knowledge of the caregiving experience as a whole and help in preventive informal 
caregiver care. Understanding the relationship between mental problems and their 
consequences for informal caregivers’ physical health could emphasize the urge 
to support informal caregivers even more. Research on the physical consequences 
of informal caregiver problems is scarce and this could be an interesting field of 
future research, which could ultimately lead to ways to prevent informal caregivers’ 
health problems. 
Novel treatments
Immunotherapy is a relatively new and promising treatment modality for certain 
groups of patients with cancer. The treatment is in most patients well-tolerated, but 
when side-effects occur they can be severe and may impact the patient seriously 
and sometimes the result will be that treatment is not continued, with long-term 
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permanent organ dysfunction. [49] The ultimate goal of immunotherapy is to create 
a durable, long-term tumour response. There is a group of patients treated with 
immunotherapy having a complete response after treatment, but there remains 
uncertainty about what this complete response means in terms of curation. On the 
other side of the spectrum there is group of patients unresponsive to this treatment, 
which is not always clear immediately as a response to this therapy takes time. This 
all has impact on the patient and will most probably impact the informal caregiver 
as well. Although informal caregiver problems seem to be mostly determined by 
their own psychological functioning and coping mechanisms, and not specifically 
the type of cancer and/or its treatment, the impact of a treatment/toxicity seem 
to influence their functioning during/after treatment. How the patients’ treatment 
with immunotherapy affects the informal caregivers could be an interesting field 
of further research. 
CONCLUSION
Informal caregivers of cancer patients are at risk of experiencing burden, which is a 
multidimensional experience which can have serious general health consequences 
and can impact informal caregivers’ functioning. There is a vulnerable group of 
informal caregivers with higher levels of burden and distress, especially among 
informal caregivers of patients treated for locally advanced head and neck cancer 
and bereaved partners of patients treated in phase I studies in the end-of-life 
phase. Furthermore, we found that baseline emotional problems and fatigue 
are an important risk factor for problems on the longer term, and therefore, early 
identification of problems seems necessary. This is a challenging task since and 
there is no “one-size-fits-all” approach. Educating informal caregivers on their role 
and the possible consequences of this role on their health needs to be implemented 
in clinical care of patients treated for cancer. Furthermore, supporting informal 
caregivers must be a team effort of healthcare professionals in the 1st, 2nd and 3rd line 
of care. Healthcare professionals in the 2nd and 3rd line need to recognize informal 
caregivers’ problems and informal caregivers must acknowledge their problems 
in order to accept help. The general practitioner as leading physician in informal 
caregiver care can play a central role in facilitating and initiating informal caregiver 
support. Further exploration of ways to help informal caregivers of cancer patients 
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In 2018 werd in Nederland bij 116.537 inwoners de diagnose kanker gesteld 
en overleden 45.206 mensen aan de gevolgen van kanker. Voor kanker 
kunnen de volgende behandelingen worden gegeven: operatie, bestraling 
en/of systemische behandeling. Systemische behandeling wordt ingedeeld 
in chemotherapie, doelgerichte therapie, immunotherapie en/of hormonale 
therapie. Systemische behandeling wordt bij een curatieve, op genezing 
gerichte, behandeling in drie verschillende fasen gegeven , te weten 1) neo-
adjuvant (voorafgaan aan operatie of bestraling), 2) concomitant (tegelijk met 
radiotherapie) en 3) adjuvant (na operatie of bestraling). Wanneer een curatieve 
behandeling niet meer mogelijk is, wordt er vaak een systeembehandeling met 
palliatieve intentie gegeven. Het doel hiervan is levensverlenging met behoud 
of verbetering van de kwaliteit van leven. Tijdens deze verschillende fases in 
de behandeling voor kanker komt een patiënt voor vele uitdagingen te staan 
en de steun van (een) mantelzorger(s) is daarbij onmisbaar. 
Mantelzorgers en hun uitdagingen
Er zijn in Nederland 4,4 miljoen mantelzorgers (25%) die zorg verlenen aan een 
naaste. Hiervan verlenen 750.000 mantelzorgers langdurige zorg (> 3 maanden) 
en/of voor meer dan 8 uur per dag. Het is niet precies bekend hoeveel van deze 
mantelzorgers zorgen voor een patiënt met kanker. Mantelzorg kan worden 
verleend door een partner, ouders, kind, broer of zus, maar ook door een goede 
vriend of buur. De zorg van mantelzorgers bestaat uit praktische en emotionele 
ondersteuning. Als gevolg van deze zorg kan een mantelzorger problemen 
ervaren, zoals overbelasting en distress, wat ook consequenties kan hebben 
op voor de eigen kwaliteit van leven en fysieke gezondheid. Daarnaast kunnen 
mantelzorgers, net als de patiënt, angst voor de terugkeer van kanker bij de 
patiënt ervaren. 
(Over)belasting
Overbelasting ontstaat wanneer de gevolgen van de zorg voor de patiënt met 
kanker niet meer in balans zijn met de veerkracht van de mantelzorger en zijn 
of haar mogelijkheden om met de nieuwe situatie om te gaan. Risicofactoren 
voor overbelasting zijn divers en bestaan uit demografische factoren (vrouw, 
samenleven met de patiënt), psychologische factoren (depressie, beperkte 
coping- strategieën, stress), sociale factoren (leven in sociaal isolement), 
financiële factoren (onderbreking van werk, financiële zorgen) en zorg-
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gerelateerde factoren (groter aantal uren besteed aan mantelzorgen). In 
Nederland zijn 380.000 mantelzorgers overbelast. Welk aandeel hiervan 
mantelzorger van patiënten met kanker zijn is niet bekend. Het geeft wel aan dat 
er een kwetsbare groep mantelzorgers is die extra ondersteuning zou kunnen 
gebruiken. 
Distress, depressie en gecompliceerde rouw
De definitie van distress is “emotionele, sociale, spirituele of fysieke pijn of 
lijden dat kan leiden tot verdriet, somberheid, angst of eenzaamheid”. Distress 
komt vaak samen voor met overbelasting. De gevolgen van distress bij de 
mantelzorger kunnen zijn dat 1) patiënten op langere termijn moeite krijgen 
om zich aan te passen aan hun ziekte en situatie, 2) patiënten meer angst 
ervaren door de angst van de mantelzorger, 3) mantelzorgers niet in staat 
zijn om te zorgen voor de patiënt en 4) zij gevolgen ervaren op hun fysieke 
gezondheid, zoals het ontwikkelen van hart- en vaatziekten. De oorzaken 
waardoor een mantelzorger meer distress ervaart verschillen per fase waarin 
de patiënt zich bevindt. Over het algemeen kan een mantelzorger distress 
ervaren door 1) de behandeling van de patiënt (twijfel over de effectiviteit van 
de behandeling, distress bij de patiënt door bijwerkingen en hoe hiermee om te 
gaan, onvoorbereid complexe zorg moeten leveren), 2) psychosociale factoren 
(sociale isolatie, veranderingen in rol in sociale leven, overspoeld voelen, de 
patiënt helpen emoties te verwerken, complexe verhoudingen binnen gezin/
familie), en / of 3) onvervulde behoeften (psychosociaal, medisch, financieel, 
kennis). Ongeveer 20% van de mantelzorgers van patiënten met kanker ervaart 
distress en er zijn aanwijzingen dat vrouwelijke mantelzorgers vaker distress 
ervaren dan mannelijke mantelzorgers. 
Distress kan op langere termijn leiden tot depressie. Depressie wordt 
gekenmerkt door gevoelens van somberheid, wanhoop, verlies van energie, 
gebrek aan een gevoel van eigenwaarde en hierdoor moeite hebben met het 
omgaan met normale dagelijkse bezigheden. Het percentage mantelzorgers 
van patiënten met kanker dat depressieve kenmerken heeft ligt tussen de 12 en 
41% en hangt samen met de fase waarin de patiënt behandeld wordt. 
Nauw verbonden met distress en depressie is gecompliceerde rouw. Rouw 
is een normale respons op een groot verlies in het leven. Normaal gesproken 
neemt de intensiteit van deze rouw in de loop van de tijd af zonder dat daarvoor 
extra hulp nodig is. Bij gecompliceerde rouw wijkt de rouw af van normale rouw 
(in culturele en maatschappelijke context gezien) door de duur, intensiteit of 
een combinatie van beiden. Gecompliceerde rouw kenmerkt zich door een 




het ontbreken van een reactie op het verlies of door een verlate reactie op 
het verlies. Een natuurlijk herstel treedt niet of nauwelijks op. Het is belangrijk 
om te weten dat symptomen van gecompliceerde rouw overeenkomsten 
vertonen met symptomen van distress en depressie. Gecompliceerde rouw 
kan ook samen met depressie voorkomen of kan verergering van depressieve 
symptomen geven. 
Gezondheids-gerelateerde kwaliteit van leven en vermoeidheid
Gezondheids-gerelateerde kwaliteit van leven wordt gedefinieerd als de mate 
waarin de gezondheid van een persoon impact heeft op zijn of haar mogelijkheid 
om te functioneren en hoe zijn of haar gezondheid het fysieke, mentale en sociale 
welzijn beïnvloedt. Er zijn studies die laten zien dat stress bij mantelzorgers een 
negatief effect kan hebben op hormonale- en ontstekingsprocessen. Ook lijkt 
er een verband te bestaan tussen mantelzorgen en een verhoogd risico op 
hart- en vaatziekten. Dit zal de gezondheids-gerelateerde kwaliteit van leven 
van mantelzorgers kunnen beïnvloeden. 
Onder mantelzorgers lijkt ook ernstige vermoeidheid een probleem te zijn. 
Bij mantelzorgers van patiënten in de palliatieve fase bleek dat 23% van deze 
mantelzorgers matig tot ernstig vermoeidheid zijn. Hier is echter nog weinig 
onderzoek naar gedaan. 
Angst voor terugkeer van kanker
Onder patiënten met kanker is angst voor terugkeer van de ziekte (angst voor 
recidief) een belangrijk probleem. Van de patiënten die succesvol behandeld 
zijn voor kanker heeft ongeveer 49% last van angst voor recidief en dit 
percentage neemt niet af in de loop van de tijd. Ernstige angst voor terugkeer 
van kanker is geassocieerd met minder goede zelfzorg, distress en een hogere 
zorgconsumptie. Er is verder nog weinig bekend over angst voor recidief bij 
mantelzorgers. Er is wel een studie verricht bij partners van patiënten met 







Mantelzorgers van patiënten die (in opzet) curatief behandeld worden 
Wanneer iemand behandeld wordt voor kanker is het essentieel dat deze 
behandeling zo optimaal mogelijk en in zijn geheel gegeven kan worden. 
Mantelzorgers zijn daarbij onmisbaar en kunnen door deze zorg belast raken. 
Hoofd-halskanker
In Nederland werd in 2019 bij 2839 patiënten de diagnose hoofd-halskanker 
gesteld, waarvan bij ongeveer de helft van hen het (ziekte) stadium III of IV betrof. 
Risicofactoren voor het krijgen van hoofd-halskanker zijn roken en overmatig 
alcoholgebruik. Daarnaast zijn er patiënten die hoofd-halskanker krijgen als gevolg 
van het humaan papilloma virus (HPV). Patiënten met lokaal uitgebreid hoofd-
halskanker (stadium III/IV) worden curatief behandeld. Hiervoor ondergaan zij 
concomitant chemo- en radiotherapie gedurende 6 of 7 weken. Bijwerkingen die 
vaak voorkomen als gevolg van deze behandeling zijn onder andere vermoeidheid, 
slijmvliesschade en ontsteking van de huid. De behandeling en de gevolgen hiervan 
kunnen leiden tot distress en het is bekend dat het percentage depressies onder 
patiënten met hoofd-halskanker hoger ligt (40%) dan bij patiënten met andere 
soorten kanker (12.5%) en de algemene bevolking (3%). Ondersteuning tijdens de 
behandeling door hun mantelzorger(s) is onmisbaar. Dit kan de mantelzorger echter 
ook belasten. 
In hoofdstuk 2 wordt een studie beschreven over mantelzorgers van 
patiënten die behandeld werden met concomitant chemo- en radiotherapie in 
verband met lokaal uitgebreid hoofd-halskanker. Allereerst is het verloop van 
de belasting en vermoeidheid van de mantelzorger in relatie tot de distress en 
vermoeidheid van de patiënt onderzocht. Daarnaast is gekeken naar risicofactoren 
voor overbelasting en vermoeidheid bij de mantelzorger nadat de patiënt de 
behandeling heeft afgerond. 
We vonden dat de vermoeidheid en belasting van mantelzorgers gemiddeld 
genomen het hoogste was op het moment dat de vermoeidheid en distress 
van patiënt ook het hoogste was, namelijk op één week na het einde van 
de chemoradiotherapie. Op dat moment werd bij de patiënt ook de laagste 
gezondheids-gerelateerde kwaliteit van leven gemeten. De gemiddelde mate van 
belasting en vermoeidheid van de mantelzorgers daalde weer naar het niveau van 




die zorgden voor een patiënt met een grote daling in zijn of haar gezondheids-
gerelateerde kwaliteit van leven hadden een groter risico op overbelasting na het 
einde van de behandeling van de patiënt. Vermoeidheid bij de mantelzorger bij 
aanvang van de behandeling bleek een risicofactor te zijn voor vermoeidheid na 
het einde van de behandeling. 
Op grond van deze resultaten lijkt het essentieel om voor het starten van 
de behandeling van de patiënt met lokaal vergevorderd hoofd-halskanker 
mantelzorgers te identificeren die bij aanvang al problemen ervaren om juist hen 
extra te kunnen ondersteunen en problemen op langere termijn te voorkomen. 
Darmkanker
In 2019 werd in Nederland bij 9237 patiënten de diagnose darmkanker gesteld, 
waarvan bij ongeveer 65% stadium II of III ziekte betrof. Na resectie van de tumor 
zal bij een deel van deze patiënten adjuvante chemotherapie geadviseerd worden 
om de kans op genezing te vergroten. De meest voorkomende bijwerkingen van 
deze chemotherapie zijn het handvoetsyndroom, misselijkheid, braken maar vooral 
ook zenuwschade aan de handen en voeten. Dit laatste is niet altijd (of veelal) 
niet omkeerbaar. Er is weinig bekend over mantelzorgers van patiënten die een 
dergelijke, in opzet curatieve, behandeling ondergaan voor darmkanker. 
In Nederland is wel eerder gekeken naar de ervaring(en) van naasten van 
darmkankerpatiënten die een operatie hadden ondergaan en die nadien tenminste 
een prognose van 6 maanden hadden. Jonge en vrouwelijke mantelzorgers bleken 
meer behoefte te hebben aan ondersteuning bij hun taken als mantelzorger. Ook 
werd er een relatie gevonden tussen een negatieve ervaring als mantelzorger en 
1) een lager inkomen, 2) zorgen voor een meer afhankelijke patiënt, 3) spanning 
binnen de relatie en 4) meer zorgtaken hebben. Verder werd beschreven dat deze 
groep jonge en vrouwelijke mantelzorgers meer risico had op het ontwikkelen 
van een depressie op langere termijn. Ook mantelzorgers die een lagere sociale 
betrokkenheid ervaarden hadden ditzelfde risico op depressies. 
In hoofdstuk 3 wordt een studie beschreven bij mantelzorgers van patiënten 
die in opzet curatief behandeld werden voor darmkanker. Er werd specifiek gekeken 
naar 1) het verloop van de belasting en distress van mantelzorgers voor, tijdens en 
na de behandeling van de patiënt en is er gekeken naar hoeveel mantelzorgers 
een hoge mate van belasting en distress ondervonden, 2) mogelijke risicofactoren 
voor een hoge ervaren belasting en distress tijdens en maanden na het einde van 
de behandeling, 3) de associatie tussen de belasting en distress van mantelzorgers 
en de distress van de patiënt en 4) het beloop van de gezondheids-gerelateerde 
kwaliteit van leven van de mantelzorgers en de associatie tussen hun belasting en 
distress en die van de patiënt. 
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Gemiddeld genomen was de ervaren belasting en distress van mantelzorgers 
tijdens en na de behandeling laag en als het wel verhoogd was nam het ook weer 
af in de loop van de tijd. Er was echter een groep van mantelzorgers die voor 
het starten van de chemotherapie een hoge mate van belasting (12%; n=7/58) en 
distress (27%; n=16/60) ervaarde (12%; n=7/58). Bij respectievelijk 8% (n=4/50) en 19% 
(n=9/48) van de mantelzorgers werd 3 maanden na het einde van de behandeling 
nog een hoge mate van belasting en distress gezien. Belasting voor en tijdens 
de behandeling van de patiënt vormt een risicofactor voor de mate van ervaren 
belasting maanden na het einde van de behandeling van de patiënt. Ditzelfde werd 
gevonden voor distress. 
Deze studie liet zien dat er een kwetsbare groep mantelzorgers is en waar 
het van toegevoegde waarde kan zijn om al voor het starten van de behandeling 
ondersteuning te bieden.
Mantelzorgers van patiënten tijdens langdurige behandeling 
Mantelzorgers van patiënten die langdurig worden behandeld voor gastro-
intestinale stromatumor (GIST)
Een GIST is een zeldzame kwaadaardige wekedelen tumor, die meestal uitgaat van 
de maag- of darmwand en uit kan zaaien in de buik of naar de lever. In Nederland 
werd in 2018 bij ongeveer 400 patiënten een GIST vastgesteld. Deze vorm van 
kanker staat erom bekend dat deze ongevoelig is voor bestraling en chemotherapie, 
waardoor lange tijd de levensverwachting van de patiënten met een GIST beperkt 
was. In 2000 heeft het medicijn imatinib, een doelgericht geneesmiddel, ervoor 
gezorgd dat de levensverwachting van patiënten met GIST aanzienlijk verbeterde 
van gemiddeld minder dan een jaar naar gemiddeld meer dan 5 jaar. Daarmee 
werd dit medicijn de hoeksteen van de behandeling bij gemetastaseerde ziekte. 
Later bleek imatinib ook effectief als adjuvante behandeling van GIST, waarbij de 
behandelduur 3 jaar is. Inmiddels zijn er meerdere doelgerichte behandelingen voor 
GIST beschikbaar. Ondanks deze indrukwekkende vooruitgang in de overleving 
krijgen patiënten ook te maken met uitdagingen. De ervaren bijwerkingen van 
de jarenlange dagelijkse medicijnen zijn vermoeidheid, diarree, misselijkheid en 
braken, vochtophoping rondom de ogen, spierkrampen en huiduitslag. Daarnaast 
hebben veel patiënten te maken met angst voor recidief of progressie van de ziekte. 





In hoofdstuk 4 wordt een studie beschreven waarin is gekeken naar 1) de 
mate van belasting en distress van mantelzorgers van patiënten die langdurig 
behandeld worden voor GIST, 2) hun gezondheids-gerelateerde kwaliteit van 
leven, tevredenheid over hun relatie en sociale ondersteuning en 3) mantelzorgers 
die een hoge mate van belasting en distress ervaarden vergeleken worden met 
mantelzorgers die een lage mate van belasting en distress ervaarden. 
Er werd gevonden dat de mate van ervaren belasting en distress bij de 
mantelzorgers (n=61) in deze studie gemiddeld laag was. De ervaren gezondheids-
gerelateerde kwaliteit van leven van deze mantelzorgers was vergelijkbaar met 
die beschreven is in de algemene bevolking. Hun mate van tevredenheid over 
hun relatie was hoog en ze ervaarden weinig tekortkomingen in de steun vanuit 
hun sociale netwerk. De helft van de patiënten ondervond hinderlijke of ernstige 
bijwerkingen van de behandeling en 34% ervaarde distress. Kijkend naar de 
mantelzorgers ervaarde 10% van hen een hoge mate van belasting en 23% een 
hoge mate van distress. Er is een relatie te bestaan tussen de mate van distress van 
de patiënt en de mate van belasting en distress van de mantelzorger. Mantelzorgers 
met een hoge mate van ervaren belasting gaven vaker aan een lagere mate van 
mentale gezondheid te ervaren, minder vitaal te zijn en meer distress te ervaren. 
Een hogere mate van belasting werd ook vaker gerapporteerd door 1) de niet-
partner mantelzorgers, 2) mantelzorgers van patiënten die meer bijwerkingen 
ondervonden, 3) mantelzorgers die meer uren besteedden aan zorgen voor de 
patiënt en 4) mantelzorgers die voor meer dan één persoon zorgden. Mantelzorgers 
die meer distress ervaarden gaven vaker aan 1) een lagere mate van algehele 
gezondheids-gerelateerde kwaliteit van leven te ervaren, 2) meer belasting te 
ervaren, 3) sociaal minder te functioneren, 4) moeite te hebben met het omgaan 
met fysieke en emotionele problemen, 5) een lagere mate van mentale gezondheid 
te ervaren en 6) minder vitaal te zijn. Daarnaast werd ook gezien dat mantelzorgers 
met meer ervaren distress zorgden voor 1) meer afhankelijke patiënten en 2) meer 
dan één persoon tegelijk. 
Deze studie laat zien dat het belangrijk is dat er aandacht is voor het welzijn van 
een kleine, maar kwetsbare groep mantelzorgers waarvan de naasten langdurig 
behandeld moeten worden voor kanker en dat de bewustwording hiervan een 




MANTELZORGERS VAN PATIËNTEN 
DIE KANKER OVERLEEFD HEBBEN
Mantelzorgers van patiënten die succesvol behandeld zijn voor prostaatkanker 
Angst voor de recidief komt voor bij bijna de helft (49%) van de patiënten die eerder 
in opzet curatief zijn behandeld voor prostaatkanker. Deze angst neemt niet af in 
de loop van de tijd. Het is bekend dat angst voor terugkeer van kanker gepaard 
kan gaan met ongezond gedrag, distress en toegenomen zorgconsumptie. Het is 
denkbaar dat ook de mantelzorgers van deze patiënten deze angst ervaren, echter 
hierover is weinig bekend. 
In hoofdstuk 5 wordt een studie beschreven over partners van patiënten 
die eerder een in opzet curatieve behandeling van prostaatkanker ondergingen 
(n=168). Er werd gekeken naar 1) hoeveel partners angst hebben voor recidief van 
prostaatkanker, 2) de relatie tussen de angst voor terugkeer van de ziekte tussen 
de partner en de patiënt, 3) de demografische gegevens van partner en patiënten 
die een hoge mate van angst voor recidief ervaren en 4) de relatie tussen een hoge 
mate van angst voor recidief bij de partners en hun gezondheids-gerelateerde 
kwaliteit van leven. 
Er werd gevonden dat ongeveer evenveel partners (35%) en patiënten (38%) 
ernstige angst voor de terugkeer van de ziekte ervaarden. Een hogere mate van 
angst voor terugkeer van de ziekte bij de partner was geassocieerd met meer angst 
bij de patiënt, hetgeen ook het geval was als de partner jonger was. Vergeleken 
met partners met een lage angst voor recidief scoorden partners met een hoge 
angst voor recidief significant lager op sociaal functioneren, mentale gezondheid 
en vitaliteit. Zij ervaarden ook significant vaker moeite met vervullen van dagelijkse 
taken door moeilijkheden in hun emotioneel functioneren. 
Deze studie benadrukt dat ernstige angst voor recidief ook een probleem kan 
zijn bij de partners van patiënten in opzet curatief behandeld zijn voor prostaatkanker. 
Het wordt aanbevolen om bij het vormgeven van toekomstige studies en beleid 







Nabestaanden van patiënten die deel hebben genomen aan experimentele 
therapie in de laatste levensfase
Wanneer een patiënt deelneemt in een fase-I experimentele studie is er geen 
reguliere behandeling voor de kanker meer voorhanden en is de prognose beperkt. 
Een patiënt die wil deelnemen aan een fase-I studie moet nog in een goede 
conditie verkeren. Er is een hele kleine kans dat de behandeling effect heeft op de 
kanker, en er kunnen wel belangrijke bijwerkingen optreden. Dit maakt de positie 
van de patiënt kwetsbaar in zijn of haar laatste levensfase. De meeste studies naar 
deze kwetsbaarheid hebben het perspectief van de patiënt en de zorgverleners 
belicht. Het perspectief van de mantelzorgers van de patiënt is nooit onderzocht. 
In hoofdstuk 6 wordt een studie beschreven met partners van patiënten die 
overleden zijn na deelname aan een experimentele behandeling in de laatste 
levensfase. Er is gekeken naar 1) hoe de partner van de patiënt terugkijkt op de 
deelname van de patiënt aan een fase-I studie en 2) naar eventuele problemen 
die de partner nog kan ervaren zoals distress, depressie, gecompliceerde rouw en 
hun gezondheids-gerelateerde kwaliteit van leven. 
Wat werd gevonden is dat, 2 jaar na het overlijden van de patiënt, partners 
aangaven dat de deelname van de patiënt aan een fase-I studie een negatief 
effect had op de gezondheids-gerelateerde kwaliteit van leven van de patiënt. 
Daar tegenover stond dat slechts 5% (n=3/58) van de partners uiteindelijk spijt had 
van deze deelname. Vergeleken met de gezonde populatie, scoorden de partners 
gemiddeld genomen lager op sociaal en mentaal functioneren. Verder had 19% 
(n=11/58) van de nabestaanden symptomen van een depressie, 36% (n=21/58) 
ervaarde distress en 46% (n=26/57) had symptomen van gecompliceerde rouw. 
Deze studie onderstreept dat verder onderzoek nodig is naar de oorzaak van 
deze problemen na het overlijden van de patiënt en welke relatie dit heeft met de 




In hoofdstuk 8 wordt de inhoud van alle hoofdstukken in relatie tot elkaar 
bediscussieerd, welke implicaties de bevindingen kunnen hebben voor de 
dagelijkste praktijk en worden aanbevelingen gedaan voor toekomstig onderzoek. 
De studies in dit proefschrift bevestigen hetgeen we in de praktijk zien, namelijk 
dat er een groep mantelzorgers is die kwetsbaar is en dat problemen bij het starten 
van de behandeling een risicofactor kunnen zijn voor het hebben van problemen 
op de langere termijn. In elke studie was een kwetsbare groep mantelzorgers te 
identificeren en vooral de mantelzorgers van patiënten die behandeld worden 
voor hoofd-halskanker en de mantelzorgers van patiënten die deelnemen aan 
experimentele behandeling in de laatste fase van hun leven vielen op door de 
mate van problemen die zij ervaarden. 
Essentieel is om een onderscheid te kunnen maken tussen een normale reactie 
op een stressvolle situatie in het leven van de mantelzorger en wanneer dit overgaat 
in een probleem die het dagelijks leven van de mantelzorger dusdanig beïnvloedt 
dat het eigen functioneren beperkt wordt. Twee studies in dit proefschrift laten zien 
dat problemen voor het starten van de behandeling, zoals belasting, distress en 
vermoeidheid, aandacht behoeven vroeg tijdens de behandeling van de patiënt, 
omdat dit op langere termijn een risicofactor blijkt voor blijvende problemen. 
Belangrijk bij verdere ondersteuning van mantelzorgers is het samenspel tussen 
het herkennen van problemen van de mantelzorger door zorgprofessionals, het 
erkennen van de mantelzorger dat er een probleem is en de mogelijkheden om 
deze problemen te objectiveren en op te lossen. Net als de zorg van de patiënt 
die steeds verder gepersonaliseerd wordt, zal ook de zorg voor mantelzorgers 
maatwerk zijn. Samenwerking tussen zorgverleners in de eerste, tweede en derde 
lijn is daarvoor onmisbaar. De huisarts zal een centrale rol spelen, aangezien de 
huisarts als enige een behandelrelatie met de mantelzorger heeft. Daarnaast zal 
ook zijn rol als “familie dokter” van toegevoegde waarde zijn aangezien de huisarts 
het systeem van de patiënt en de mantelzorger goed kent, wat helpt om zorg op 
maat te leveren. 
Er is steeds meer kennis over hoe mantelzorgers ondersteund kunnen worden. 
Het is bekend dat psycho-educatie, ondersteunende interventies, mindfulness-
based stress-reductie en cognitieve gedragstherapie de ervaren belasting van 
mantelzorgers kunnen verlichten, waar ook behoefte is aan meer kennis over 
copingsmechanismen van mantelzorgers en wat nader onderzocht dient te worden. 
Verder zal de belasting en distress van de mantelzorger ook gevolgen kunnen 
hebben voor de fysieke gezondheid van de mantelzorger. Het onderzoek hiernaar 




consequenties mantelzorgen kan hebben. Daarnaast kan deze kennis, samen met 
de verder te verwerven kennis over de mentale gevolgen van het mantelzorgen, 
leiden tot proactieve en preventieve interventies om problemen op langere termijn 
te voorkomen. 
Kijkend naar nieuwe ontwikkelingen, van nieuwe behandelingen als 
immunotherapie tot de gevolgen die de coronapandemie heeft op het welzijn van 
mantelzorgers, is het belangrijk om door middel van verder onderzoek te kijken 
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The results of the studies in this thesis are based on human studies. All procedures 
performed were in accordance 1964 Helsinki Declaration and its later amendments 
or comparable ethical standards. For all studies in this thesis, approval of the 
medical ethical review board Committee on Research Involving Human Subjects 
Region Arnhem Nijmegen was granted (2009/191; 2010/461; 2013/184; 2013/278; 
2013/393). Informed consent was obtained from all participants. 
All the document of this study, including data of patients and their informal 
caregivers, are deposited on the Radboudumc Medical Oncology server (\\
Umcfs074\oncodata$\Mantelzorgstudie). This folder is created for this project and 
only accessible for authorized personnel. For all the studies in this thesis we used 
paper and pencil questionnaires. The questionnaires and informed consent forms 
are stored in the archives of the department of Medical Oncology and Medical 
Psychology. Data management and monitoring were performed by using Microsoft 
office Excel files and “Statistical Package for the Social Sciences” (SPSS). All these 
files were stored on the Radboudumc Medical Oncology server (\\Umcfs074\
oncodata$\Mantelzorgstudie). The questionnaires were coded, providing each 
participant an unique code. The databases used for analyses of the studies in this 
thesis only contained coded anonymous information and hereby warranted the 
privacy of the participants. The data stored in the archives will be saved for 15 years 
after termination of the studies. The datasets analyzed for the studies in this thesis 
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Mijn proefschrift afronden heb ik niet kunnen doen zonder heel veel steun en 
hulp van de mensen om mij heen. Ik heb er dan ook erg naar uit gekeken om 
dit dankwoord te mogen schrijven. Allereerst om het moment waarop je dat 
mag doen, namelijk wanneer het einde echt in zicht is. Bovenal omdat ik zoveel 
dankbaarheid voel voor iedereen die op mijn pad is gekomen sinds de start van 
mijn promotietraject. Dit is toch het uitgelezen moment om daar eens goed bij 
stil te staan. Nou ben ik nooit iemand van weinig woorden geweest, dus zet je 
schrap, daar gaan we! 
Allereerst wil ik alle mantelzorgers en patiënten die deel hebben willen nemen 
aan mijn onderzoek bedanken. Het heeft mij elke keer verwonderd dat mensen 
op zo'n moeilijk en stressvol moment in hun leven bereid zijn om deel te nemen 
aan onderzoek. Het altruïsme, wat vaak de basis was voor hun deelname aan 
mijn studies, vind ik bewonderenswaardig. Het was voor mij een extra motivatie 
om dit proefschrift naar mijn beste kunnen af te ronden. 
Professor Van der Graaf, beste Winette, hartelijk dank dat ik dit promotietraject 
onder jouw supervisie heb mogen doen. Jouw kritische blik en deskundigheid 
op vele gebieden zijn van grote waarde geweest voor mijn onderzoek. Je hebt 
voor mij ook veel kansen gecreëerd om mijn onderzoek te presenteren en mij 
gestimuleerd om dat te doen. Daarnaast heb je rondom life-changing events, 
zoals bij de geboorte van mijn twee kinderen, altijd jouw betrokkenheid getoond. 
Dat heb ik echt gewaardeerd. Dankjewel. 
Professor Prins, beste Judith, je hebt mij alle ruimte gegeven om te kunnen 
groeien als onderzoeker. Jouw kennis en deskundigheid op het gebied van de 
psychosociale oncologie is onmisbaar geweest voor mijn onderzoek. Daarnaast 
was je voor mij altijd laagdrempelig bereikbaar en dacht je mee graag over 
oplossingen. Je hebt er ook voor gezorgd dat ik binnen de afdeling medische 
psychologie kennis kon maken met andere onderzoekers. Dat bracht naast het 
delen van kennis ook de nodige gezelligheid met zich mee, zoals tijdens het 
etentje dat je organiseerde bij jouw thuis. Jouw enthousiasme bij het behalen 
van een mijlpaal, zoals de award voor beste poster op het jaarlijkse NVPO 
congres, maakte dat ik nog meer kon genieten van het behaalde resultaat. 
Heel veel dank. 
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Professor Van Herpen, beste Carla, ik ben je heel erg dankbaar voor jouw 
vertrouwen in mij. Wanneer zich een hobbel in de weg voordeed kon ik bij je 
terecht en sprak je dit vertrouwen ook uit. Jij maakte dat wat voor mij complex 
was, weer simpel. Dat heeft mij geholpen om deze hobbels te nemen en mijn 
weg weer te vervolgen. Ik waardeer jouw pragmatisme en kennis enorm en ik 
kijk altijd met veel bewondering naar jouw inzet voor patiënten en hun naasten. 
Jouw drive om hen de best mogelijke zorg te leveren, deel ik. Ik hoop dat wij 
deze energie in de toekomst nog vaak in iets constructiefs kunnen omzetten.
Doctor Wymenga, beste Machteld, ik kan mij nog goed herinneren dat ik jou 
voor het eerst leerde kennen als tutor tijdens mijn eerste co-schap bij de interne 
geneeskunde in Medisch Spectrum Twente. Je inspireerde mij door je gedrevenheid, 
duidelijkheid en hart voor de patiënt. Toen ik net begon als dokter, heb je mij "onder 
je vleugels genomen" en veel kansen voor mij gecreëerd, waaronder de mogelijkheid 
om dit promotietraject te starten. Ik zal het nooit vergeten en ik ben je heel dankbaar. 
Ondanks dat onze wegen zich "promotie-technisch” nu scheiden, hoop ik dat wij 
elkaar in de toekomst nog mogen vinden in de gedeelde passie die “palliatieve zorg” 
heet. 
Prof. dr. Speckens, prof. dr. Blijlevens en prof. dr. Van der Rijt, heel veel dank voor 
het lezen en beoordelen van mijn manuscript en jullie deelname aan de oppositie 
tijdens de verdediging van mijn proefschrift. 
Co-auteurs, jullie feedback op de inhoud van de verschillende hoofdstukken 
was erg waardevol waarvoor mijn dank. In het bijzonder wil ik een aantal mensen 
bedanken. Marlies Peters, het was fijn om met jou samen te mogen werken aan de 
fase I studie en jouw nuchtere woorden waren altijd weer een stimulans om verder 
te gaan. Claudia van Opstal, jouw drive voor patiënten met hoofdhalskanker en 
hun naasten werkte aanstekelijk en ik ben blij dat ik “jouw pilot” ook de mijne heb 
mogen maken. Veel dank daarvoor. Marieke van de Wal, met je doortastendheid en 
heldere kijk op de data hebben we een waardevolle paper kunnen schrijven over 
een belangrijk onderwerp. Bedankt voor de vlotte en prettige samenwerking. Prof.
dr. An Reyners, bedankt voor je hulp bij het mede mogelijk maken van de studie 
naar mantelzorgers van patiënten met GIST en ook voor de waardevolle feedback 
op mijn paper. Carel Veldhoven, jouw pragmatische inborst als huisarts heeft mijn 
hoofdstuk over mantelzorgers van GIST patiënten een mooie draai gegeven. Veel 
dank voor je input en ik ben blij dat we kunnen blijven samenwerken binnen het Team 




Alle betrokken oncologen en verpleegkundigen in de deelnemende ziekenhuizen 
(Radboudumc te Nijmegen, Medisch Spectrum Twente te Enschede, Isala Klinieken 
te Zwolle, Slingeland Ziekenhuis te Doetinchem en het Universitair Medisch Centrum 
Groningen) wil ik heel hartelijk danken voor hun inzet voor de CoCare en GIVE studie. Ik 
wil hier in het bijzonder Manon Hijmans-van der Vegte, Gerry Sieling, Chris Leverink 
en Brigitte Heck bedanken voor hun inzet en fijne samenwerking. 
Lieve medebewoners van de “Villa Interna Oude Stijl”: Chantal, Steve, Annelieke, 
Marye, Eline, Janneke, Marlies, Floor, Kalijn, Harm, Claudia, Daniëlle, Annemarie 
en Pieter, veel dank voor de gezellige lunches, borrels en congresbezoeken. Ook 
de mijlpalen mocht ik met jullie vieren en dat was altijd een feest. In het bijzonder 
wil ik Chantal bedanken. Als kamergenoten heb we lief en leed gedeeld. Ik kijk 
nog steeds met een goed gevoel terug naar die tijd. Jij hebt mij geleerd dat ik het 
niet allemaal alleen hoef te doen en dat vragen altijd mag. Steve, ook met jou op 
de kamer kon ik altijd rekenen op gezelligheid. Ik heb altijd gelachen om jouw 
droge uitspraken, waarvan “Kun je rekenen? Reken er maar niet op!” toch echt 
mijn favoriet was. Marlies, jouw warme onthaal in Nijmegen heeft mij zacht doen 
landen en ik heb altijd genoten van onze mooie gesprekken. Floor, jouw luisterend 
oor en behulpzaamheid, ook bij de eindsprint voor mijn proefschrift, heb ik erg 
gewaardeerd. Je bent een topper. En ik wil hier ook even Roos noemen. Lieve 
Roos, ik beschouw het als een voorrecht dat ik je heb mogen leren kennen. Jouw 
warme persoonlijkheid en schaterlach zorgden er mede voor dat ik mij erg thuis 
heb gevoeld in de villa. Ook daarna heb ik met je mogen samenwerken als fellow 
bij de oncologie. Ik heb veel van je mogen leren. Dankjewel. Ik mis je. 
Alle collega’s van de afdeling medische oncologie, hartelijk dank voor de rol die 
jullie hebben gehad bij mijn onderzoek en de steun die ik heb mogen ervaren! 
De dames van het secretariaat, Esther, Anja, Natasja en Sietske, bedankt voor 
jullie ondersteuning bij praktische zaken, zoals het maken van afspraken met het 
promotieteam. Jullie zijn echte “puzzelpro’s” wat mij betreft! Daarbij heb ik mij 
altijd welkom gevoeld en de persoonlijke gesprekken waren altijd gezellig. Ook 
alle verpleegkundige wil ik bedanken. Jullie oprechte interesse in mij en ook mijn 
onderzoek hebben mij altijd gesteund en jullie oog voor mantelzorgers is van grote 
waarde! In het bijzonder wil ik daarbij Annemiek van Geffen bedanken. Wij kennen 
elkaar al uit onze tijd in Medisch Spectrum Twente. Je bent een prachtmens en ik 
haal altijd veel uit onze gesprekken. Na jouw vertrek uit het Radboudumc hebben 
we contact gehouden en daar ben ik heel blij mee! De fellows waar ik mee heb 
mogen samenwerken toen ik de opleiding combineerde met het onderzoek. Veel 
dank voor jullie collegialiteit en steun! Ik ben blij dat ik die tijd met jullie heb mogen 
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samenwerken. Rafke, ik ben blij dat wij als collega’s elkaar weten te vinden om samen 
te sparren. Dat is van grote waarde én natuurlijk ook gewoon gezellig. Ik wil mijn 
opleiders en supervisoren tijdens mijn opleidingstijd bij de oncologie bedanken voor 
hun geduld en steun. Het was prettig om van de besten te mogen leren. Bedankt. 
Karin, your Ladyship, El Condor, ik kon mij tijdens mijn stage op de afdeling geen 
betere supervisor wensen. Je liet me vrij en gaf mij veel vertrouwen. Het gaf de ruimte 
om soms ook te kunnen werken aan mijn onderzoek. Daarnaast hebben we veel 
kunnen lachen en zal ik nooit meer hetzelfde kunnen kijken naar Mr. Potato Head. 
Je werkt nu ergens anders, maar gelukkig zoeken we elkaar zo nu en dan toch nog 
wel eens op en dat vind ik onwijs leuk! Lieve Ingrid, je hebt mij als opleider altijd 
aangemoedigd om mijn eigen pad te gaan bewandelen en dat werpt nu zijn vruchten 
af. Ik kijk altijd met veel bewondering naar jouw vermogen om enkel uitdagingen te 
zien in plaats van problemen. Dat is een enorme inspiratie geweest en heeft mij ook 
geholpen om mijn promotietraject succesvol af te ronden. Heel veel dank.
Alle collega’s van de afdeling Pijn en Palliatieve zorg en in het bijzonder Kris, 
Heinrich, Evelien, Marieke, Carel, Hans, Henny, Floor, Nicole en Rina, allen dank 
voor jullie steun! Beste prof. dr. Kris Vissers, wij delen een interesse voor de rol van 
de mantelzorger en ik ben je dankbaar voor de momenten dat ik hierover met je heb 
mogen sparren. Jouw oog voor de drukte tijdens de eindsprint van mijn proefschrift 
en hoe je mij daarbij uit de wind hebt gehouden, waardeer ik enorm. Nu volle kracht 
vooruit met mooie projecten in het verschiet! Lieve Floor, wat kan ik met je lachen 
en wat geniet ik daarvan! Lieve Henny, jouw oog voor naasten is onmisbaar in ons 
team en ik werk graag met je samen! Lieve Heinrich, naast een top collega ben je 
ook gewoon een heel fijn mens. Ik kijk uit naar meer dates samen met onze naasten, 
op een fijne plek en uiteraard met lekker eten en drinken! Lieve Evelien, tijdens mijn 
mammastage als fellow oncologie is onze samenwerking begonnen en dat hebben 
we mogen voortzetten tot op de dag van vandaag. Ik word daar blij van. Jij gaat 
altijd uit van het goede van de mens en maakt het ingewikkelde weer simpel. Zo 
heeft jouw slogan “dan promoveer ik toch gewoon een weekje later” de uitdagende 
momenten weer gerelativeerd. Lieve Marieke, Eucalypta senior, vanaf het moment 
dat wij mochten gaan samenwerken was er een klik. Het is top om met je te kunnen 
sparren en samen te lachen. Je hebt mij ook aangemoedigd om dit proefschrift 
af te ronden en tijd gecreëerd om hieraan te kunnen werken. Ik ben blij met jou 
als collega en ik hoop nog vele jaren met je samen te mogen werken! Lieve Hans, 
Hanssie, wat is het toch een voorrecht om jou als collega te mogen hebben. Jouw 
immer positieve kijk op de wereld werkt aanstekelijk. Bedankt voor je luisterend oor, 
de gezelligheid en “gewoon” voor het zijn van mijn maatje. Lieve Maaike Haan, ik 




en jouw prachtige boek hierover. Onze gesprekken over dit onderwerp gaven mij 
elke keer weer nieuwe energie om verder te schrijven. Het bleek overigens al snel 
dat het gespreksonderwerp zich vaak niet beperkte tot praten over mantelzorgers. 
Wij praten de lunch zo vol over andere onderwerpen, zoals het moederschap en 
natuurlijk “de blauwe aap”. Ik hoop dat we contact zullen houden! 
Voor de mensen die mij gecoacht hebben, Josefien, Nico en Mincka: heel veel 
dank. Lieve Josefien, jij hebt mij zoveel helderheid gebracht. Wij hebben samen 
gewerkt aan mijn motto in het leven: “life isn’t about waiting for the storm to pass, 
it’s about learning to dance in the rain”. Bedankt daarvoor! Beste Nico, bedankt 
voor het delen van jouw glasheldere kijk op succes! Het heeft mij geholpen om 
te komen waar ik nu sta. Lieve Mincka, jij hebt mij met veel humor en luchtigheid 
geleerd hoe fijn het is om de weg tussen het hoofd en het hart te onderhouden. Ik 
ben blij dat je op mijn pad gekomen bent! 
Aan mijn lieve vrienden: heel veel dank voor jullie steun! Jullie maken mijn leven 
zoveel rijker en mooier. "As de moed oe in de kloompe zakt, dan mö'j 'n moal op 
oe'n kop goan stoan". Wijzen komen echt uit het Oosten. Lieve Hilward, Marieke, 
Aafke, Ardo, Erwin, Dewi, Bianca, Jeroen, Leon, Linda, Nanda, Marloes, Ingrid, 
Hilde-Marie, Wilbert, Emile en Mireille, jullie nuchtere kijk op de zaak geeft veel 
helderheid aan deze westerling. Ik ben heel blij dat ik jullie door Arjan heb mogen 
leren kennen! Lieve Miranda, naast jouw hulp thuis, beleef ik ook veel plezier aan 
onze gesprekken en de gezelligheid die dat brengt. Je bent een topper! Lieve 
Cynthia, ik zal nooit vergeten hoe jij mij gesteund hebt toen ik voor het eerst 
moeder werd. Jouw no-nonsense kijk op het leven is verfrissend en ik geniet van 
de gezelligheid tijdens een wandeling of etentje samen! Lieve Bertine, zonder dat 
je het misschien door hebt gehad, heb ook jij een belangrijke bijdrage geleverd aan 
het af komen van dit boekje. Na onze gezellige sportmomenten samen ging ik altijd 
weer met veel focus en energie aan het werk! Bedankt! Lieve Elsemieke, wij kennen 
elkaar nog niet lang, maar tijdens de eindsprint van mijn proefschrift was jij daar 
met een een goede bak Maastrichtse thee of gewoon een Brownie per post. Op 
naar meer mooie wandelingen, zanglessen en genieten met onze kindjes samen! 
Lieve dames van Saffier, de afronding van dit proefschrift zal er wat mij betreft zeker 
aan bijdragen dat we elkaar weer vaker kunnen zien. Ik kijk ernaar uit, want uit het 
oog is zeker niet uit het hart! Lieve Lotgenoten, Middel, Baussie, Carin en Sonja, 
wat is het toch mooi dat wij elkaar tijdens de co-schappen hebben gevonden en 
elkaar niet meer hebben losgelaten. We kunnen samen lachen, huilen en huilen 
van het lachen. Hoe “fijn” en “zalig” is dat!? Ik ben super blij met jullie in mij leven! 
Lieve Nyn, Makkjèr, wat is het toch een feest om jouw in mij leven te hebben! Jouw 
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steun, liefde, humor en energie zijn voor mij echt onmisbaar! Ik heb veel respect hoe 
jij jouw veerkracht elke keer weer toont. Nu er meer tijd komt zeg ik: op naar heel 
veel mooie, hysterische, play-back, “framboise” en fabulous momenten samen! Ik 
hou van je, toen, nu en voor altijd. Lieve Té, wij moeten jou missen, maar ik weet 
dat je met mij meekijkt, waar je ook bent. Jij zou ontzettend trots zijn geweest op 
wat ik voor elkaar heb gekregen. Ik zal nooit vergeten wat je zei als mantelzorger 
van Gerrit: "maar wie vraagt mij nou eigenlijk hoe het met mij gaat?". Dat heeft mij 
geïnspireerd om dit onderzoek te doen. Je bent voor mij een voorbeeld geweest 
als mens en als moeder van Nyn. Ik mis je. Lieve Gerrit, ik heb bewondering voor 
jou, voor hoe je in het leven staat en je door niks en niemand van jouw pad af laat 
brengen. Jij bent zo blij met de kleinste dingen. Bedankt voor onze herinneringen 
samen. Van “stop, ik moet dit doen” tot de BBQ’s in de tuin in Leek samen met Nyn 
en Té; alle geven mij een grote glimlach op mijn gezicht. 
Lieve Martine en Hanneke, wat ben ik trots dat jullie naast mij staan als paranimf. 
Jullie hebben een heel belangrijke rol gespeeld in alle fasen die ik heb doorlopen 
om dit proefschrift af te ronden. Lieve Martine, wat prijs ik mij gelukkig met een 
vriendin zoals jij. Jij bent mijn spiegel en geweten. En waar ik normaal “een mens van 
veel woorden” ben, heb ik er bij jou niet veel nodig om mij begrepen te voelen. Onze 
onvoorwaardelijke vriendschap is van de buitencategorie. Om samen met jou door 
het leven te mogen navigeren, wat wij al mogen doen vanaf 3 VWO, zie ik als een 
groot cadeau. Bedankt voor jouw onvoorwaardelijke steun. Lieve Hanneke, vanaf 
het moment dat wij elkaar hebben leren kennen tijdens de introductie cursus van de 
RIHS zijn we niet meer gestopt met praten. Jouw gedrevenheid en doortastendheid 
zijn inspirerend voor mij geweest en ik word altijd weer blij van jouw scherpe geest 
en goede gevoel voor humor. Op de Wolfsberg, bij Beluga, Krentemans of lekker 
thuis; onder het genot van een goed glas wijn en lekker eten praten we samen over 
“het leven”. Dat we dit in alle eerlijkheid kunnen doen is zo fijn. Wat bof ik toch met 
jou als vriendin. Ik vind je echt een prachtmens! 
Aan mijn familie die mij hebben gesteund tijdens mijn promotietraject: heel veel 
dank! Lieve Stan, onze aankomst in het mooie Zutphen in 2013 was er dankzij 
jou één met een gouden randje. Jij hebt ons wegwijs gemaakt en laten zien 
wat Zutphen allemaal te bieden heeft. Ik geniet van jouw positieve inborst en 
verhalen over vroeger. Ik hoop nog vele kopjes koffie of borrels (bij voorkeur op 
de Bokbierdag) met je te mogen drinken. Lieve Roos en Tom, van een goed glas 
wijn in de sneeuw in Méribel, een onvergetelijke rit in de Alvis op onze bruiloft tot 
gewoon dat een appje op de verjaardagen; ik geniet van het contact dat er is. Lieve 




het leuk om samen herinneringen op te halen, ook aan opa en oma Langenberg. 
Ik mag ook nog graag in het fotoboek kijken wat jullie hebben gegeven. Jullie 
interesse in mij en mijn gezin waardeer ik ontzettend. Bedankt! Lieve Peter, wat 
hebben wij een fijne traditie in het voorjaar in het mooie Schönried! Ook de borrels 
samen en de kaasfondue zijn altijd weer een feest! Maar bovenal jouw interesse in 
wat ik doe en wat mij bezighoudt ben ik je dankbaar voor. Ik hoop nog lang van je 
te mogen genieten en samen de fijne herinneringen aan opa Siem en oma Door 
Nadorp levendig te mogen houden! Lieve Dick, in onze gesprekken “als collega’s 
onder elkaar" kwam ik tot de ontdekking dat wij een interesse delen: het welzijn van 
mantelzorgers. Jij hebt als huisarts hier een belangrijk bijdrage geleverd in de regio 
rondom Bemmel. Ook spreek ik soms patiënten of collega's die jou nog hebben 
gekend als huisarts. De mooie woorden die volgen maken mij trots en motiveren 
mij om mij als dokter volledig in te blijven zetten voor de mens achter de patiënt. 
Je geniet samen met Ria van het leven. Jullie zijn een ijzersterk duo en dat vind ik 
mooi om te zien. Lieve Door en Frans, jullie wonen dicht in de buurt en vanaf dat 
ik een klein meisje ben kom ik graag bij jullie. Met het afronden van dit proefschrift 
hoop ik dat ik vaker richting het Lochemse kan komen! Lieve Jos, met trots kan ik 
zeggen dat ik in jouw voetsporen ben getreden als internist. En dat niet alleen. In 
1974 mocht ook jij in Nijmegen jouw proefschrift verdedigen. Je was dan ook blij 
verrast te horen over mijn voornemen datzelfde te gaan doen. Helaas kunnen we 
deze mijlpaal niet meer samen vieren, maar ik weet zeker dat jij heel trots op mij 
zou zijn geweest. Lieve Tineke, ik bewonder jou om de vrouw die je bent: sterk, 
doortastend, warm en oprecht. Ook na het overlijden van Jos toon jij jouw kracht. 
Daar heb ik veel respect voor. 
Lieve Rogier, jij brengt altijd reuring en gezelligheid met je mee. Daar kan ik echt 
van genieten en dat heeft zeker bijdragen aan de ontspanning die nodig was om 
elke keer weer met nieuwe energie aan het werk te gaan om dit traject af te ronden. 
Bedankt! Lieve Monique, ik vind je een onwijs mooi mens en ik bewonder jouw 
geduld en veerkracht echt. Het is een geluk om jouw als schoonzus te mogen 
hebben. Lieve Pien, ik kan mij het moment dat wij voor het eerst kennis maakten 
nog goed herinneren. Je was zo mooi en dat ben je nog steeds, in alle opzichten. 
Jou op te mogen zien groeien tot de mooie dame die jij bent, vind ik zo bijzonder 
leuk. Lieve Jonas, jij bent er één uit duizenden. Zo lief en in het bezit van een goede 
dosis humor. Ik kan daar met een grote glimlach en veel trots naar kijken! Lieve 
Henk en Gera, dit proefschrift was nog lang niet af geweest als jullie er niet geweest 
waren. Ik waardeer jullie steun en liefde ontzettend. Het denken in oplossingen, 
zoals jullie dat als de besten kunnen, hebben mij enorm geholpen. Ik geniet ervan 
om te zien hoe mooi jullie band is met Hugo en Milou en ik hoop daar nog lang 
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(en nu het proefschrift af is nog meer) van te mogen genieten. Op naar nog meer 
fijne momenten samen; thuis, op Texel of in de sneeuw! Lieve Oma Oma, vanaf 
het eerste moment dat je mij zag, heb je mij omarmt en niet meer losgelaten. Het 
was zo’n warm welkom in jullie familie. Tijdens de start van mijn promotietraject 
heb je bijgedragen aan de nodige ontspanning en mochten we regelmatig bij je 
aanschuiven voor pannenkoeken of een heerlijke jachtschotel. Ik had deze mijlpaal 
dan ook graag met je gevierd. Als ik het glas hef om te proosten op de afsluiting 
van dit traject, zal ik zeker aan je denken! 
Lieve Francis, wij hebben een speciale band en daar ben ik elke keer weer blij 
mee. Wij lijken op elkaar en toch ook weer niet. Je bent voor mij altijd een inspiratie 
geweest om recht op je doel af te gaan en daar ook veel voor over te hebben. Wat 
ik altijd fijn heb gevonden en wat nog altijd zo is, is de wetenschap dat jij er voor 
me zal zijn als ik je nodig heb. Bedankt voor wie je bent en wie je voor mij bent. Ik 
hou van je. Lieve Sanne, wat ben ik blij dat jij in onze familie bent gekomen. Jouw 
nuchtere kijk op zaken heeft mij echt geholpen. Ik ben blij dat wij “de liefde voor 
het genieten van het leven” mogen delen. Ik hoop dat dan ook nog vaak samen 
te mogen doen. Natuurlijk ben ik ook zo blij met jullie mooie kindjes Just en Jo. 
Lieve Just, jouw nieuwsgierigheid en prettige eigenwijsheid toveren elke keer weer 
een lach op mijn gezicht. Lieve Jo, die ondeugende blik in jouw ogen en de gekke 
bekken die je trekken kan, maken mij altijd vrolijk. Jullie hebben een speciaal plekje 
in mijn hart. Lieve papa, ik voel mij altijd gesterkt, wetende hoe trots je op mij bent. 
Bedankt voor jouw geloof in mij. Het was onmisbaar en dat heeft mij echt gesteund 
tijdens mijn promotietraject. Ik kan met bewondering kijken naar hoe jij je met veel 
daadkracht en energie inzet voor iets waar jij in gelooft en waar jij om geeft. Daar 
mag ook ik de vruchten van plukken! Ik hou van jou en ik hoop dat er nu tijd komt 
om eens samen af te reizen naar Wenen! Lieve mama, bedankt voor wie je bent, 
voor wat je mij geleerd hebt, voor je oneindige liefde, geduld, interesse en steun. 
Zonder jou had ik dit zeker weten niet tot zo’n mooi einde weten te brengen. Jouw 
zorgen voor anderen en de liefde en energie die je aan anderen geeft (en je soms 
ook iets teveel kosten), zijn een inspiratie geweest om dit onderzoek te willen doen. 
Ik hoop dat met de tijd die vrij komt na het afronden van dit werk, er meer tijd komt 
om samen te genieten zoals wij dat samen kunnen…Ik hou van jou. 
Lieve Hugo en Milou, dat jullie in mijn leven gekomen zijn, is echt een impuls 
geweest om dit proefschrift af te willen ronden. Alle tijd die ik met jullie mag 
doorbrengen is namelijk één groot cadeau. Om de gezelligheid, maar ook om de 
lessen die ik leren mag. Elke dag weer kijk ik met zoveel bewondering naar jullie. 
Jullie leren mij waar het echt om draait in het leven. Lieve Hugo, je bent zo wijs, 
sterk en oprecht en ik bewonder je daarom enorm. Met een grote lach op je gezicht 
geniet jij van het leven, omarm je iedereen op jouw pad en mag ik er getuige van 
zijn hoe jij met grote nieuwsgierigheid de wereld ontdekt. Wat een feest! Lieve 
Milou, wanneer jij met een twinkeling in je ogen voor mij “laat het los, laat het 
gaan” zingt en daarbij jouw mooiste dans danst, raak je mij en weet ik waar ik het 
allemaal voor doe. Jij bent zo’n onwijs lieve mantelzorger voor je knuffels en poppen 
en ik geniet ervan dat te mogen aanschouwen. De wetenschap dat ik nu meer tijd 
overhoud om samen met jullie op avontuur te gaan, maakt mij heel gelukkig! Ik hou 
van jullie! Lieve Arjan, makker, jouw steun in alle fasen van mijn promotietraject zijn 
van ongekende waarde geweest. Zoals je zelf altijd zo mooi zegt: “luctor et emergo”. 
Ik worstel en kom boven. Dat lukt ook elke keer weer, wetende dat jij daar staat, met 
open armen en de beste omhelzing die ik me maar kan wensen. In alle opzichten, 
zowel praktisch als emotioneel, wist je mij te steunen. Niks was jou teveel. Jij bent 
voor mij zo’n bijzonder, mooi en uniek mens. Jij herinnert mij er elke keer weer aan 
dat ik er mag zijn, gewoon zoals ik ben. Het is een voorrecht om met jou samen te 
mogen zijn en ik geniet van onze momenten met elkaar, groot en klein. Ik hou van 
jou, je bent mijn alles(sie)! Nu dit avontuur tot een einde komt, staat ons samen 
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